LV10099B - Bicyclic heterocyclic compounds - Google Patents

Bicyclic heterocyclic compounds Download PDF

Info

Publication number
LV10099B
LV10099B LVP-93-136A LV930136A LV10099B LV 10099 B LV10099 B LV 10099B LV 930136 A LV930136 A LV 930136A LV 10099 B LV10099 B LV 10099B
Authority
LV
Latvia
Prior art keywords
oxo
benzopyran
methyl
phenyl
piperazinyl
Prior art date
Application number
LVP-93-136A
Other languages
Latvian (lv)
Other versions
LV10099A (en
Inventor
Amedeo Leonardi
Gianni Motta
Carlo Riva
Rodolfo Testa
Original Assignee
Recordati Chem Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI920408A external-priority patent/IT1254469B/en
Application filed by Recordati Chem Pharm filed Critical Recordati Chem Pharm
Publication of LV10099A publication Critical patent/LV10099A/en
Publication of LV10099B publication Critical patent/LV10099B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)

Description

LV 10099
TITLE
Bicyclic Heterocyclic Compounds 5 DESCRIPTION
The invention relates to bicyclic heterocyclic compounds and to pharmaceutical compositions containing them. 10 Flavoxate, which is 8-(2-piperidinoethoxycarbonyl)-3--methyl-4-oxo-2-phenyl-4H-l-benzopyran, and has the formula 0
25 is used as a pharmaceutical aģent for urinary tract disturbances as it possesses a smooth muscle relaxing activity attributable to its calcium antagonist activity. This act'ivity is exerted on the bladder dome 30 smooth muscles or can be related to the micturition center in the Central nervous system.
The compounds of the invention, described below, essentially include more complex amino moieties in place 35 of the piperidino group. Further changes include alternatives to the ethoxycarbonyl group which spaces the amino moiety from the benzopyran ring, alternative 2-, 3-, 6- and 7-substitution pattems in the benzopyran ring, replacement of the ring heteroatom by a sulphur atom or by a sulphinyl, sulphonyl or imino group, and/or 2,3-dihydrogenation of the benzopyran ring. These structural variations give the new compounds a capability of interacting with different biological systems, as supported by the affinity of the new compounds for the αι-adrenergic and 5HTiA~serotoninergic receptors. Flavoxate is practically devoid of affinity for these receptors.
COMPOUNDS OF THE INVENTION
The compounds of the invention have the general formula I
vrtierein ---- represents a single or double bond; X represents an oxygen or sulphur atom or an imino, alkylimino, sulphinyl or sulphonyl group; w represents a valence bond or a carbonyl, thiocar-bonyl, methylene or hydroxymethylene group; R2 represents a hydrogen atom or an alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, substituted heterocyclyl or aroyl group; the substituents for the aforesaid substituted groups being one or more halogen atoms, such as fluorine and/or one or more alkyl, cyano, hydroxy, alkoxy, phenyl, phenoxy, trifluoromethyl, LV 10099 R3
nitro, amino, alkylamino, dialkylamino, acylamino, alkylsulpho- nylamino or benzoyl groups; represents a hydrogen atom or an alkyl, hydroxyalkyl, alkoxyalkyl, aralkoxyalkyl# phenyl, hydroxy, alkoxy or aralkoxy group; represents a hydrogen or halogen atom or a nitro, amino, alkylamino, dialkylamino, acylamino, alkylsulphonylamino, cyano, hydroxy, alkoxy or alkyl group;
10 R7 Y 15 represents a hydrogen atom or an alkoxy group; represents one of the following groups, each of vrtiich is depicted with its left hand end being the end which attaches to the heterobicyclic ring and its right hand end being the end which attaches to the group Z: 20 25 30 (Yl) 1 O 0 1 <Y2> -coo-, (Y3) -CONH-, (Y4) -CON(CH3)-, (Y5) -CON(OH) (Y6) -CH(OH) (Y7) -CH(OAlkyl)-, (Y8) -CH=CH-, (Y9) -CH=CH-COO-, (Υ10) -CH=CH-CONH-, (Υ11) -CH=NO-, (Υ12) -CH2-, (Υ13) -CH2COO-, (Υ14) -CH2CONH-, (Υ15) -CH2NH-, (Υ16) -CH2N(CH3)-, (Υ17) -CH2N{COCH3)- (Υ18) -CH2N(CONH2)- (Υ19) -CH2NHCO-, (Υ20) -CH2N(CH3)CO- (Υ21) -CH2NH-CONH-, (Υ22) -CH2NHSO2-, 35 4 (Υ23) -CH20-, (Υ24) -CH2S-, (Υ25) -CH2SO-, (Υ26) -CH2SO2-, (Υ27) -CH2S02NH-, (Υ28) -CH2SO2N(CH3)- (Υ29) -NH-, (Υ30) -N(CH3)-, (Υ31) -N(C0CH3)-, (Υ32) -N(CONH2)- / (Υ33) -NHCO-# (Υ34) -N(CH3)CO-, (Υ35) -NH-CONH-, (Υ36) -NHS02-/ (Υ37) -0-/ (Υ38) -s-, (Υ39) -so-, (Υ40) -S02-/ (Υ41) -S02NH-, (Υ42) -S02N(CH3>-/ (Υ43) -CONHO-, (Υ44) -CON(COCH3) (Υ45) -CSNH-, (Υ46) -CSN(CH3) (Υ47) (Υ48) -NHCOO-, and (Υ49) -COS-; represents a linear or branched chain alkylene group having from 1 to 6 carbon atoms and optionally having one hydroxy substituent; and represents pne of the following groups: / \ (Bi)
N
N — A
Q -C0N(0
5 LV 10099 5 wherein Q represents a methylene or ethylene group and A represents one of the following groups; (AI) a phenyl group substituted by one or more halogen atoms and/or one or more alkyl, alkoxy or hydroxy groups, (A2) a 2-pyrimidinyl group, and (A3) a group of the general formula 10
wherein ---- is as above defined and E 15 represents an oxygen atom or a valence bond, (B2) 20.
25 wherein each of Li and L2 independently represents a hydrogen atom, a phenyl, 4-fluorobenzoyl or 2-oxo-l-benzimidazolinyl group, or a group of the general formula (CH2)n-0-A wherein n is 0, 1 or 2 and A is as above defined, with the proviso that Li and L2 do not both represent hydrogen atoms, 30
35 6 wherein each of Rio and Rn independently represents a hydrogen atom or an alkoxy or alkylthio group, R12 represents a hydrogen atom or an alkyl group, and n is 2 or 3, (B4) (B5) R13 -N-CH2
I R12 wherein R12 is as above defined and R13 represents a hydrogen atom or an alkoxy group, and 0
v/herein R12 is as above defined, when ---- represents a double bond, W represents a carbonyl group and X represents an imino group, the ring may undergo tautomerization to give a 4-hydroxy--guinoline structure; such tautomeric compounds are included within the invention.
The invention also includes prodrugs, enantiomers, diastereoisomers, N-oxides and pharmaceutically acceptable salts of the compounds of the general formula I.
The term "prodrug" is used herein to mean a derivative of a compound of the general formula I in which reactive groups such as amino, imino or hydroxy groups (particularly as or within the W, R2, R3/ R6/ Z, B1 and B2 moieties) or acidic imino groups (e.g. those present LV 10099 in Y3, ΥΙΟ, Υ19, Υ27, Υ36 and Υ41) have been masked; the derivative releasing the compound itself within a living body and thus having the same pharmacological effect on the body as the compound itself, Prodrugs may be 5 prepared so as to alter the pharmacokinetic properties of the compound, for instance so as to prepare a delayed release or sustained release form of the compound, or otherwise modify the metabolism, adsorbtion, distribution or plasmatic half-life of the compound. The 10 compound prepared in Examples 114 and 120-122 below are examples of prodrugs.
The group
will be abbreviated hereinafter as Fl. The preferred 20 values of the substituents in the group follows: a double bond, X: an oxygen atom, W: a carbonyl group, 25 R2: a phenyl group, R3' a methyl group, R6: a hydrogen atom, and R7: a hydrogen atom. 30 The group having ali these preferred substituents is the 3-methy1-4-oxo-2-pheny1-4H-1-benzopyran-8-yl group.
The preferred groups which Z may represent are trimethylene and tetramethylene. Y preferably represents 35 one of the groups Y2, Y3, Υ37, Υ40, Υ41 or Υ42. B preferably represents one of the groups B1 or B3, especially the 1-(2-methoxyphenyl)-piperazinyl group. 8
Other conventional abbreviations used herein include Me for methyl, Et for thyl, Ac for acetyl, Alk for alkyl, THF for tetrahydrofuran, DMF for dimethyl-formamide, and DMSO for dimethylsulphoxide.
The adrenergic antagonist activity of the compounds of the invention renders them useful as aģents acting on body tissues particularly rich in α ļ-adrenergic receptors (such as blood vessels, prostate and urethra). Accordingly, anti-adrenergic compounds within the invention established as such on the basis of their receptor binding profilē, may be useful therapeutic aģents for the treatment, for example, of hypertension and micturition troubles associated with obstructive disorders of the lower urinary tract, including but not limited to those caused by benign prostatic hypertrophy.
The serotoninergic activity of the compounds of the invention renders them useful as aģents acting on tissues, particularly in the Central nervous system, where 5HTia receptors are functioning. 5HTia receptors are believed to regulate the action and release of serotonin as well as the release of other neuromediators and are found both pre- and post-synaptically. The compounds of the invention have biological activity in blocking binding between these receptors and their various specific ligands (e.g. serotonin). Accordingly, the compounds of the invention which interact with the 5HTia receptor (established as such on the basis of their receptor binding profilē) may be useful therapeutic aģents for the treatment of anxiety disorders and depression.
Surprisingly, the compounds of the invention (especially those displaying affinity for both the ai-adrenergic and the 5HTxA_serotoninergic receptors) show high selectivity for the mammalian lower urinary tract, i.e. LV 10099 9 they are substantially more active in antagonizing urethral contractions than in lowering blood pressure. On the contrary, known ai-antagonists, such as prazosin, which is l-(4-araino-6,7-dimethoxy-2-quinazonlinyl)-4-(2--furoyl)-piperazine (GB 1156973), do not exhibit such selectivity (and in fact cause hypotension as a most common side effect) while flavone derivatives structurally similar to flavoxate, such as terflavoxate, which is 8-{l,l-dimethyl-2-piperidino-ethoxycarbonyl)-3--methyl-4-oxo-2-phenyl-4H-l-benzopyran hydrochloride (EP 0072620), have no effect on urethral contractions. Naturally, those compounds of the invention that are not selective for the lower urinary tract are preferred as antihypertensive aģents, but even the selective compounds can often be used as antihypertensives because of their low toxicity.
Compounds of the invention have also shovm a good antagonist effect against contractions of rat bladder strip induced by potassium chloride. This effect can be attributed to a calcium antagonistic activity, and renders the new compounds useful as spasmolytics of the lower urinary tract (i.e. useful in the treatment of urinary incontinence, urge syndrome and other similar disorders).
The majority of the compounds of the invention exhibit low toxicity. Thus they can be used in higher amounts, an advantage that often more than compensates for a relatively lower Ievel of activity that some of these compounds have. Naturally, those compounds exhibiting both activity and low toxicity are preferred.
The invention further provides a pharmaceutical composition comprising a compound according to the invention, or a prodrug, enantiomer, diastereoisomer, N-oxide or pharmaceutically acceptable salt of such a 10 compound, in admixture with a pharmaceutically acceptable diluent or carrier.
SYNTHESIS OF THE COMPOUNDS OF THE INVENTION
The compounds according to the invention may generally be prepared (except when the groups Rg and the substituents at R2 are OH, NH2 or aminoalkyl and Y = Υ15 or Υ29) as follows:
Path ai
By condensing compounds Fl-Y-Z-L, wherein L represents a halogen atom or a leaving group such as a tosyloxy group, with a compound H-B. The condensation 1s preferably, but not necessarily/ carried out at a temperature within the range of 20-140'C in a polar solvent such as dimethylformamide or methanol/ usually in the presence of a base such as potassium carbonate. Such condensations are illustrated in Examples 1 to 3, 7 to 9, 11, 13 to 16, 21, 23 to 31, 38 to 42, 46 to 49, 54 to 59, 69, 73, 77, 78 and 84 below. See also Gibson's chapter in Patai, The Cheml8try of the Amino Group, p.45 et seq., Wiley Interscience, New York, 1968.
An alternative method for the preparation of the compounds of the invention is condensation (under the same conditions described in the preceding paragraph) of a compound Fl-Y-H with a compound L-Z-B wherein L is as above defined. This condensation is illustrated in Examples 5, 6, 66, 79 and 81 below. By this route, compounds having Y = Υ15 or Υ29 can also be prepared (see Gibson's chapter in Patai, supra).
Compounds of formula (I) bearing a NH2 group in Rg or as substituent in R2, may be prepared by reduction of the corresponding compounds (I) wherein R6 or the substituent in R2 are N02 groups. Such reduction can be carried out: LV 10099 11 - with Ni-Raney catalyst in a protic solvent selected from methanol, ethanol, isopropanol, water and mixtures of them; or - with SnCl2, H20, optionally in presence of hydrochloric acid, either in a protic solvent such as methanol, ethanol, isopropanol, water, acetic acid and mixtures of them, or in an aprotic solvent such as ethyl acetate; or - with Fe and aqueous hydrochloric acid in a protic solvent such as methanol, ethanol, isopropanol, water and mixtures of them.
The temperatures of the above reactions will be chosen in a range between 20*C and 100’C. (J.March, Advanced Organic Chemistry, III Ed., page 1103, Wiley. Interscience, 1985) .
Examples of this reduction are given in Examples 94 and 124.
Compounds of formula (I) having a NHAlk group as a Rg substituent can be prepared by monoalkylation, starting from the corresponding parent compounds (I) where R6 = NH2. For example, this may be done by first reacting the amino compound (I) with an excess of trifluoroacetic anhydride, then reacting the obtained trifluoroacetyl derivative with an alkyl-L reaģent and finally unprotecting the thus-obtained trifluoroacetyl--alkylated derivative by treatment with potassium carbonate in methanol or with sodium borohydride in methanol or dimethylsulphoxide. These reactions are described in Examples 32 and 33, where they were carried out on Y groups.
Altematively, compounds of foraula I having a NHAlk or N(Alk)2 groups as a R6 substituent or as a substituent on the phenyl group in R2 can be obtained by alkylation of the corresponding parent compounds (I) where R6 = NH2 with the appropriate alkanais in presence of a reducing 12 aģent, such as sodium cyanoborohydride. Descriptions of these reactions are given in Examples 96 and 97 below. Compounds bearing a OH group as R6 or as a substituent in R2 may be prepared starting from the corresponding parent compounds (I) alkoxy-substituted at said positions. This can be accomplished by treating the parent compounds for example, with BBr3 in dichloromethane at 0-40*C (T.W. Greene,Protective Groups in Organic Synthesis, page 87, wiley Interscience, 1981) or according to other methods described in the same reference.
Compounds of the general formula I in which ---- represents a single bond can be obtained either by selective hydrogenation of the corresponding compounds in which ---- represents a double bond or by conversion of appropriate starting materiāls in which the 2,3-bond is already saturated, such starting materiāls being obtainable according to Reaction Schemes 4, 6 to 9, 11, 12 and 14 below. The latter route is illustrated in Example 87 below, and is particularly preferred when the compound concerned contains a nitro group, as hydrogenation could convert the nitro group to an amino group. The selective hydrogenations can be carried out using alternatively: - hydrogen in presence of a mētai or mētai oxide catalyst (e.g. palladium on charcoal, or platinum dioxide) in protic solvent at 20-120'C (E.H. Rodd, Chemistry of Carbon Compounds, Vol. IVB, page 903, Elsevier, 1959); or - di(isobutyl)aluminium hydride in an aprotic solvent (e.g. tetrahydrofuran and/or dichloromethane) at -70 to 0‘C (H. Sarges et al., J. Med. Chem., H, 1859, 1990) .
Compounds in which W represents a hydroxymethylene group and the 2,3-bond is saturated can be obtained by reduction with sodium borohydride of corresponding 510 15 20 25 30 LV 10099
13 compounds in which w represents a carbonyl group and the 2,3-bond is saturated, as reported in Example 123 below. in some cases, the compounds of the general formula I may be prepared by conversion of other (parent) compounds of the invention. Such conversions include: Path b; Fl-CO-Z-B -> Fl-CH(OH)-Z-B
Path c:
Path d! £a t h e;
Path F:
Path q:
Path h;
Path i:
Path i;
Path k: by reduction as illustrated in Examples 17 to 20 below, Fl-CH(OH)-Z-B -» Fl-CH(OAlkyl)-Z-B by etherification as illustrated in Example 22 below, Fl-(CH2)n-NH-Z-B -> Fl(CH2)n-N(CH3)-Z-B where n = 0 or 1, by N-methylation as illustrated in Example 35 below, Fl-(CH2)n-NH-Z-B -> Fl-(CH2)n-N(COCH3)-Z-B where n = 0 or 1, by N-acetylation as illustrated in Example 36 below, Fl-(CH2)n-NH-Z-B Fl-(CH2)n-N(CONH2)-Z-B where n = 0 or 1, by reaction with potassium isocyanate as illustrated in Example 50 below, Fl-CH(OH)-Z-B -» Fl-CO-Z-B by oxidation, as illustrated in Example 51 below, Fl-Y-Z-B -> Fl-Y-Z-B(N-oxide) by oxidation as illustrated in Examples 43 and 122 below, H2N-F1-Y-Z-B CH3C0NH-F1-Y-Z-B (wherein H2N-F1 represents a Fl group in which R6 is an amino group or R2 includes an amino group) using the N-acylation method described in Examples 36 and 95 below, F1(R6 = NH2)-Υ-Ζ-Β —» Fl(Rg = CH3SO2NH)-Υ-Ζ-Β by amidification using the method described in Example 112 below, Rl0~y— Fl-Y-Z-NH-(CH2.)n-0-V 7 ->
Rll—' 35 14 14
Rl0*V-A -> Fl -Υ-Ζ-Ν (Alk) - (CH2 ) n~0~ y ^
Rll- or ‘13
or
Fl-Y-Z-NH-CH2 Fl-Y-Z-N(Alk)-CH2- αν όο by N-alkylation using the procedure described in Examples 35 and 62 below.
Some compounds may be prepared by addition reactions. For example those in which Z contains a hydroxy substituent may be prepared by addition across an epoxy group. /°\
Path 1; F1-Y-CH2-CH-CH2 + H-B -» Fl-Y-CH2-CH(OH)-CH2-B as illustrated in Example 45 hereinbelow.
Addition across a double bond is also possible, e.g.: Path m: F1-Y-CH=CH2 + H-B -> Fl-Y-CH2-CH2-B as illustrated in Examples 37, 63 and 82 below.
Other synthetic schemes include the formation of Υ, z or B during the reaction, for example:
Path n: Fl-(X)-(Q)-Cl- + A-HN-Z-B ->
-> F1-(X)-(Q)-N(A)-Z-B LV 10099 15 (wherein X = bond, CH2 or CH=CH, Q = CO or SO2, and A = H, alkyl or OPr wherein Pr is a protective group) as illustrated in Example 12 (particularly preferred) and in Examples 60, 61, 64, 67, 68, 72, 87, 88, 93, 98, 116, 129 and 130.
The same compounds may also be prepared by other routes including:
Fl-(x)-COOH + A-NH-Z-B in presence of a coupling aģent (e.g. dicyclohexylcarbodiiinide, N,N'-carbonyl-diimidazole or diethyl cyano-phosphonate) optionally in the presence of a promoting aģent (e.g. 4-dimethylaminopyridine or N-hydroxybenzotriazole) in an aprotic or a chlorinated solvent (e.g. dimethylformamide, chloroform) at -10/140'C (Albertson, Org. React., 12, 205-218, 1962; Doherty et al., J. Med. Chem., 15., 9, 1992; Staab et al., Newer MethodB Prep. Org. Chem., 5, 61, 1968;
Ishihara, Chem. Pharm. Buli., 1£, 3236, 1991); as illustrated in Examples 80, 86, 89, 90, 92, 99 to 111, 113 to 115, 117 to 119 and 128. Fl-(X)-COOH + A-NH-Z-B without a solvent at 150-220’C (Mitchell et al., J. Am. Chem. Soc., 5i/ 1879, 1931) or in high-boiling etheral solvents (e.g. diglyme);
Fl-(X)-COO-Alk + A-NH-Z-B optionally in the presence of a coupling aģent (e.g. trimethylaluminium) in an aprotic and/or a chlorinated solvent (e.g. hexane, dichloromethane) at -10/80*C, or without solvents at 80-180*C (S.M. Weinreb et al., Tetrahedron, 4171, 1977; M.F.Lipton et al., Org. Svnth.. 59. 49, 1979);
Fl-(X)-COOH + alkylchloroformate in the presence of a tertiary amine (e.g. triethylamine) followed by addition of 16 16 Path ο: Pž.th. Ώ.Ι Path σ: Path r;
Path s: Path t; Path u: Path v: Path w; F1-y-z-NH2 + L-CH2-
Fl-Y-Z-B4 A-NH-Z-B at 0-80'C; optionally a promoting aģent (e.g. l-hydroxypiperidine) may be added before the amine addition (Albertson, Org. React., 12, 157, 1962).
F1-COC1 + HS-Z-B -> Fl-Y49-Z-B F1-C0C1 + HO-Z-B Fl-Y2-Z~B as illustrated im Example 10 below.
Fl-CHO + H2NO-Z-B -» Fl-Yll-Z-B as illustrated in example 70 below.
Fl-CHO + A-HN-Z-B -> Fl-CS-N(A)-Z-B (where A = H or CH3) in the presence of sulphur in an aprotic solvent, e.g. DMF or pyridine, at 60-120*C (M. Carmack et al., Org. Reaction., jL2., 1947; R.Benassi et al.,
Org.Magn. Rea., ļji, 25 1981), as illustrated in Example 83 below. F1-NH2 + HCO-Z-B -> Fl-Y29-Z-B as illustrated in Example 34 below.
Fl-Y-CH3 + HO-CH2-B -» F1-Y-CH2-CH2-B as illustrated in Example 4 below. Fl-CH=CH-CONH2 + HOCH2-B —> F1-Y10-CH2-B.
Rl0_ Π-Υ-Ζ-Ν3 + HCO-CH2-0- ^ β -> Fl-Y-Z-B3
Rll^ under reducing conditions as illustrated in Example 44 below. *10 —· r. \ F1-Y-Z-NH2 + L-(CH2)n-0-V V Fl-Y-Z-B3 *11' as illustrated in Examples 74, 75 and 76 below. as illustrated in Example 52 below. ο LV 10099 17 CH Ρ1-Υ-Ζ-ΝΗ2 4
-> Fl-Y-Z-B
Path χ: as illustrated in Example 65 below.
Path v; F1-Y-Z-CH0 + HB —> Fl-Y-Z-B as illustrated in Example 53 below.
Path z: Fl-(X=S)-Υ-Ζ-Β -> Fl-(X=SO or S02)-Υ-Ζ-Β by oxidation with hydrogen peroxide in acetic acid or other oxidizing aģents in the presence of acids.
Persons skilled in the art wiļl be aware that ali the above synthetic pathways b) to y) might be simplified provided that the reacting intermediate does not bear further groups sensitive to the same reactants (for example: CO, NH2> NHAlk or OH groups). Compounds of formula I bearing such reactive groups can be prepared through paths b) to y) provided that the reactive groups present in the starting materiāls are protected befotehand and then deprotected after the reaction as illustrated in Example 71. Several examples of protection and deprotection for various reactive groups can be found in T.W. Green, Protective Groups in Organic Synthesis, Wiley Interscience,1 1981 (2nd Edition 1991) . Altematively, unreactive groups (e.g. NO2) can be left unconverted during the first reaction and then converted to reactive ones (e.g. NH2) as a final step of the pathway. See for example path a).
Which synthetic technique will be preferred depends on the compound desired to be synthesized, but path n) is generally preferred for the compounds that can be made by it. Additional synthetic methods will be apparent to those skilled in the art.
STARTING MATERIALS
The starting materiāls (Fl-Y-Z-L and Fl-Y-H and others) used in the preparations described above, may themselves 18 be prepared from aimple compounds such as Fl-COOH, Fl-CHO, F1-COC1, F1-NH2 and Fl-OH by transformations known to those skilled in the art. Numerous such transformations are described in detail hereinbelow. Many of these simple compounds (Fl-COOH, Fl-CHO, Fl-COCl, F1-NH2 and Fl-OH) are commercially available or their synthesis has been reported in the literature. Those which are not available may be synthesized according to one or more of the following Reaction Schemes 1 to 16.
Reaction Scheme 1 leads to compounds in which W represents a carbonyl group and X represents an oxygen atom.
Step.la
Procedure without isolation of the intermediate phenyl ester: R3CH2COCI or (R3CH2CO) 20 and a Lewis acid (e.g. AICI3 or ZnCl2)/ without solvent or in an aprotic solvent (e.g. nitrobenzene or chlorinated solvent) at 20-180’C.
Procedure with isolation of the intermediate phenyl ester: R3CH2COCI or (R3CH2CO)20 heated with the starting material or other esterification methods, such as the Schotten-Bauman procedure. The isolated ester is then heated in nitrobenzene or another non protic solvent (e.g. a chlorinated solvent), or without any solvent, at 20-180’C, in the presence of a Lewis acid such as AICI3 or Znci3 (Ά.Μ. Blatt, Org. React., 1, 342, 1942).
Step lb R2COC1 or (R2CO)20 and R2COONa alone or in a high-boiling non-protic solvent (such as 0-dichlo-robenzene) at 150-220*C; this reaction also allows the direct transformation of compounds (2) to compounds (6), when compounds (2) have A=COOH; SCHEME1
4 A = C02CH3, C02C2H5, N02, CH=CHCH B = CO2H, NH2 20 R2C(OAlk)3 in the presence of HCIO4 at 20-40'C or in pyridine in the presence of piperidine at 60-80 *C; R2C0C1 or {R2CO)20 in a chlorinated solvent at -10 to 120’C in the presence of a base such as 1,8-diazabicycloundecene (DBU).
Step lc R2C0C1 in pyridine at 20-100’C or in a non-protic solvent at 0-80’C, optionally in the presence of a base such as NEt3 or 4-dimethylaminopyridine.
Step ld K2CO3 in acetone or methyl ethyl ketone at 20-80 *C; NaH in DMSO or THF at 0-40’C; KOH or potassium t-butoxide in pyridine at 20-100’C.
Step le HC1 or H2SO4 in AcOH at reflux or in an alcohol (MeOH, EtOH, isopropanol) at 20’C to reflux temperature; CF3COOH in dichloromethane at 20-40*C; p-toluenesulphonic acid in benzene or toluene at reflux.
Step lf R2COC1 and K2CO3 or KOH in water and a phase transfer catalyst in benzene or toluene at reflux; R2COOAlk and lithium bis(trimethylsilyl)amide or lithium diisopropylamide in THF at -78 to 0’C. fifcBP „iq
When A is a COOCH3 or COOC2H5 group:
NaOH in aqueous EtOH at 0-75*C;
LiOH in aqueous DMF, MeOH or THF or a mixture thereof at 10-100’C;'’ HC1 in an aprotic solvent such as dioxane at 60-120 *C.
When A is NO2: LV 10099 21
Reduction with Ni-Raney catalyst in a protic solvent (e.g. isopropanol) or a mixture of protic solvents at 20-100’C;
Reduction with hydrogen and a catalyst (e.g. Ni-Raney or Pd/C) in a protic solvent (e.g. MeOH, EtOH, isopropanol or a mixture thereof) at 20-100‘C;
Reduction with SnCl2 in the presence of aqueous HC1 in a protic solvent (e.g. AcOH) at 20-100*C; Reduction in the presence of Fe and agueous HC1 in a protic solvent at 20-100*C.
When A is a CH=CHCH3 group:
Oxidation with Na2Cr207 or other oxidizing aģents such as KMn04 in acetone/H2S04 at 0-100*C.
Reaction Scheme 2 leads to compounds in which X represents a sulphur atom or a sulphinyl or sulphonyl group and W represents a carbonyl group. The starting o-mercaptobenzoates (1) are commercially available or can be prepared by knovm methods, for example by transformation of the corresponding o-alkoxycarbonyl--benzenediazonium salts upon treatment with potassium ethylxanthate (M.S. Cohen et al., J. Org. Chem., 18. 1394, 1953). S£..ep_2a R2COCH(R3)CN or R2COCH(R3)COOAlk in polyphosphoric acid at 50-120‘C; R2C=C-COOAlk and AI2O3 in an aprotic solvent (e.g. Et20) at 0-40*C; R2C=C-COOAlk and a base in an aprotic solvent (e.g. THF or DMF) at 20-140*C.
The last two options are both followed by treatment with polyphosphoric acid at 50-120*C.
Step 2b
NaOH in aqueous EtOH at 40-75’C;
LiOH in agueous DMF at 40-100*C. 22 SCHEME2
LV 10099 23 steg--2.g
Stoichiometric 30% H2O2 in AcOH at 25-60‘C; m-chloroperbenzoic acid in chloroform at 0-30*C. StfiPJŽd 30% H2O2 in AeOH at 50-80*C.
Reaction Scheme 3 leads to compounds in which R7 represents a methoxy group, W represents a carbonyl group and X represents an oxygen or sulphur atom. Compounds (1) can be prepared according to Reaction Schemes 1 and 2 starting from the appropriate phenols or thiophenols (not substituted at position 2 or 6 with COOAlk or N02). SCHEME 3
Step 3a HCHO and gaseous HC1 in AcOH containing aqueous HC1 (d=1.18) at 50-100*C (P. Da Re et al., Ann. Chim., Afif 904, 1956).
This method can be used when R3 is other than H or ... CH2OH. 24 SCHEME4
6 7 LV 10099 25
The resulting Intermediates 2 can be converted using known methods to starting materiāls suitable for obtaining the desired compounds of the invention (see intermediate LXIX).
Simple 2,3-dihydro intermediates (----= single bond) can be prepared according to Reaction Scheme 4 provided that other reactive groups possibly present (e.g. NH2, OH) have been previously protected as described before. The compounds (4) thus obtained can be converted to the corresponding derivatives having A=COOH or NH2 according to the method of Step lg.
Step 4a R2-CHO, aqueous NaOH in EtOH or another protic solvent; R2-CHO, NaH or potassium t-butoxide in THF (or another dipolar aprotic solvent) at 0-150’C.
Step 4b
Mineral acid (e.g. HC1 or H2SO4) in water or another protic solvent (e.g. EtOH, AcOH) at 0-100‘C.
Step 4s R2-CHO, 0.1N to IN aqueous NaOH or another suitable base in a protic solvent; R2-CHO, pyrrolidine in a protic (e.g. MeOH) or polar aprotic solvent at 0-100’C (H.J. Kabbe,
Synthesie, p.886, 1978).
Step 4d
Lithium diisopropylamide in THF at 0-20*C; then trimethylsilyl chloride and organic base (e.g. NEt3) (S.E. Kelly et al., J. Org. Chem., 51/ 1325, 1991).
Step 4e R2-CHO in a chlorinated solvent (e.g. dichloromethane) at -78’C, then TiCl4 or other 26
Lewis acid (S.E. Kelly et al., J. Org. Chem., ££./ 1325, 1991).
St<SP_ 4_f
Lithium diisopropylamide in THF at -78*C, then R2-CHO (A. Banerij et al., Tetrahedron Letter, 3685, 1979).
SteP-.4g R2-CH=CR3C0C1, a Lewis acid (e.g. AICI3) in a suitable solvent (e.g. nitrobenzene) or without solvent at 20-180’C. gte.P- 4b R2-CH=CR3COOAlk, triethylbenzylammonium hydroxide in an aprotic solvent (e.g. benzene) or vithout solvent at 50-150*C; then aqueous NaOH in MeOH at 20-50 *C or LiOH in aqueous DMF. (In this case compounds having A=COOCH3 or COOC2H5 are also hydrolyzed to compounds having A=COOH). gtep, 4 i
Concentrated H2SO4 or P2O5 or polyphosphoric acid or a Lewis acid in nitrobenzene or toluene or without solvent at 0-180*C. (Also in this case hydrolysis of A=COOAlk to A=COOH occurs).
Simple starting materiāls having R3=OH or OR8, where Re is alkyl or aralkyl, may be prepared according to Reaction Scheme 5 where A has the same meaning as in Reaction Scheme 1. Compounds (1) and (2) (which are the same as (2) and (4) in Reaction Scheme 4 but with R3=H) can be prepared according to Reaction Scheme 4 starting from the appropriate phenols or thiophenols having R3=H. The compounds (4) used in Reaction Scheme 5 can be prepared by known methods from the corresponding salycilates or thiosalycilates (see J, March, Advanced Organic Chemistry, 486, John Wiley and Sons, New York, 1985; L. Renē et al., Eur. J. Med. Chem. - Chim. Ter., 4., 385, 1977 and references cited therein) . The substituent A in compounds (3) and (6) of Reaction LV 10099 27SCHEME5
28
Scheme 5 can be transformed by the processes of Step lg into a substituent B as defined in Reaction Scheme 1.
Step 5a
Agueous NaOH in an alcoholic solvent (e.g. MeOH or EtOH) followed by 30¾ H2O2 at -10 to -78'C. (N.D. Meyer et al ., J. Med. Chem,, £4., 736, 1991 and references cited therein). (Not when A is CH = CH-CH3/ when A=COOR it is simultaneously transformed into COOH).
St.eP-5.b
When ---- * single bond:
Amyl nitrite or other alkyl nitrite without solvent or in a suitable solvent (e.g. EtOH or benzene) in the presence of a catalyst such as 37¾ HC1 (Orgr. React., 7, 327, 1953 and references cited therein); then aqueous H2SO4 in a protic solvent (e.g. AcOH) at 10-1Q0*C (Acheson R.M., An Introduction to the Chemietry of Heterocyclic Compounde, 347, John wiley and Sons, New York, 1976).
When ---- = double bond: lithium diisopropylamide in dry THF at -78*C; then AcOH and 30¾ H2O2 (B.D.M. Cunningham et al., Anti-Cancer Drug Design, 2/ 365, 1992).
SfceiL ,5s R2-CH=CH-N02 (1 to 1.5 eguivalent) in a suitable solvent (e.g. diisobutyl ether, DMSO or DMF) in the presence of a base (e.g. KOH or NaOH) in catalytic or stoichiometric quantity at 20-150*C (see L. Renē, supra, and T, Sakakibara et al., Buli. Chem. Soc. Jpn., 51, 3095, 1978).
Sfc£B. 5d 15¾ H2O2, NaOH or another base (e.g. NEt3) in a protic solvent such as MeOH at 20-100*C (S.R. Deshpande et al., Syntheeis, 835, 1983) or photolysis and alkaline hydrolysis (Rao T.S. et al., Heterocyclea, 22., 1377, 1984), or K02 in LV 10099 29 benzene containing 18-crown-6 ether at 20-100*C (Rao T.S., Heterocycles, 2£, 2117, 1987). (Not when A is CH=CH-CH3; when A=COOR it is simultaneously transformed into COOH). R8L, where L represents a leaving group (e.g. alkylsulphate, halogen, tosyl) and a base (e.g. K2CO3, NaH, KOH, NaOH or LiOH) in a suitable solvent (e.g. THF, DMSO, DMF, benzene) in the presence or otherwise of a phase transfer catalyst (e.g.benzyltriethylammonium bromide) at 0-180*C. Step 5f
By the methods of Step lb.
Reaction Scheme 6, in which A has the same meaning as in Reaction Scheme 1, leads to compounds in which W represents a thiocarbonyl group. The compounds (1) and (2) of Reaction Scheme 6 can be prepared according to Reaction Schemes 1, 2, 4 and 5. The substituent A in compound (4) of Reaction Scheme 6 can be transformed by the processes of step lg into a substituent B as defined in Reaction Scheme 1.
Sten 6a P2S5 in pyridine at 50-100*C (Stavaux et al., Buli. Soc. Chim. Fr.t 2082, 1967).
Step.frb P2S5 or B2S3 or SiS2 or Lawesson's reaģent in a chlorinated solvent (e.g. chloroform) or in an aromatic solvent (e.g. benzene, toluene, xylene) at reflux (Dean et al., J. Chem. Soc. C., 2192, 1963; R.K. Razdan et al., J. Med. Chem., 21, 643, 1978; K.Clausen et al., Tetraheāron, 37, 3635, 1991). Step 6c COCI2 without solvent or with an inert solvent (e.g. benzene) at 40-90*C (A. Schonberg et al., Chem. Ber., 101. 701, 1968). 30 SCHEME6
2 3 LV 10099 31
fltfiP-M
Thioacetic or thiobenzoic acid or potassium diethylxantogenate in a suitable solvent (e,g. benzene) at reflux (A. Schonberg, supra). 5
Reaction Scheme 7, in which A has the same meaning as in Reaction Scheme 1, leads to compounds in which W represents a methylene or hydroxymethylene group. The compounds (1), (2) and (4) of Reaction Scheme 7 can be 10 prepared according to Reaction Schemes 1, 2, 5 and 6. The substituent A in compounds (7) of Reaction Scheme 7 can be transformed by the processes of Step lg into a substituent B as defined in Reaction Scheme 1. 15 Step 7a 1,2-ethanedithiol or 1,3-propanedithiol in an aprotic solvent (e.g. dichloromethane or benzene or toluene) at 0-110*C in the presence of a catalyst (e.g. p-toluenesulphonic acid or borontrifluoride 20 etherate).
StfiP_7b R2COCH2R3 in a suitable mixture of solvents (e.g. EtOAc or dichloromethane plus EtOH or MeOH) saturated with gaseous HC1 at 0-40’C; then agueous 25 HCIO4 in AcOH at 20-100*C (L. Jurd, Tetrahedron, 25, 493, 1972).
Step 7g L1AIH4 in THF at reflux (if A is other than COOR and NO2); 30 - Znl2 and sodium cyanoborohydride (6 eguivalents) in a chlorinated solvent (e.g. 1,2-dichloroethane) at room temperature to reflux (C.K. Lau et al., J. Org. Chem., £1, 3083, 1986). 5.tep-JZ.d 35 - Raney-Ni in an alcoholic solvent (e.g. isopropanol) at r.t. to reflux (Hilton et al., J. Am. Chem. Soc., 6887, 1968). 32 SCHEME7
3 5 LV 10099 33
Step 7e
NaBH4 in a suitable solvent (e.g. MeOH or EtOH or DMSO) at -10 to 50*C (L. Jurd, aupra); L1AIH4 in THF (or another suitable solvent) at 5 0-50*C (when A is other than COOR or NO2) (Degani et al., Ann. Chim., 51, 793, 1971; Kurosawa, Buli. Chem. Soc. Jpn., 51, 1175, 1978). step 7t
Trityl perchlorate in acetonitrile at room 10 temperature (Degani et al., eupra).
Step 7q
Melting with P2O5 at 80-180*C (Hortmann et al., J. Am. Chem. Soc., 55, 6118, 1974).
Step 7h 15 - NaBH4 in EtOH or another suitable solvent at 0’C to reflux (K. Anaya, Buli. Chem. Soc. Jpn., 45/ 1884, 1967) .
Hydrogen (1-10 atm) in EtOH (or another suitable solvent) in the presence of a catalyst such as 5% 20 or 10% Pd/C or Raney-Ni or Pt02 at r.t. to 80*C (K.
Hanaya, eupra). Not when A is CH=CH-CH3. When A=N02 it is simultaneously reduced to NH2.
Aluminium triisopropoxide in isopropanol at room temperature to 92*C. 25
Reaction Scheme 8 shows the preparation of simple starting materiāls such as (4), (5), (6) and (9), where A has the same meanings as in Reaction Scheme 1. Compounds (1), (2), (3), (7), (8) can be prepared 30 according to Reaction Scheme 1, 2, 4, 5, 7, 9, 11. The substituent A in compounds (4), (5), (6) and (9) of
Reaction Scheme 8 can be transformed by the processes of Step lg into a substituent B as defined in Reaction Scheme 1. 35 34SCHEME8
R8 = H, Ac LV 10099 35
Step.....8a
Pb(OAc)4 in a suitable solvent (e.g. benzene, toluene) at reflux (G.A. Russel et al., J. Am. Chem, Soc., 1906, 1975). 5
Step.flb 10
NaBH4 in alcohols (see Reaction Scheme 7, Step 7a), then alkaline hydrolysis (when A=COOR it can be simultaneously converted into COOH); aluminium isopropoxide as described in Reaction Scheme 7, Step 7f; 15 diborane in THF at -10’C to r.t.; then aqueous H2O2 in the presence of NaOH (not when A is CH=CH-CH3; when A=COOR it is simultaneously converted into COOH).(Kirkiacharian et al., C.R. Hebd. Seaucea Acad. Sci. Ser. C., 289. 227, 1979); L1AIH4 and AICI3 in a suitable solvent (e.g. THF) at 0*C to reflux (not for A=COOR or NO2) (Bokadia et al., J. Chem. Soc., 4663, 1961).
Step 8c 20
Hydrogen (100 atm), copper chromite in EtOH at 140'C, see M.A. Vickars, Tetrahedron, 2SL·, 2873, 1964. Vihen A=N02 it is simultaneously converted into a NH2 group.
Step 8d 25 30 KMn04 in t-butanol (or another suitable solvent) in the presence of agueous NaOH at -10 to 0*C. (K. Hanaya, Buli. Chem. Soc. Jpn., M, 1884, 1967). (Not when A is CH=CH-CH3). (See also A.H. Haines, Methods for the Oxidation of Organic Compounds, Academic Press Inc, (London), 1985, chapter 3.2.2). Osmium tetroxide (see A.H. Haines, supra, chapter 3.2.1) in a suitable solvent (e.g. ET2O) at room temperatūre (Baranton et al., Buli. Soc. Chim. Fr., 4203, 1968) (not when A is CH=CH-CH3); aqueous H2O2 in formic or acetic acid at -20 to -50*C; then NaOH, H2O, 45*C (Baranton et al., supra; A.H. Haines, supra, chapter 3.2.7) (not when 35 36 A is CH=CH-CH3; when A=COOR it is simultaneously converted into COOH); silver acetate and iodine in wet AcOH at 0-20*C (K. Hanaya, supra/ A.H. Haines, supra, chapters 3.2.3, 3.2.4, 3.2.9) (Not when A is CH=CH-CH3). - 30¾ H2O2 in the presence of NaHC03 in benzonitrile at 0-110*C, then L1AIH4 in THF at 0-40*C (not for A=COOR and CH=CH-CH3) (Clark et al., Aust. Journ. of Chem., 21. 865, 1974).
Step 8f
Hydrogen (1-50 atm) in a suitable solvent (e.g. EtOH) in the presence of a metallic catalyst (e.g. PdCl2) at r.t. to 78'C. (when A=N02 it is simultaneously converted into NH2)· (Bolger et al., Tetraheāron, 21. 341, 1967).
Step 8g
See Step 8b (Clark et al., supra).
StSP ,8¾ 0.4 M cerium trichloride heptahydrate in MeOH, in a suitable solvent (e.g. MeOH); then NaBH4 at 0*C to 78‘C. (WO 89/06650);
NaBH4 in diglyme at 0*C to reflux (G.P. Thakar, ladian J. Chem., 2., 74, 1965) (when A=N02 it is converted into NH2)»
NaBH4 and AICI3 in a suitable solvent (e.g. THF or benzene) at 0’C to reflux (not with A*COOR) (G.P. Thakar, supra); diborane in THF at room temperature (not when A is CH=CH-CH3) (G.P. Thakar, supra). LV 10099 37
Simple starting materiāls having W=CH2 and a single bond at position 2,3 may be prepared according to Reaction Scheme 9 where A has the same meanings as in Reaction Scheme 1. Compounds (1) of Reaction Scheme 9 may be 5 prepared according to Reaction Scheme 6. Compounds (1) of Reaction Scheme 9 may alternatively be obtained from compounds (2) by conversion of the latter into a 4-toluenesulphonic acid ester or a methanesulphonic acid ester or into a halogenoderivative, which may be 10 transformed into a thioether derivative (1) by nucleophilic substitution with a thiol. These simple conversions can be performed by techniques known to those skilled in the art. Compounds (2) of Reaction Scheme 9 may be prepared according to Reaction Scheme 7. 15 Compounds (3) of Reaction Scheme 9 where P=OC(S)-aryl or OC(S)-heteroaryl or 0C(S)0-alkyl or 0C(S)0-aryl or OC(S)S-alkyl may be obtained by reacting compounds (2) with the appropriate chlorothioformate or chlorothiocarbonate or 1,1'-thiocarbonyl-diimidazole as 20 described in J. Org> Chem., 55., 924, 1990 and Synthesi8, 362, 1991 and references cited therein. Compounds (4) may be obtained from compounds (1) or (3) by simple elimination reactions with bases. Compounds (5) may be obtained according to Reaction Scheme 4. The substituent 25 A in compounds (6) of Reaction Scheme 9 can be transformed by the processes of Step lg into a substituent B as defined in Reaction Scheme 1. 38 SCHEME9
R8 = Alkyl, aryl, heteroaryl, H or nothing P = halogen, 0-tosyl, 0-mesyl, OC(S)aryl, OC(S) heteroaryl, 1 -imidazolyl, 0C(S)0-aryl, OC(S)0-heteroaryl LV 10099 39
Stsp..3a
Raney-Ni in a suitable solvent (e.g. isopropanol) at r.t. to 100*C. When A is NO2 it is simultaneously converted to NH2; 5 - triethyltin hydride in benzene or another aromatic solvent at 30-150‘c. For other methods like nickel chloride and NaBH4 in MeOH or borane-pyridine complex in trif luoracetic acid or in dichloromethane in the presence of AICI3, (J. 10 March, Advanced Organic Chemiatry, page 728, Jj.
Wiley and Sons, New York, 1992 and references cited therein. (Not when A is CH=CH-CH3).
StSP, 3b
Hydrogen with a catalyst according to Reaction 15 Scheme 8, Step 8f. When A is NO2 it is simultaneously converted to NH2.
Stap„3c
Where P is an )-C derivative: tributyltin hydride or tris(trimethylsilyl)silane 20 in the presence of azaisobutyronitrile in a suitable solvent (e.g. toluene) at 80-150*C; (M. Drescher, Synthesi8, 362. 1991; M. Sekine, J. Org. Chem., 55, 924, 1990);
a silane (e.g. triethylsilane or diphenylsilane) in 25 a suitable solvent (e.g. dichloromethane) at -20*C to reflux in the presence of CF3COOH or BF3 (F.M. Mauser, J. Org. Chem., 55/ 555, 1990); triethylchlorosilane, sodiura iodide in acetonitrile; then Zn. powder in AcOH and 30 acetonitrile at r.t. to 80*C (T. Morita et al.,
Syntheei8, 32, 1981).
Where P is halogen or an O-S derivative: a reducing aģent (e.g. sodium cyanoborohydride in hexamethylphosphotriamide or NaBH4 in DMSO) chosen 35 from those cited in J. March, Advanc. Org. Chem., J. Wiley, New Yourk, 1992, chapter 0-76, 0-77. 40 steg 9.d
Hydrogen (1-5 atm) in a suitable solvent (e.g. EtOH) in the presence of a catalyst (e.g. 10% Pd/C at 50-78*C) (Sarcevic, Helv. Chim. Acta, 3£, 1457, 5 1973). (When A=N02 it is simultaneously converted to NH2);
Zn and gaseous HC1 in Et20, or Ac20 in toluene at 0-80'C. (Todah, Buli. Chem. Soc. Jpn., 45./ 264, 1972) (not for A=N02). 10 jStep .Sq
Zn and aqueous HC1 in a suitable solvent (e.g. EtOH) at 0-78*C; - according to Step 9d above (when A=N02 it is simultaneously converted to NH2); 15 - hydrazine, NaOH in ethane-1,2-diol at 200 *Č (Chemical Ahatracta, TAt (1971): 22699) (not for A=CCOR, N02) or other methods cited in J. March, aupra (not for A=CCOR, NO2); according to Step 7c (not for a=N02).
Reaction Scheme 10 shows routes to compounds in which w represents a valence bond and X represents an oxygen atom or a sulphur atom. 20 LV 10099 41ŠCHEME 10
A = COOAIk, N02, CH3 B = COOH, NH2 42
Step IPa
According to Step la, but utilizing R3COCI or (R3CO)2O instead of R3CH2COCI or (R3CH2CO)20, with or without isolation of the intermediate phenyl ester; hexamethylenetetramine in CF3COOH at reflux followed by addition of aqueous HC1. IfA=COOAlk, it may be hydrolysed to COOH in such strong acid conditions, and thus need re-esterefication with the appropriate alcohol (e.g. using thinyl chloride at reflux temperature) before step 10c.
Step lQh R3COCH(R2)Hal in acetone or methyl ethyl ketone or dichloromethane or chloroform in the presence of a suitable base such as K2CO3, NEt3 or NaH, at 20-80 *C.
Step 10c R2CH(Hal)COOAlk in an aprotic solvent, e.g. DMF, in the presence of a base, e.g. K2CO3, at 70-100*C followed by hydrolysis of the crude intermediates with a strong base (e.g. KOH) in a protic solvent such as EtOH at reflux, and finally submitting to decarboxylation - dehydration conditions using a non-protic solvent (e.g. xylene) and an acid catalyst (e.g. p-toluenesulphonic acid) at reflux or simply heating at 240*C in quinoline; R2CH2Hal and KOH in refluxing EtOH followed by cyclization of the isolated intermediate phenyl(thio)ether with sodium methoxide in a boiling DMF/MeOH mixture. When A is COOAlk, intermediates (4) having A=COOH can be obtained; using ArCOCH2Br and K2CO3 in acetone at reflux, Compounds (4), having R2=ArCO, are obtained.
Step lOd
Vigorous stirring in preheated polyphosphoric acid at 90-140’C; LV 10099 43
Lewis acid (e.g. AICI3) in chlorobenzene at 70-90*C. The cyclizations carried out on Compounds (3) having R3=C1 with a Lewis acid (e.g. AICI3) in o-dichlorobenzene at 45*C or with BP3 in Et20 at 5 20-25*C gives the Compounds (4) where R3=OH, as reported by K. Davies, J. Chem. Soc. P.T., 1, 2624, 1957 for compounds having X=S and R2=H.
Sten lOe
Sodium alcoholate (1 eguivalent) in the same 10 alcohol at 0-90’C; when A=COOAlk it may be suitable to use the corresponding AlkOH as reaction solVent; When R2=COOAlk and X=S, compounds (4) can be hydrolyzed to the corresponding R2=COOH with sulphuric-acetic acid mixture, (if A=COOAlk is 15 present, it also can give A=COOH), and can be selectively decarboxylated with copper in anhydrous guinoline at 210-220’C, to give compounds (4) where R2=H according to J. Cooper et al., J. Chem. Soc. (C), 3405, 1971. 20 Sten lOf R2CH2XH and one equivalent of sodium in EtOH at reflux or with NaHC03 in EtOH:water mixture at 60-90’C.
Step lQg 25 - When A=COOAlk or NO2, the methods described in Step lg can be used. It must be noted that reduction of the NO2 group to the NH2 group by catalytic hydrogenation can simultaneously afford hydrogenation of the double bond at position 2-3, 30 as reported by S.L. Meisel et al., Heterocyclic
Compounds, Ed. Interscience Publ.: "Compounds with Condensed Thiophene Rings", p. 34, 1954 and M.
Ahmed, ibidem, Ed. Wiley-Interscience: "Benzofu-rans", p. 56, 1974.
When A=N02 and R2=COAr the reduction carried out with hydrogen in the presence of Pt on carbon as 35 5 4410 15 20 25 30 catalyst gives the 2,3-dihydro compounds (5) where B=NH2 and R2=CH2Ar as reported in W0 86/07056; when A=CH3 and R2, R3/ R6 are not CH3 or R2 does not bear a CH3 group, the compounds can be transformed into the corresponding; A=CH2Br by reaction with N-bromosuccinimide in CCI4 and 2,2'-azobisisobutyronitrile or benzoyl peroxide as catalysts at reflux; A=CHO by reaction of the above compounds with hexamethylenetetramine in refluxing chloroform followed by acid hydrolysis of the salt in boiling AcOH or by reaction of compounds having A=CH3 with tetrabutylammonium dichromate in refluxing chloroform according to Valenti et al., Arzneim. Forech., M/ 122, 1990; A=COOH by oxidation of the above compounds (A=CH0) with silver oxide in a mixture of protic agueous solvent (e.g. EtOH-DMF at 0-70*C according to H.R. Rodriguez et al., Tetrahedron, 24/ 6 587, 1968) or with KMn04 in t-butanol in the presence of NaH2P04 agueous solution at 70-75*C according to S. Maruzama et al., Tetrahedron Letters, 27., 4537, 1986. Compounds (4) of the above Reaction Scheme 10 having R3=C6H5 or t-butyl, R2=H and X=0 can be transformed into the corresponding intermediates having R2=C6H5 or t-butyl and R3=H by reacting with polyphosphoric acid at 132’C according to Davies et al., J. Chem. Soc., 822, 1958.
When X represents a nitrogen atom and W has other claimed meanings except a valence bond, the simple 35 starting materiāls may be prepared according to the following Reaction Scheme 11. LV 10099 45 SCHEME 11
A = COOAIk, N02 R - H, aikyl 46
Step Uft
EtOC(R2)=C(COOEt)2 at 80-140*C without solvents or in a polar solvent (e.g. isopropanol).
Stgp 11¾ R2COC(R3)COOAlk and p-toluenesulphonic acid or methanesulphonic acid in a chlorinated solvent (e.g. chloroform or dichloromethane) or aprotic solvent (e.g. benzene) at reflux under azeotropic conditions.
Step lļg
Heating in Ph2 0 in the presence of p-toluenesulphonic acid or phosphoric acid or ZnO as catalysts at 245-255'C according to Hung. Teljies 6251 (Chemical AbatractB, 7J2., 92026v, 1973); heating in a high boiling solvent (e.g. PI12O) followed by hydrolysis of the not isolated compounds (4) (R3=COOEt) with a strong acid (e.g. HC1) in a protic solvent (e.g. acetic acid)at reflux to give compounds (4) where R3=COOH. The above isolated acids can be decarboxolated by heating in a high boiling solvent (e.g. PI12O) to give compounds (4) where R3=H according to R. Albrecht et al., Ber., 105. 3118, 1972.
SteP-Ufl
Heating in a high-boiling solvent (e.g. PI12O) at 2 5 5 * C; when R=Alk compounds (4) are obtained directly from compounds (1), without isolation of compounds (3), by condensation with R2COCH (R3 )COOAlk in polyphosphoric acid at 90-150*C according to F. Piozzi et al., Gazz. Chim. It., 100. 678, 1970. ste P JJ.e
Al/Hg amalgam in agueous EtOH solution at reflux followed by acidification with a strong acid (e.g. HC1) and treatment with FeC.13 at reflux according to W.A. Denny et al., J. Med. Chem., 22, 396, 1989; LV 10099 47 when A=COOAlk compounds (4) should be hydrolyzed to the corresponding A=COOH before performing Step Īle; when A=N02/ intermediates (5) having A=NH2 are obtained.
Step, Uf R2CH=CHCHO and arsenic acid in a strong acidic medium (e.g. concentrated H2SO4) and water at 105-115'C according to EP 0206802.
When A=COOAlk, compounds (1) should be hydrolyzed to the corresponding A=COOH before performing Step llf. Ali compounds (1) have R=H and the obtained compounds (5) have R3+H.
Step ll.g R2CH(Hal)-CH(R3)COOH in a protic solvent (e.g. water) in the presence of a strong base such as NaOH at 100-125*C followed by cyclization of the isolated compounds β-anilinopropionic acids with preheated polyphosphoric acid at 120-125*C or with phosphorous pentoxide in a high-boiling aprotic solvent (e.g.xylene) at 120-140*C. In some cases, it is useful to start from compounds (1), where R=tosyl or other suitable protective groups; the obtained compounds (6), where R=tosyl, can be easily converted into compounds (6), where R=H, by hydrolysis with a strong acid (e.g. HC1) in a protic solvent (e.g. AcOH) at reflux.
When A=COOAlk, compounds (6) having A=COOH, are obtained.
Step llh R2CHO and ethylene in AcOH and HCl at 25-30*C according to K.D. Hesse, Liebigs Ann. Chem., 741. 117, 1970. Where compounds (1) have R=H starting materiāls (7), having R=R3=H are obtained; epichlorohydrin followed by cyclization of the isolated anilinopropanol derivatives in refluxing N,N-diethylaniline or o-dichlorobenzene in the 48 presence of a proton acceptor (e.g. NEt3) according to S.D Boyd et al., J. Org. Chem., 10., 2801, 1965. In this case, compounds (7) having R=R2=H and R3=OH are obtained.
Step 11i
By hydrogenation in the presence of a catalyst (e.g. platinum oxide) in a protic solvent (e.g. EtOH) at 20-30*C and 2-4 atm according to G.M. Coppola, J. Heter. Chem., 1$, 645, 1978.
When A=N02, compounds (7) having A=NH2 are obtained.
Compounds (4), (6) and (7) thus obtained can be converted to the corresponding derivatives having A=C00H or NH2 according to the methods of Reaction Scheme 1, Step lg.
The synthesis of the simple compounds (7) of Reaction Scheme 11 having R=H and A=COOH can be also pursued using the method showed in the Reaction Scheme 12. SCHEME 12
W = CH2 orbond 3. LV 10099 49
Step 12a
OxalyI chloride in a polar solvent (e.g. THF) at reflux followed by internai Friedel-Crafts acylation of the crude chlorooxalylamide with a Lewis acid (e.g. AICI3) in a non-polar solvent (e.g. CS2) at reflux, according to EP 0402859.
Step 12 b 30-35% aqueous H2O2 and a strong base (e.g. NaOH) in a polar solvent (e.g. water) at 20-30*C followed by addition of a strong acid (e.g. HC1), as reported in EP 0402859.
Reaction Schemes 13 and 14 lead to simple starting materiāls in which X represents an imino group and W represents a valence bond. In these two Reaction Schemes, Ά has the same meanings as in Reaction Scheme 1.
Step 13a CICH2C(Cl)=CH2 in the presence of K2CO3 at 40-80’C according to L. Purdie, J. Chem. Soc. (C), 1126, 1970.
Step 13b R2COHal in pyridine or in a chlorinated solvent (e.g. dichloromethane) in the presence of proton acceptor (e.g. NEt3) at 20-100'C or in a polar solvent (e.g. acetone) in the presence of K2CO3 at 20-80 *C.
Step 13c BF3 in MeOH at 130 tO 155*C; heating at 100 to 110‘C.
The compounds (5) obtained by Step 13c always have R2=CH3.
Step 13d R2COČH(OAlk)2 in a non polar solvent (e.g. toluene) in the presence of iodine as catalyst at reflux in 50 SCHEME13
LV 10099 51 azeotropic conditions followed by reduction of the isolated (or not isolated) imino compound with NaBH4 in a polar solvent (e.g. MeOH) in the presence of NaOH as catalyst at reflux. If A=COOAlk, it will be hydrolysed to COOH.
Step.-13e
Sodium amide in a high-boiling solvent (e.g. N/N-diethylaniline) at 220-250*C according to F. Piozzi et al., Gazz. Chim. It., S2., 1382, 1963/ potassium t-butoxide in a polar solvent (e.g. DMF) at 20-100*C according to EP 0042298.
Step_13.f BF3 in an apolar solvent (e.g. benzene) at 5 to 10‘C.
Stgp.13q
Zn or Fe dust in an acidic medium (e.g. AcOH) and water at 70-100*C. If A=N02, it will be reduced to NH2 · gfr<? P.J.3.&
Thionyl chloride at reflux. The resultant acyl chlorides are isolated, and reacted with sodium azide in an acidic medium (e.g. AcOH) at 10-20*C, subsequently heating at 50-70*C.
Step 13i
Diazotation with NaN02 in concentrated H2SO4 followed by agueous ZnCl2 addition at 5-10‘C and by reaction of the isolated diazonium salts with CH2=C(R2)COOH in a polar solvent (e.g. acetone) in the presence of a copper salt (e.g. CuCl2) at 25-30'C. Examples of Steps 13g, 13h and 13i are given by A. Allais et al., Eur. J. Med. Chem., 10. 187, 1975. gVtep. 13 j R2CH2NO2 in a polar solvent (e.g. EtOH) in the presence of a base (e.g. n-butylamine) and catalytic amounts of an acid (e.g. AcOH) at reflux. 52
The compounds (5) thus obtained can be converted to the corresponding derivatives having A=COOH or NH2 according to the methods of Reaction Scheme 1 Step lg.
With regard to Reaction Scheme 14, it is to be intended that compounds (4) having R3=H correspond to compounds (5) of Reaction Scheme 13.
Step 14a
NaN02 in agueous acidic medium (e.g. HC1) at -5 to +5*C; isoamyl nitrite in a polar solvent (e.g. BtOH) at 5-10 *C.
Step. .141?
Aqueous solution of S02 at 0-10*C according to Pfannstiel et al., Ber., 7JL, 1096, 1942; triphenylphosphine and heating of the isolated phosphonium salt in an aqueous-alcoholic HC1 solution at reflux according to Horner et al., Ber., &£, 1073, 1953.
Step Ms R2COCH(R3)Hal in a basie high-boiling solvent (e.g. N,N-diethylaniline) at 160-180’C or by simply heating without solvents at 180*C; R3COCH(R2)Hal in a polar solvent (e.g. acetone) in the presence of a suitable proton acceptor (e.g. K2CO3) at reflux followed by cyclization of the isolated β-anilinoketone intermediates with freshly melted ZnCl2 in a protic solvent (e.g. EtOH) at reflux; R2CH (Hal)CN in the presence of BCI3 and a Lewis acid (e.g. TiCl4) in an apolar solvent (e.g. benzene) at reflux followed by cyclization of the isolated 2-amino-a-haloacetophenones compounds with a suitable reducing aģent (e.g. NaBH4) in a polar medium (e.g. dioxane-water) at reflux, according to LV 10099 53 SCHEME14
R = Alkyl 54 T. Sagusawa et al., J. Org. Chem., 44, 578, 1979. By the above method, compounds (4), having R3=H are obtalned; R2COCH (R3 )Hal (half an equivalent) in a polar solvent (e.g. MeOH) at reflux followed by cyclization of the isolated Schiff base intermediates with a strong acid (e.g. CF3COOH) at 20-30 *C.
Step 14d R2COCH2R3 by heating at 100’C without solvents or at reflux in a polar solvent (e.g. MeOH) followed by cyclization of the isolated hydrazone compounds with polyphosphoric acid at 100-130*C or by simply heating in ethyleneglycol or aqueous formic acid or ethanolic formic acid; cyclization can be also carried out by heating in ethanolic HCl at reflux or in an AcOH/HCl mixture at reflux or in orthophosphoric acid at 95-105*C or by simply heating with anhydrous ZnCl2 at 100-220*C. When A=COOAlk, compounds (4) having A=COOH can be obtained.
Step 14e
Borane-pyridine complex at 0-30*C followed by a protonating aģent addition (e.g. HCl); tin or zinc and aqueous HCl at 50-100*C;
NaBH4 in the presence of a Lewis acid (e.g. AICI3) in pyridine at 0-30*C or alternatively in the presence of a salt like cobalt or zinc chloride; sodium borocyanohydride in AcOH at 20-80*C; hydrogen in the presence of a catalyst (e.g. Pt) in a polar solvent (e.g. EtOH) at 20-80*C.
Other general methods are reported by Houlihan in Heterocyclic Compounds, part one, Ed. wiley--Interscience; "Indoles", 462, 1972. When A=N02/ compounds (4) can be reduced to the corresponding compounds (5) having A=NH2. LV 10099 55
Step—llf
NaH and RHal in an anhydrous polar solvent (e.g. DMF) at 20-80’C; RHal in the presence of potassium carbonate in a polar solvent (e.g. acetone) at reflux; sodium amide and RHal in a polar anhydrous solvent (e.g. THF) at low temperature (-70*0.
Compounds (4), bearing other reactive groups such as NH2 or OH, have to be protected using suitable protective groups which can be selectively cleaved at the end by deprotecting methods.
Step 14q RHal in the presence of alkaline mētai carbonates (e.g. potassium carbonate) as reported by Houlian in Heterocyclic Compounds, part two, Ed. Wiley--Interscience: "Indoles", 90/ 1972 and references cited therein; compounds (5), bearing other reactive groups such as NH2 or OH, have to be protected as reported above.
Step 14.h tetrachloro-[1,4]-benzoquinone in a polar solvent (e.g. ethylene glycol monomethyl ether) at reflux; copper (II) chloride in pyridine at reflux according to Kikugawa et al., J. Heter. Chem., 1£., 1325, 1979.
Compounds (6) having R2 and R3 other than H, can be reduced to the corresponding starting materiāls (7) by lithium aluminium hydride according to H.C. Printy et al., J. Am. Chem. Soc., 71, 3206, 1949. Compounds (4) of Reaction Scheme 14 having R2=H and R3 =OH may be obtained from compounds (7) of Reaction Scheme 11 having R=R2=H and R3=OH by ring contraction using an oxidant (e.g. sodium periodate) and a base (e.g. NaOH) in aqueous EtOH at reflux according to S.D. Boyd et al., J. Org. Chem., 2801, 1965. 56
Starting materiāls (4), (5), (6) and (7) can be converted into the corresponding A=COOH or NH2 according to the method of Reaction Scheme 1, Step lg, and from these into the alternative final Products. When nh is present and might interfere on the following reactions, it can be protected as reported by T.w. Green in Protective Groupe in Organic Synthesi8, Wiley-Interscience, 1981. Alternatively, unreactive groups (e.g. N02) can be converted to reactive ones (e.g. NH2) as a final step of the pathway.
Starting materiāls in which W represents a valence bond, X represents an imino group and the 7-substituent is a carboxymethyl group can be obtained according to Reaction Scheme 15. S.tgp. 15a
Hydrogen in the presence of 10¾ Pd/C as catalyst at 45 lbs in water containing one eguivalent of NaOH, followed by diazotation with sodium nitrite in HC1 at 0-5‘C and stannous chloride. Cyclization is performed during acidification of the tin salt with H2S and completed by refluxing in xylene, see H.E. Baumgarten et al.,J. Am. Chem. Soc., £2., 3977# 1960. flfcep 15b R3CH2COR2 in the presence of an acid (e.g. acetic acid) in a polar solvent (e.g. EtOH) at reflux as reported by W.J. Vielstead et al., J. Med. Chem., 22, 1074, 1979 for R2=CH3 and R3=C6H5, where also Step 15c and 15d are reported.
Step 15c
Lower alkanol (e.g. MeOH, EtOH) at reflux in the presence of a hydrogen chloride stream. LV 10099 57 SCHEME15
Hoocr 5 58
Step 15fl A strong base (e.g. KOH) in a polar solvent (e.g. water) at reflux.
The preparation of simple starting materiāls having R3 = hydroxyalkyl and/or the corresponding ethers can be carried out by reacting either compounds (3) of Reaction Scheme 1, compounds (2), (4) or (5) of Reaction Scheme 2, compounds (4) of Reaction Schemes 6, 10, 11 and 15, compounds (5) of Reaction Scheme 13 and compounds (4) and (6) of Reaction Scheme 14 having R3=H, CH3 according to the Reaction Scheme 16, wherein A and B have the same meanings as in Reaction Scheme 1, R4 represents an alkyl or aralkyl group and R5 represents an H or alkyl group.
Step 16a R3=H, W=CO, CS (and no activated phenyl rings present): formaldehyde and HCl in water, EtOH or AcOH at 50-10 0 * C; chloromethyl methyl ether and fuming sulphuric acid at 50-70’C (H. Nakarumo et al., Buli. Chem. Soc. Jap., 12, 2323, 1984; R3=CH3, W=CO, CS, bond and no other methyl groups in the molecule: N-bromosuccinimide in presence of benzoyl peroxide or 2,2'-azobisisobutyronitrile in CCI4 at 50-80*C. Step Ižh r 3 =H, w=bond, x=0, s, NH or N-Alk and no electrondonating groups are present on the other rings of the molecule: phosphorous oxychloride and DMF at 50-140*C, or other Vilsmeyer-Haack reaģents (Jutz, Adv. Org. Chem., !, 225, 1976); LV 10099 59 SCHEME 16
R^-zAlkjAi-a.lk Rs = H, Alk 60 R3=CH3/ W=bond, X=0, S, NH or N-Alk and no other CH3 groups are present: irradiation with a Hg high-pressure lamp in a protic solvent (e.g. AcOH) at 20-100*C (Frasca et al., Tetrahedron, 603, 1973. fl.tep...USc
Sodium or potassium acetate in aprotic solvents (e.g. acetone, DMF) at 40-120*C.
Step 16d R5 in compounds (5) = H: a reducing hydride (e.g. NaBH4) in a polar solvent (e.g. MeOH or EtOH or dioxane) at 0-80*C; R5 in compounds (5) » alkyl: alkyl magnesium bromide in aprotic solvents (e.g. Et20, THF) at 0-60’C.
Step16s
NaOH or LiOH in protic solvents (e.g. alcohols, water) or mixture thereof at 25-50‘C. (In this case, when A=COOAlk it can be simultaneously hydrolized to COOH).
Step 16f
The same methods reported in Step lg of Reaction Scheme 1, but the oxidation of CH=CHCH3 to COOH for compounds (5).
Step 16g A strong base (e.g. NaH) and an R4-L reaģent (where L is an halogen atom or a tosyloxy group) in anhydrous aprotic solvents (e.g. DMF or THF) at 20-140 *C.
Step 16h R4OH and a base (e.g. Na, NaH) in excess R4OH or in aprotic solvents (e.g. DMF or THF) at 20-140*C.
The simple compounds (6) having an hydroxyalkyl group at position 3, obtained in this way, can be reacted as such or, alternatively, derivatized at the hydroxymethyl group with knovm reaģents and methods, so that said LV 10099 61 group does not interfere in the further reaction steps necessary to prepare those compounds of formula (I) which bear a protected hydroxyalkyl group such as R3. The protected final compounds are finally converted by deprotecting methods to compounds of formula (I) having R3 * hydroxyalkyl group.
Prodrugs, as above defined, may be prepared from the corresponding hydroxy compounds by Method 1 below or from the corresponding amide compounds by Method 2 below. - by reacting with a chloroformate, an isocyanate or isothiocyanate, a carbonyl chloride or bromide or another activated acid derivative (e.g. anhydride) in a suitable solvent (e.g. chlorinated solvent, DMF, THF, dioxane, acetonitrile, pyridine) in the presence or absence of a base (for instance, NEt3, pyridine, 4-dimethylaminopyridine, NaOH, potassium carbonate or I, 10-diazabicycloundecene or others not specified) at -20/100 *C; - by reacting with a carboxylic acid in the same solvents as above, in the presence of a condensing aģent such as N.N'-carbonyldiimidazole, carbodiimides or others known to the people skilled in the art; - by reacting with a dialkyl or diaryl chlorophosphate or dialkyl cyanophosphonate in the same conditions described above (for examples of such derivatization methods see Example 114 below and S.O. Thorberg et al., J. Med. Chem., 2008, 1987). 62
Method 3
Prodrugs derivatives of "acidic" NH groups according to "Compounds of the Invention" can be synthesized from the compounds of formula I considered in the chapter by preparing an N-hydroxy(substituted)methyl derivative and reacting that one exactly in the same conditions described above for oxygen derivatization.
The intermediate N-hydroxy(substituted)methyl derivative can be isolated or directly reacted to give the desired compound. N-hydoxy(substituted)methyl derivatives of the type Ny-CH(Ri)OH where Ri = H or CCI3 can be obtained by reacting the appropriate compounds of formula I with formaldehyde or CCI3CHO as described in H.E. Zaugg, Organic Reactions, 14, Chapter 2, 52, J. Wiley and Sons, New York, 1965 or in J.P. Chupp, J. Org. Chem., 28. 2592, 1965.
In the case where Ri phenyl said compounds can be synthesized by reacting with benzaldehyde and cyclic amine (e.g. morpholine) in MeOH or dichloromethane:MeOH 1:1 at 0*C to reflux and hydrolyzing the intermediate with 0.1N HC1 at pH 4. (0. Jacobseen, Annaien, 157. 243, 1884; H. Bundgaard et al., Int. J. Pharm., 22.t 45, 1984) .
Ali the above described reaction pathways and steps are to be intended as examples and are not limiting the scope of the invention. Those skilled in the art are aware that said Chemical transformations are performed on polyfunctional substrates and that the reaģents used might interfere, reacting also with other groups present in the molecules. For example, catalytic hydrogenation can transform nitro groups into amino groups as desired, but also isolated double bonds might be hydrogenated and halogen atoms removed; lithium aluminium hydride can LV 10099 63 reduce conjugated ketones to alkanes as desired (e.g Step 7c in Reaction Scheme 7) but also COOAlk groups to CH2OH or NO2 groups to -N=N- etc.. The undesired side reactions can be avoided or minimized by choosing the 5 appropriate conditions or by using alternative reaģents or different synthetic pathways. Should this "alternative" approach give negative results, the undesired obtained intermediates must be transformed into useful ones using methods knovm. to those skilled in 10 the art. 64
DETAILED PREPARATION OF INTERMEDIATES 8-(3-bromopropoxvcarbonvl)-3-methvl-4-oxo-2-phenvl-4H--1-benzopvran (Intermediate I) 30 g of 1,3-dibromopropane was added dropwise at ambient temperature to a suspension of 30 g of sodium 3-methyl--4-oxo-2-phenyl-4H-l-benzopyran-8-carboxylate in 150 ml of dimethylformamide and 35 ml of water. The reaction mixture was stirred at ambient temperature for 5 days. 100 ml of water was added and stirring was continued for a further 15 minūtes. The precipitate was filtered off by suction, washed with water and purified by flash chromatography on silica gel, eluting with chloroform:ethyl acetate 95:5. The collected fractions were evaporated to dryness in vacuo and the residue was recrystallized from ethanol to give 27.7 g of the title compound, m.p. 114-115*C.
The benzopyran carboxylate salt used in the foregoing synthesis was prepared by dissolving 104 g of the corresponding acid in 560 ml of hot methanol and adding 280 ml of an aqueous solution of 31 g of sodium hydrogen carbonate. 850 ml of acetone was added to the solution to precipitate the desired salt, which was collected by suction filtratioii (62g, m.p. > 280*0 . The corresponding acid was prepared according to Da Re, P. et al.,J. Med. Pharm. Chem., 2, 263, 1960. 8-hvdroxvmethvl-3-methvl-4-oxo-2-phenyl-4H-1-benzopvran (Intermediate II) 467 ml of a 1.48N solution of sodium borohydride in anhydrous dimethylformamide was added over a period of 30 minūtes, under stirring at ambient temperature, to a solution of 100 g of 3-methyl-4-oxo-2-phenyl-4H-l-benzo-pyran-8-carbonyl chloride in 1 litre of anhydrous dimethylformamide. The reaction mixture was stirred for 21/a hours at ambient temperature. 88 ml of 2N hydrochloric acid was added while maintaining the LV 10099 65 temperature at 0-5’C. 102 ml of 12.7N sodium hydroxide solution was then added. The mixture was poured into 6 litres of water, stirred for 3 hours, and filtered on a Buchner funnel. The fllter cake was washed with 4N sodium hydroxide solution and then with water. The resultant white solid was crystallized from methanol to give 50 g of the title compound, m.p. 145-147*C. E-_a.- (2-carboxyvinvI)^3-inethyl-4-ΟΧΟ-2-Phenyļ-4H-1--benzopvran (Intermediate III) A mixture of 7.92 g of 8-formyl-3-methyl-4-oxo-2-phenyl--4H-l-benzopyran (prepared as described in K. Uneyama et al., Buli. Chem. Soc. Jap., 33, 2361, 1985), 3.75 g of malonic acid and 0,46 ml of piperidine in 15 ml of anhydrous pyridine was stirred at 100'C for 3 hours. After cooling to 20-25*C the reaction mixture was poured into a mixture of 90 g of crushed ice and 33 ml of hydrochloric acid (d=1.18). The resultant precipitate was collected by suction filtration, washed with water and crystallized twice from 95% ethanol to give 5.5 g of the title compound, m.p. 226-229*C. E-8-(2-chlorocarbonvlvinvl)-3-methvl-4-oxo-2-phenvl-4H--1-benzopvran (Intermediate IV) A solution of 9.2 g of Intermediate III and 7.8 g of thionyl chloride in 75 ml of toluene was refluxed for 3 hours. After cooling to 20-25*C the resultant crystals were collected by suction filtration, washed with acetone and dried in vacuo to give 6.8 g of the title compound, m.p. (190) 196-198*C after recrystallization from toluene. 8-acetvl-3-methvl-4-oxo-2-phenvl-4H-l-benzopyran (Intermediate V) 1.17 g of magnesium turnings, 7.4 ml of anhydrous ethanol and 0.2 ml of anhydrous carbon tetrachloride were placed in a round bottomed flask under a stream of 66 nitrogen. When the temperature began to rise, 7.5 ml of anhydrous chlorobenzene was added, followed by the slow dropping (25 minūtes) of a solution of 5.28 ml of anhydrous diethylmalonate and 3.5 ml of anhydrous chlorobenzene in 16 ml of anhydrous ethanol. The reaction flask was heated to 75’C for two hours, cooled to 25’C and a solution of 8.8 g of 3-methyl-4-oxo-2--phenyl-4H-l-benzopyran-8-carbonyl chloride in 88 ml of anhydrous chlorobenzene was slowly added/ without exceeding 35*C. The reaction mixture was further stirred for two hours at 35’C and then cooled to O’C. 13 ml of water and 1.9 ml of sulphuric acid (d=1.84) were added. The solution obtained was decanted from the insoluble inorganic matter and stripped in vacuo.
The crude acylmalonate obtained was refluxed for six hours with 10.4 ml of acetic acid, 7 ml of water and 1.3 ml of sulphuric acid (d=1.84). After cooling, the solution was poured into iced water and the precipitate was collected by suction filtration and washed with aqueous sodium carbonate. Crystallization from 90% ethanol gavē 6.5 g of the title compound, m.p. 159-161’C. 8-hromoacetvl-3-methvl-4-oxo-2-phenvl-4H-1-benzonvran (Intermediate VI) A solution of 11.2 g of bromine in 250 ml of chloroform was added, over a period of two hours at 20-25’C, to a solution of 19.5 g of the Intermediate V in 700 ml of chloroform. After stirring for 1 hour at 20-25’C, the solution was washed with 400 ml of 2N aqueous sodium hydroxide solution and then repeatedly with water, dried with anhydrous sodium sulphate and stripped in vacuo. The crude product was treated with diethyl ether, collected by suction filtration and crystallized from acetone, yielding 16 g of the title compound, m.p, 134-135’C. LV 10099 67 8-(2-hvdroxvethvlcarbajaovl)-3-methvl-4-oxo-2-phenvl-4H--l-benzoovran (Intermediate VII)
The title compound was prepared in the same manner as intermediate XXXVI, but using 2-aminoethanol instead of 3-aminopropanol. M.p. 206-208’C. 3-methvl-4-oxo-2-phenvl-4H-1-benzopvran-8-sulphonvl chloride (Intermediate VIII) A solution of 4.55 g of sodium nitrite in 12 ml of water was added dropwise to a stirred mixture of 15.1 g of 8-amino-3-me thy1-4-oxo-2-pheny1-4 Η-1-benzopyran [prepared as described in Da Re, P. et al., II. Farmaco (Ed. Sci.), 11, 67 0, 1956] in 150 ml of hydrochloric acid (d=1.18) at -5'C. Stirring was continued at 0*C for 30 minūtes. The solution was poured, over a period of 10 minūtes and at -5 to 0’C, into 120 ml of a 30¾ by weight solution of sulphur dioxide in acetic acid containing 1.53 g of cupric chloride dihydrate and 13 ml of water. After 1 hour at 0’C and 1 hour at 20-25*C, 300 ml of iced water was added to the mixture. A precipitate formed and was collected by suction filtration, washed with water and dried in a desiccator over sodium hydroxide until of constant weight to give 18 g of crude title product, m.p. 165-170’C, for use without further purification. 8-(3-chloropropoxy)-3-methyl-4-oxo-2-phenvl-4H-l--benzoovran (Intermediate IX)
This compound was prepared in the same manner as Intermediate XI, but using l-bromo-3-chloropropane instead of l-bromo-2-chloroethane. M.p. 98-102*C after washing with Petroleum ether:diethyl ether 7:3. 68 8-acrvlamido-3-methvl-4-oxo-2-phenvl-4H-l-benzopvran (Intermediate X) A solution of 1.75 ml of acryloyl chloride in 15 ml of anhydrous tetrahydrofuran was added dropwise at -10*C to a stirred mixture of 5 g of 8-amino-3-methyl-4-oxo-2--phenyl-4H-l-benzopyran and 3 ml of triethylamine in 60 ml of anhydrous tetrahydrofuran. After stirring at 0*C for 1 hour and at ambient temperature for 1 hour, the reaction mixture was poured into water and filtered under suction. The filter cake was washed with water. Dessication gavē 5.5 g of the title compound, m.p. 229-230 *C. B-(2^chloroethoxy)-3-methvl-4-oxo-2-phenvl-4H-l--benzopvran (Intermediate XI) A mixture of 7.52 g of 8-hydroxy-3-methyl-4-oxo-2--phenyl-4H-l-benzopyran (prepared as described in Da Re, P. et al./ Ann. Chim.,p.506 et seq., 1962), 6.22 g of anhydrous potassium carbonate and 25.5 ml of l-bromo-2--chloroethane in 70 ml of dimethylformamide was stirred at 60*C for 25 hours. The mixture was cooled to 20-25*C and poured into 600 ml of vrater. The organic solution, obtained by extraction with dichloromethane, was washed with agueous sodium chloride solution and dried on anhydrous sodium sulphate. The solvents and excess l-bromo-2-chloroethane were evaporated off in vacuo to yield 8.8 g of the title compound, m.p. 141-142*C after crystallization from chloroform:hexane. 8-(2-azidoethoxv)-3-methvl-4-oxo-2-phenvl-4H-l--benzopvran (Intermediate XIX) A mixture of 15.2 g of Intermediate XI and 6.24 g of sodium azide in 150 ml of anhydrous dimethylformamide was stirred at 70-75’C for 12 hours. After cooling to 20-25 *C, the reaction mixture was poured into V-/2 litres of water and extracted with dichloromethane. The organic solution was washed with agueous sodium chloride LV 10099 69 solution and dried on anhydrous sodium sulphate. The solvents were evaporated off in vacuo. The residue was taken up in water, collected by suction filtration and dried to give 14 g of the title compound, m.p. 119-5 120 *c. 8- [N- (2-hydroxvethyl)_-iarntethyl-carbaiņovl] -3-methvl-4--0X0-2-phenvl-4H-l-benzoOvran (Intermediate XIII) A solution of 1.6 ml of 2-methylamino-ethanol in 10 ml 10 of water was added dropwise over a period of 5 minūtes to a suspension of 6 g of 8-chlorocarbonyl-3-methyl-4--oxo-2-phenyl-4H-l-benzopyran and 1.52 g of potassium carbonate in 60 ml of acetone. After stirring for 21t2 hours at 20-25*C, the solvent was removed in vacuo and 15 the residue was taken up in 150 ml of acetone. The mixture was refluxed for 15 minūtes, and was then filtered. The solvent was evaporated from the filtrate and the residue was dissolved in 20 ml of dimethylformamide, treated with 14 ml of 1.4% sodium 20 carbonate solution, stirred for 30 minūtes at 20-25*C and diluted by addition of 150 ml of water. The mixture was extracted with chloroform and the organic layer was washed with 0.5N hydrochloric acid and then with water. The solution was dried over anhydrous sodium sulphate 25 and the chloroform was evaporated off. The resulting oil was taken up in 200 ml of diethyl ether and stirred for 2 hours at 20-25’C. The solīds were collected by filtration and crystallized from ethyl acetate to give 4.97 g of the title compound, m.p. 128-130’C. 30 8-(2-chloroethylcarbamovl)-3-methvl-4-oxo-2-phenvl-4H-l--benzopvran (intermediate XIV)
The title compound was prepared in the same manner as Intermediate XXXVII, but using Intermediate VII in place 35 of Intermediate XXXVI and carrying out the reaction at ambient temperature. M.p. 181-182*C (ethyl acetate). 70 8-(N-methvl-2-chloro-ethvlcarbamovl)-3-methvl-4-oxo-2--phenvl-4H-l-benzopvran (Intermediate XV) A solution of 1.1 ml of thionyl chloride in 2 ml of dichloromethane was added to a solution of 3.37 g of Intermediate XIII in 20 ml of dichloromethane/ and the mixture was stirred for 4 hours at ambient temperature. Removal of the solvent gavē an oil which was taken up in diethyl ether. The title compound precipitated as a white solid, collected by filtration for use without further purification. M.p, (118) 126-128*C (diethyl ether). 8 - (4 -bromobu toxy) -3-methvl-4-oxo-2-phenyl-4H-l-_ -benzopyran (intermediate XVI) A mixture of 5 g of 8-hydroxy-3-methyl-4-oxo-2-phenyl--4H-l-benzopyran, 4.2 g of anhydrous potassium carbonate and 4 3.6 g of 1,4-dibromobutane in 45 ml of dimethylformamide was stirred at 75*C for 2 hours. The mixture was cooled to 20-25*C, poured into 100 ml of water and extracted with dichloromethane. The organic solution was washed with aqueous sodium chloride solution and dried on anhydrous sodium sulphate. The solvents and excess 1,4-dibromobutane were evaporated off in vacuo. The residue was rinsed with 55 ml of Petroleum ether:diethyl ether 7:4 and collected by suction filtration to yield 5.6 g of the title compound, m.p. 91-92’C. 9 (5 - bf 0mĢpĢntylQxy) - 3 -methvl - 4 - qxq-2-phenyl - 4H -1 --benzopvran (intermediate XVII)
This compound was prepared by the method described for the preparation of Intermediate XVI, but using 1,5-dibromopentane in place of 1,4-dibromobutane and purifying the crude product by column chromatography on silica gel (elution with dichloromethane:ethyl ether 99:1). M.p. 75-76*C, after rinsing with Petroleum ether:diethyl ether 30:4. LV 10099 71 8- (2-chloroethoxvmethvl) -3-methvl-4-oxo-2-phenvl-4H-l--benzopvran (Intermediate XVIII) 6 ml of thionyl chloride in 18 ml of chloroform was added at O'C to a stirred solution of 23 g of Intermediate XXII and 11 ml of triethylamine in 185 ml of chloroform. The reaction mixture was warmed to 70*C and stirred for 2 hours. After cooling to ambient temperature, it was poured into water. The organic layer was separated, washed with sodium chloride solution, dried on anhydrous sodium sulphate and evaporated to dryness in vacuo. Yield: 24 g of the title compound. A sample crystallized from ethanol had a melting point of 102-103 *C. 8-chloromethvl-3-me thvl-4-oxo-2-phenv1-4H-1-benzopvran (intermediate XIX) 53.4 g of Intermediate II and 38.8 ml of anhydrous triethylamine were dissolved in 440 ml of chloroform. into this solution, maintained at -10 to -2’C, there was dropped a solution of 19.8 ml of thionyl chloride in 80 ml of anhydrous chloroform. The reaction mixture was stirred at ambient temperature for 4 hours, and then diluted with 4 00 ml of water, The aqueous phase was extracted with chloroform, and the extracts were added to the chloroform phase. The chloroform solution was washed with brine, dried on anhydrous sodium sulphate and evaporated to dryness in vacuo. Yield: 56 g of the title compound, which on recrystallization from ethanol was shown to have a melting point of 112-113’C. 8-methvlaminomethvl-3-methvl-4-ΟΧΟ-2-phenvl-4H-l--benzopvran (intermediate XX) A solution of 15.1 g of anhydrous zinc chloride and 14.5 g of sodium cyanoborohydride in 400 ml of anhydrous methanol was added dropwise at 0*C into a stirred mixture of 58.8 g of 8-formyl-3-methyl-4-oxo-2-phenyl--4H-l-benzopyran, 60.7 g of methylamine hydrochloride 72 and 125 ml of triethylamine in 600 ml of anhydrous methanol. After stirring for 5 hours at 20-25*C, the solvent was evaporated off in vacuo and the residue was taken up in 200 ml of water and collected by suction 5 filtration. The crude product was dissolved in aqueous acetic acid, washed with ethyl acetate and reprecipitated by addition of cold 6N sodium hydroxide solution. 49 g of the title compound was obtained. M.p. 97-99‘C, after crystallization from 75¾ ethanol. 10 8-(2-chloroethvlthiomethvl)-3-methyl-4-oxo-2-phenvl-4H--1-benzopvran (Intermediate XXI) A solution of 37 g of Intermediate XIX and 10.5 g of thiourea in 370 ml of ethanol was refluxed for 1 hour. 15 The reaction mixture was cooled to ambient temperatūra, and 42 g of 8-amidinothiomethyl-3-methyl-4-oxo-2-phenyl-“4H-l-benzopyran spontaneously crystallized. A sample recrystallized from ethanol had a melting point 233-235 *C. 20 48 ml of 35% agueous sodium hydroxide solution was added to a vigorously stirred suspension of 35 g of the compound thus prepared and 1.05 g of benzyl triethylammonium chloride in 440 ml of 1,2-dichloroethane. The mixture was stirred for 21/, hours 25 and then poured into 300 ml of water. The agueous layer was extracted with 1,2-dichloroethane and the extracts were added to the organic layer which was washed with sodium chloride solution, dried on anhydrous sodium sulphate, and evaporated to dryness in vacuo. The 30 residue was crystallized from methanol, giving 22 g of the title compound, m.p. 82-83*C. 8- (2-hvdroxvethoxvmethvl) -3-methvl-4-oxo-2-phenvl-4H-l--benzopvran (Intermediate XXII) 35 A solution of 2.5 g of Intermediate XIX in 25 ml of xylene and 3 ml of dioxane was prepared. 0.15 g of sodium was dissolved in 3.10 ml of anhydrous ethylene LV 10099 73 glycol, and this solution was added dropwise at ambient temperature to the solution of Intermediate XIX. After refluxing for 51^ hours, the reaction mixture was cooled to ambient temperature and poured into 50 ml of water. It was extracted with dichloromethane, and the extract was washed with sodium chloride solution, dried on anhydrous sodium sulphate and evaporated to dryness in vacuo. The solid residue was recrystallized from ethanol, giving 2.1 g of the title compound, m.p. 132-133 *C. 8-trifluoEoacetamido-3-methvl-4-oxo-2-Phenvl-4H-1--benzoovran (Intermediate XXIII) A solution of 9.5 ml of trifluoroacetic anhydride in 20 ml of anhydrous dichloromethane was added dropwise at -5 to O’C to a solution of 5 g of 8-amino-3-methyl-4-oxo-2--phenyl-4H-l-benzopyran in 50 ml of anhydrous dichloromethane. The reaction mixture was stirred for 2 hours at 20-25*C and then poured on to crushed ice. The organic solution obtained by extraction with dichloromethane was washed with cold 5% agueous sodium bicarbonate solution and with water, and was dried on anhydrous sodium sulphate. The solvent was removed in vacuo and the residue was crystallized from ethanol to give 5.2. g of the title compound, m.p. 175-176’C. 8-aminomethvl-3-methvl-4-oxo-2-phenvl-4H-l-benzopvran (Intermediate XXIV) A mixture of 21 g of Intermediate XXIX and 19 g of trlphenylphosphine in 160 ml of tetrahydrofuran was stirred at ambient temperature for 8 hours. Thin layer chromatography showed the disappearence of Intermediate XXIX. 3 ml of water was added, and stirring was continued for a further 24 hours. The solvents were removed on a rotary evaporator, and the residue was dissolved in water as its acetate. The agueous solution was washed with ethyl acetate, made basie with 37% 74 sodium hydroxide solution and filtered on a Buchner funnel. The filter cake was washed with water and desiccated to give 18 g of the title compound. The hydrochloride, recrystallized from ethanol, had a 5 melting point of 256-258’C. 8-(2-chloroethvlsulPhonvlmethvl)-3-methvl-4-oxo-2--phenvl-4H-l-benzopyran (Intermediate XXV) 41.6 ml of agueous 30% hydrogen peroxide was added 10 dropwise at 40’C over a period of 20 minūtes to a solution of 26.2 g of Intermediate XXI in 300 ml of glacial acetic acid. The mixture was heated to 60*C, stirred at that temperature for 4χ/3 hours, cooled to ambient temperature and poured into 60 ml of water. 15 Filtration on a Buchner funnel gavē a filter cake which was washed with water and desiccated, yielding 29.4 g of the title compound. A sample was crystallized from ethanol. M.p. (89) 159-161*C. 20 8-(2-chloroethvlsulphinvlmethvl)-3-methvl-4-oxo-2- -phenvl-4H-l-benzopvran (Intermediate XXVI) 36 ml of agueous 30% hydrogen peroxide was quickly added dropwise at 10*C to a solution of 12 g of Intermediate XXI in 84 ml of glacial acetic acid. The reaction 25 mixture was stirred for 4 hours at ambient temperature, and then poured into 220 ml of water. The title compound was collected by suction filtration, washed with water and desiccated. Yield 12.4 g, m.p. 142-145‘C (methanol). 30 8-ΓΝ-methvl-N-(2-chloroethvl)-aminomethvll-3-methvl-4- -oxo-2-phenvl-4H-l-benzopvran (Intermediate XXVII) A mixture of 22 g of Intermediate XX, 66 ml of 1-bromo--2-chloroethane and 11 g of anhydrous potassium carbonate in 88 ml of dimēthylformamide was stirred at 35 20-25’C for 12 hours. The reaction mixture was then poured into 600 ml of water and extracted with dichloromethane. The organic layer was washed with LV 10099 75 water, dried on anhydrous sodium sulphate and acidified with ethanolic hydrogen chloride. The solvent and the excess l-bromo-2-chloroethane were distilled off in vacuo at 70-80*C. The residue was taken up in cold 1N aqueous sodium hydroxide solution and extracted with dichloromethane. The organic solution was washed with water, dried on anhydrous sodium sulphate and evaporated to dryness in vacuo at 25-30*C. The crude title product was purified by flash chromatography on silica gel, eluting with ethyl acetate:petroleum ether 7:3, to give 18 g of the title compound melting at 118-120’C after crystallization from ethanol. 1-(2-hvdroxy-2-methylpropvl)-4-(2-methoxvphenvl)--pjperazine (Intermediate XXVIII) A mixture of 7 g of 1-(2-methoxyphenyl)-piperazine, 7.33 g of anhydrous potassium carbonate, 1.75 g of potassium iodide and 5.6 ml of l-chloro-2-methyl-2-propanol was stirred for 90 minūtes at 70*C and for a further 6 hours at 90*C. The reaction mixture was poured into iced water and extracted with ethyl acetate. The organic layer was washed with agueous sodium chloride solution, dried on anhydrous sodium sulphate and evaporated to dryness in vacuo. The title product was obtained as an oil, and was characterised as its dihydrochloride, crystallized from ethanol, melting at 225-227’C. 8-az idomethvl-3-methvl-4-oxo-2-phenvl-4H-1-benzopvran (Intermediate XXIX) A mixture of 22.8 g of Intermediate XIX and 6.8 g of sodium azide in 110 ml of dimethylformamide was stirred for 3 hours at 100’C. After cooling to ambient temperature, 130 ml of water and 88 ml of ethanol were added to the reaction mixture. After 1 hour, the crystals were collected by vacuum filtration, washed with water, and desiccated. Yield: 22 g of the title 76 product. A sample recrystallized from ethanol hada melting point of 132-134’C. 8-f N- (2-hvdoxyethvl)-aminomethvl1-3-methvl-4-oxo-2--phenvl-4H-l-benzopvran (Intermediate XXX) A solution of 2.38 g of anhydrous zinc chloride and 2.30 g of sodium cyanoborohydride in 71 ml of anhydrous methanol was added dropwise under stirring to a mixture of 9.24 g of 8-formyl-3-methyl-4-oxo-2-phenyl-4H-l--benzopyran and 9.12 g of ethanolamine in 90 ml of anhydrous methanol. Stirring was continued at 20-25’C for 5 hours, before removal of the solvent in vacuo. 250 ml of water was added to the residue/ and the insoluble matter was collected by suction filtration and washed with water. The crude product was dissolved in ln acetic acid and the solution was washed with ethyl acetate. The agueous solution was then made alkaline by addition of 2N sodium hydroxide solution and the precipitate was collected by suction filtration and washed with water to give 8.5 g of the title compound, m.p. 117-121*C after drying at 60*C. 8-(N-methvl-N-chloracetvl-aminomethvl) -3-methvl-4-oxo--2-phenvl-4H-l-benzopvran (Intermediate XXXI) A solution of 6 ml chloracetyl chloride in 60 ml of 1,2-dichloroethane was added dropwise at -5 to 0*C to a solution of 20 g of Intermediate XX and 10 ml of triethylamine in 200 ml of 1,2-dichloroethane. After stirring at 20-25’C for 2 hours, 150 ml of water was added to the reaction mixture and the phases were separated. The organic phase was washed with water and dried on anhydrous sodium sulphate. The solvent was removed in vacuo, and the rsidue was crystallized from ethanol to give 22.5 g of the title compound, m.p. 146-148’C. LV 10099 77 8 -chlorace t amidomet hvl - 3 -me thvl -4 -oxo-2-phenvl-4H-1--benzopvran (Intermediate XXXII) A solution of 3.2 ml of chloracetyl chloride in 32 ml of 1.2- dichloroethane was added dropwise, under stirring at -5*C, to a mixture of 10 g of Intermediate XXIV and 5.5 ml of triethylamine in 80 ml of 1,2-dichloroethane. The reaction mixture was stirred at ambient temperature for 1 hour and then 150 ml of water was added. The phases were separated; the aqueous phase was extracted with 1.2- dichloroethane and the extracts were added to the organic phase which was then washed with a cold saturated solution of sodium bicarbonate, washed with water, dried on anhydrous sodium sulphate and evaporated to dryness in vacuo. The residue was crystallized from ethanol to give 10.7 g of the title compound, m.p. 152-155’C. 8- ΓΝ-acetvl-N- (2-chloroethvl> -am-Īnnmethvll -3-methvl-4--oxo-2-Dhenvl-4H-l-benzopvran (Intermediate XXXIII) 8.65 g of Intermediate XXX and 4.15 ml of triethylamine were dissolved in 70 ml of tetrahydrofuran. To this solution, at -10*C, there was added dropwise over a period of 40 minūtes a solution of 2.35 ml of acetyl chloride in 23 ml of tetrahydrofuran. After stirring for 3 hours at 0-10’C and for 2 hours at 20-25*C, the solvent was evaporated off in vacuo. 100 ml of water was added to the residue, and extraction with dichloromethane was effected, pooling the successive organic extracts and then removing the solvent in vacuo. The residue was dissolved in 50 ml of methanol and 3 g of potassium carbonate and 10 ml of water were added. After stirring at 50*C for 20 minūtes, to hydrolyse the N,0-diacetyl derivative which had formed, the solvent was removed in vacuo and the residue was treated with water and dichloromethane as above described. The dichloromethane solution was again evaporated to dryness, and 5.9 g of 8-[N-acetyl-N-(2-hydroxyethyl)- 78 -aminomethy1]-3-methyl-4-oxo-2-pheny1-4H-1-benzopyran, m.p. 171-172’C, was obtained. 3.6 ml of thionyl chloride in 30 ml of dichloromethane was added dropwise at O'C to a solution of 6.1 g of the compound thus prepared in 70 ml of dichloromethane. After stirring for 90 minūtes at 20-25’C, the reaction mixture was washed with water and dried. The sovent was removed in vacuo to give the crude title product for use without further purification. 8-(3-chloropropvlthio)-3-methvl-4-oxo-2-phenvl-4H-l--benzoovran (intermediate XXXIV) A solution of 20.1 g of stannous chloride dihydrate in 18 ml of hydrochloric acid (d=1.18) was added over a period of 5 minūtes at 65’C to a solution of 6 g of Intermediate VIII in 70 ml of acetic acid. After 10 minūtes, the reaction mixture was cooled to 30-35’C and the solvent was removed in vacuo. The residue was taken up in water, and the insoluble matter was collected by suction filtration, washed with water and dried. Yield: 3.2 g of 8-mercapto-3-methyl-4-oxo-2-phenyl-4H-l--benzopyran, melting at 115-118’C after crystallization from ethanol. A mixture of 8 g of the compound so prepared, 27 ml of l-bromo-3-chloro-propane, 0.2 g of tetrabutylammonium bromide and 6.2 ml of 35¾ sodium hydroxide in 80 ml of benzene was vigorously stirred for 4 hours at 20-25’C. 100 ml of water and 40 ml of dichloromethane were added. The organic layer was separated off, washed with water and dried on anhydrous sodium sulphate. The solvents and excess l-bromo-3-chloro-propane were removed in vacuo. The residue was purified by column chromatography on silica gel, eluting with Petroleum ether:ethyl acetate 9:1, and 5.7 g of the title compound was obtained. After crystallization from methanol, it showed a melting point of 84-86’C. LV 10099 79 8-(3-chloropropvlsulphonvl)-3-methvl-4-oxo-2-Phenvl-4H-“1-benzopvran (Intermediate XXXV) 7 ml of 30% hydrogen peroxide was added at 20-25*C to a solution Of 3.45 g of Intermediate XXXIV in 35 ml of 5 acetic acid. After stirring for 4 hours at 60‘C, the reaction mixture was cooled to 20-25*C. 30 ml of water was added. A precipitate formed, and was collected by suction filtration, washed with water and dried, yielding 3.4 g of the title compound. After 10 crystallization from acetone, it showed a melting point of 160-163 *C. 8-(3-hvdroxvt>ropvlcarbamovl)-3-methvl-4-oxo-2-phenvl-4H--1-benzopvran (Intermediate XXXVI) 15 A solution of 7.6 ml of 3-aminopropanol in 50 ml of water was added dropwise over a period of 30 minūtes to a suspension of 30 g of 3-methyl-4-oxo-2-phenyl-4H-l--benzopyran-8-carbonyl chloride and 15.2 g of potassium carbonate in 400 ml of acetone. The thick suspension was 20 stirred for 3 hours at 20-25*C. The solvents were removed in vacuo and the residue was taken up in 300 ml of water. After stirring for 1 hour, the precipitate was collected by suction filtration and washed with water. The crude product was purified by crystallization from 25 95% ethanol and 23.8 g of the title compound were obtained, m.p. 191-193*C. An additional 4.7 g of the title compound was obtained by concentration in vacuo of the crystallization filtrate. 30 8-(3-chloropropvlcarbamovl)-3-methvl-4-oxo-2-phenvl-4H- -1-benzopvran (Intermediate XXXVII) A solution of 1.1 ml of thionyl chloride in 2 ml of chloroform was added to a boiling solution of 3.37 g of
Intermediate XXXVI in 20 ml of chloroform. After 35 stirring for 90 minūtes under reflux, the solvent was removed in vacuo and the residue was crystallized from 80 acetonitrile to give 3 g of pure title compound, m.p. (188) 193-194'C. 8-n-hvdroxv-4-(4-methvlphenvlsulphonvloxv)-butvll-3--methvl-4-oxo-2-phenvl-4H-l-benzopvran (Intermediate XXXVIII) 1.12 g of sodium cyanide in 3 ml of water was added at 20-25*C to a stirred mixture of 3.96 g of 8-formyl-3--methyl-4-oxo-2-phenyl-4H-l-benzopyran, 2.61 g of morpholine and 4.48 g of p-toluenesulphonic acid in 20 ml of tetrahydrofuran and 30 ml of 1,2-dichloroethane. The reaction mixture was refluxed for 4 hours, and then 10 ml of cold water was added. The tetrahydrofuran was distilled off at normai pressure, and 10 ml of 1,2-dichloromethane and 10 ml of chloroform were added. The organic phase was separated, washed with aqueous sodium chloride solution, dried over anhydrous sodium sulphate and evaporated to dryness in vacuo. The residue was suspended in diethyl ether, filtered off, and crystallized from chloroform:ethyl acetate. Yield: 3.55 g of 8-(morpholino-cyanomethyl)-3-methyl-4-oxo-2-phenyl--4H-l-benzopyran, m.p. 236-238*C. 3.5 ml of a 30¾ solution of potassium hydroxide in anhydrous methanol was added under stirring at ambient temperature to a suspension of 22.8 g of the compound thus prepared in 520 ml of anhydrous tetrahydrofuran. 6.3 ml of acrylonitrile in 20 ml of tetrahydrofuran was dropped into this suspension, and the reaction mixture was stirred at ambient temperature for 1 hour. The solvents were evaporated off in vacuo. Crystallization of the residue from methanol gavē 23.22 g of 8-(1,3--d icyano-1-morpho1ino-propy1)-3-methyl-4-oxo-2-phenyl--4 Η-1-benz opyran. 23.2 g of the compound thus prepared was dissolved in 250 ml of dioxane. 250 ml of 6M hydrochloric acid was added and the mixture was refluxed for 21^ hours. After cooling to ambient temperature, the mixture was poured LV 10099 81 into 7 00 ml of agueous sodium chloride solution and extracted with ethyl acetate. The extracts were washed with agueous sodium chloride solution and treated with 7 00 ml of 1M sodium hydroxide solution. The aqueous layer was washed with ethyl acetate and acidified with 37¾ hydrochloric acid. The precipitate was collected by suction filtration and crystallized from ethanol to give 10.2 g of 8-(3-carboxy-l-oxopropyl)-3-methyl-4-oxo-2--phenyl-4H-l-benzopyran, m.p. 191-192*C.
Diborane, generated by dropping a solution of 2.1 ml of freshly distilled boron trifluoride diethyl etherate in 10 ml of anhydrous diglyme into 19 ml of a 0.66M solution of sodium borohydride in diglyme, was bubbled into a suspension of 2.28 g of the compound thus prepared in 23 ml of anhydrous tetrahydrofuran, stirred at 0 *C under nitrogen flux. Stirring was continued for 20 minūtes at 0*C and for further 20 minūtes at ambient temperature. Methanol was cautiously dropped into the mixture at 0’C to quench the reaction. The solvents were removed by evaporation in vacuo. The residue was purified by flash chromatography on silica gel, eluting with petroleum ether:ethyl acetate 3:7. The collected fractions were evaporated in vacuo to leave 2 g of 8-(1,4-dihydroxybutyl)-3-methyl-4-oxo-2-phenyl-4H-l--benzopyran, m.p. 133-134*C. 2.8 g of p-toluenesulphonyl chloride was added at 0*C to a stirred solution of 3.17 g of the compound thus prepared in 32 ml of anhydrous pyridine. The mixture was stirred for 6 hours at 0*C and stood ovemight at -4*C without stirring. It was then poured into 200 ml of agueous sodium chloride solution, acidified with 10 ml of 12N hydrochloric acid and filtered under suction. The filter cake was dissolved in chloroform, and the solution was washed with aqueous sodium chloride solution and dried on anhydrous sodium sulphate. The solvent was distilled off in a rotary evaporator. The residue was purified by flash chromatography on silica 82 gel, eluting with Petroleum ether:ethyl acetate 1:1. The collected fractions were evaporated to dryness in vacuo, yielding 3.04 g of pure title product, m.p. 123-124*C. 4-Γ 4 - (2-methoxyphenvl)-1-pjperazinvll-butvraldehvde (Intermediate XXXIX) A solution of 5.4 g of 2-(3-chloropropyl)-dioxolan and 15.9 g of 1-(2-methoxyphenyl)-piperazine in 60 ml of dimethylformamide was stirred at 80*C for 4 hours. After cooling to 20-25’C, the reaction mixture was poured into 500 ml of ice cold 0.5N sodium hydroxide solution and extracted with dichloromethane. The organic phase was washed with water and dried on anhydrous sodium sulphate. The solvent was removed in vacuo/ and the residue was purified by flash chromatography on silica gel, eluting with dichloromethane:ethanol 95:5. 9.8 g of 2-{3-[4-(2-methoxyphenyl)-l-piperazinyl]-propyl}--dioxolan was obtained as an oil. NMR CDCL^ (δ) 1.5-2.0 (4H, m, CH2CB2CH) 2.2-3.2 (10H, r m 5 x CH2N) 3.7-4.0 (7H, m, OCH3 and 2 x OCH2) 4.8 (1H, t, OCHO) 6.7-6.9 (4H, m, aromatic protons). A solution of 12.8 g of the compound thus prepared in 200 ml of tetrahydrofuran and 420 ml of IN hydrochloric acid was maintained at 20-25*C for hours. It was then made alkaline with 5N sodium hydroxide solution and immediately extracted with dichloromethane. The organic layer was washed with water and dried on anhydrous sodium sulphate. The solvent was evaporated off in vacuo, and the residue was purified by flash chromatography on silica gel, eluting with dichloromethane smethanol 97:3. 6.4 g of the title compound was obtained as an oil. LV 10099 83 NMR .CPCfo— 1.5-2.0 (2H, m, CH2CH2CH2) 2.2-2.8 (8H, m, 3 x CH2N and CH2CHO) 2.9-3.2 (4H, m, 2 x CH2NAr) 3.8 (3H, s, OCH3) 6.8 (4H, s, aromatic protons) 9.3 (1H, s, CHO) . 8- (2.3-βΡΟχνΡΓΟΡΟχν)-3-methvl-4-oxo-2-phenvl-4H-l--benzopvran (Intermediate XL) 7 ml of 2,3-epoxypropyl chloride was added dropwise at 20-25*C to a stirred mixture of 5 g of 8-hydroxy-3--methyl-4-oxo-2-phenyl-4H-l-benzopyran and 9.7 ml of 2N sodium hydroxide in 10 ml of ethanol. After 6 hours at 20-25*C, the reaction mixture was poured into 100 ml of water and the precipitate which formed was collected by suction filtration. After drying and purifying by flash chromatography on silica gel (eluant Petroleum ether: ethyl acetate 65:35), there was obtained 4.45 g of the title compound, m.p. 128-129’C. 8-rN-methvl-2-(4-methvlPhenvlsulphonvloxv)-ethvlsuloha-movlT-3-methvl-4-oxo-2-phenvl-4H-l-benzopvran (Intermediate XLI) A solution of 5 g of Intermediate Vili in 60 ml of dichloromethane and 20 ml of tetrahydrofuran was added dropwise at 0’C to a mixture of 2.5 ml of 2-methylaminoethanol and 2.1 ml of triethylamine in 20 ml of dichloromethane. After stirring for 2 hours at 20-25’C, 100 ml of water and 100 ml of dichloromethane were added to the reaction mixture. The phases were separated and the organic solution was dried on anhydrous sodium sulphate. The solvent was removed in vacuo, and the residue was purified by column chromatography on silica gel, eluting with petroleum ether:ethyl acetate 3:7. There was thus obtained 4.5 g of 8-(N-methyl-2--hydroxyethylsulphamoyl)-3-methyl-4-oxo-2-phenyl-4H-1- 84 -benzopyran, melting at 146-147’c after crystallization from ethanol.
The compound thus prepared was converted to the title compound by p-toluenesulphonylation according to the 5 second step of the procedūra described below for the preparation of Intermediate XLII. The title compound was used without purification. 8-Γ2- (4-methylphenylsulphonvloxv)-ethvlsulphamovlļ-3-10 -methvl-4-oxo-2-phenvl-4H-l-benzopvran (inetrmediate XLH0 A solution of 5 g of Intermediate VIII in 37 ml of tetrahydrofuran was added dropwise at 0*C to a mixture of 2.5 ml of ethanolamine and 2.5 ml of triethylamine in 15 25 ml of tetrahydrofuran. After stirring at 20-25*C, the reaction mixture was poured into 400 ml of water. A precipitate formed, and was collected by suction filtration, washed with water and air dried, yielding 4.6 g of 8-(2-hydroxyethylsulphamoyl)-3-methyl-4-oxo-2-20 -phenyl-4H-l-benzopyran, melting at 186-187*C after crystallization from ethyl acetate. 2.1 g of p-toluenesulphonyl chloride was added portionwise at O'C to a solution of 3.6 g of the compound thus prepared in 25 ml of pyridine. After 6 25 hours at 20-25'C, the reaction mixture was slowly poured on to crushed ice containing a slight excess of hydrochloric acid. A precipitate formed and was collected by suction filtration and washed with water. 4.9 g of the title compound was obtained, melting at 30 (163) 166-169’C after crystallization from ethyl acetate. 8- (3-aminopropvlcarhaTnnyi.) -3-methvl-4-oxo-2-phenvl-4H-l--benzopvran hvdrochloride (Intermediate XLIII) 35 A solution of 21.6 g of 3-methyl-4-oxo-2-phenyl-4H-l--benzopyran-8-carbonyl chloride in 250 ml of anhydrous tetrahydrofuran was dropped at 0-10*C into a stirred LV 10099 85 solution of 17 g of 3-(2-methyl-2-propoxycarbamoyl)--propylamine (prepared as described in Saari, W.S. et al., J. Med. Chem., 3_i, 97, 1990) and 13 ml of triethylamine. After stirring for 2 hours at ambient temperatūre, the reaction mixture was poured into water and filtered to recover 12.3 g of 3-(2-methyl-2--propoxycarbamoyl)-propyl-3-methy1-4-oxo-2-pheny1-4H-1--benzopyran-8-carboxamide which was recrystallized from ethanol. M.p. 178-180*C. A solution of 4.3 ml of trifluoroacetic acid in 15 ml of anhydrous dichloromethane was added dropwise at -5’C under stirring to a solution of 3.3 g of the compound thus prepared in 35 ml of anhydrous dichloromethane. After warming to ambient temperatūre, the mixture was stirred for 8 hours. The dichloromethane and the excess trifluoroacetic acid were evaporated off at 20-25‘C using a rotary evaporator. The oily residue was dissolved in dichloromethane and IN sodium hydroxide solution was added. The organic layer was washed with water, dried on anhydrous sodium sulphate and filtered. Excess ethanolic hydrogen chloride was added to the filtrate, and the solvent was removed in vacuo. The residue was crystallized from ethanol to give 1.5 g of the title compound, m.p. 253-255’C. 8-(2-chloroethvlureido)-3-methvl-4-oxo-2-phenvl-4H-l--benzopvran (Intermediate XLIV) 4 ml of 2-chloroethyl isocyanate were added, under stirring at ambient temperature, to a solution of 3.9 g of 8-amino-3-methyl-4-oxo-2-phenyl-4H-l-benzopyran in 52 ml of anhydrous dimethylformamide. Stirring was continued at 70’C for 5 hours. Water was added to the reaction mixture, which was then extracted with ethyl acetate. The organic phase was evaporated to dryness in vacuo. The residue was suspended in diethyl ether under stirring. The title product was then filtered off and 86 recrystallized from methanol. Yield 3.74 g, m.p. 213-214 * C. (Z.E) -8-(4- Γ2- (1,3-dioxanvl) 1 -1-butenvl)-3-methvl-4-oxo--2-phenvl-4H-l-benzopvran (Intermediate XLV) 1.6 ml of 2.5N butyllithium in hexane was added dropwise at -20’C to a solution of 1.53 g of 2-[2-(l,3--dioxanyl)]-ethyl triphenylphosphonium bromide in 10 ml of anhydrous tetrahydrofuran. The mixture was stirred for 20 minūtes at -20*C. A solution of 0.8 g of 8-formyl-3-methyl-4-oxo-2-phenyl-4H-l-benzopyran in 11 ml of anhydrous tetrahydrofuran was dropped into the mixture, which was then warmed to 0*C over a period of 90 minūtes and then to ambient temperature over a period of 30 minūtes. The reaction was quenched by addition of methanol. The solvents were evaporated off in vacuo and the residue was purified by flash chromatography on silica gel, eluting with ethyl acetate:Petroleum ether 3:7, to give the title compound, as a mixture of diastereoisomers E and Z, m.p.(93) 98-100’C. The ratio of the two isomers was determined by NMR spectroscopy and resulted in E:Z = 65:35. NMR CDCIn (5) 8.1- 8.2 (m, 1H, CH in position 5 of the benzopyran ring) 7.2- 7.8 (m, 7H, other aromatic CH groups of the benzopyran and phenyl rings) 6.9 (dt, 1H, Fl'-CH of the E isomer) 6.8 (dt, 1H, Fl'-CH of the Z isomer) 6.4 (dt, 1H, F1'-CH=CH of the E isomer) 5.9 (dt, 1H, F1'-CH=CH of the Z isomer) 4.6- 4.7 (m, 1H, OCHO) 3.6- 4.2 (m, 4H, OCH2O of the dioxane ring) 2.4-2.7 (m, 2H, CHCH2CH) 1.9-2.3 (m, 5H, CH3 and CH2 in position 5 of the dioxane ring). LV 10099 87 8-(4- [2-(1,3-dioxanvl)Ί-butvl>-3-methvl-4-oxo-2-phenvl--4H-1-benzopvran (intermediate_XLVI) A mixture of 0.2 g of 10¾ palladium-on-carbon catalyst and of 1 g of Intermediate XLV in 24 ml of methanol was hydrogenated in a Parr apparatus at ambient temperature with a hydrogen pressure of 1.5 atmospheres. After the theoretical hydrogen consumption, the catalyst was filtered off and the solvent was removed by evaporation in vacuo. The residue was crystallized from cyclohexane to give the title eompound, m.p. 118-119.5*C. 8-carboxvmethvl-3-methvl-4-oxo-2-phenvl-4H-l-benzopvran (Intermediate XLVII) 4.5 g of potassium permanganate was added, portionwise over a period of ll/2 hours under stirring at 0-10’C, to a mixture of 2.76 g of 8-allyl-3-methyl-4-oxo-2-phenyl-4H--l-benzopyran (P. Da Re, US 3,350,411), 0.17 g of
Aliquat 336, 1.12 ml of acetic acid, 56 ml of dichloromethane, 3.2 ml of sulphuric acid (d=1.84) and 60 ml of water. Stirring was continued at ambient temperature for 5 hours. 3.4 g of sodium metabisulphite were added portionwise at 0-5"C within 15 minūtes. The organic layer was separated, washed with water and extracted with 60 ml of IN aqueous sodium hydroxide solution. The aqueous phase was acidified by addition of dilute hydrochloric acid and extracted with ethyl acetate. The organic phase was washed with water, dried on anhydrous sodium sulphate and, after filtration, evaporated to dryness in vacuo. The residue was treated with carbon tetrachloride and the solid was collected by suction filtration to give 1 g of the title eompound, m.p. 191-192'C (acetinitrile). 8-(4-chlorobutvramido)-3-methyl-4-oxo-2-phenvl-4H-l--benzoovran (Intermediate XLVIII)
The title eompound was prepared in the same manner as Intermediate X, but using 4-chlorobutyryl chloride 88 instead of acryloyl chloride. The solid obtained, filtered from water and dried, was rinsed with hot diethyl ether and collected by suction to give the title compound. A sample, crystallized from 50% aqueous ethanol and washed with diethyl ether, melted at (153) 162-164 *C. 8 -me thvlamino- 3 -me t hvl - 4 -oxo - 2 -phenvl - 4 Η-1 -benzopvran (Intermediate xlix) A solution of 0.5 g of Intermediate XXIII in 1.5 ml of anhydrous dimethylformamide was added dropwise under stirring, at -5*C, to a suspension of 0.045 g of sodium hydride (80% in mineral oil). After stirring at room temperature for 1 hour, 0.092 ml of methyl iodide in 0.6 ml of anhydrous dimethylformamide was added dropwise. Then the reaction mixture was stirred at 50 *C for 1 hour, cooled to 20*c, poured into water, filtered by suction and dried at 60 *C for 3 hours to recover 0.6 g of 8-(N-methyltrifluoroacetamido)-3-methyl-4-oxo-2--pheny1-4 Η-1-benzopyran. NMR CDCM (6) 8.15 (dd, 1H, benzopyran CH in 5) 7.10-7.60 (m, 7H, other benzopyran and phenyl CH3) 3.30 (s, 3H, CH3-N) 2.10 (s, 3H, benzopyran CH3 in 3). A mixture of 0.44 g of the above compound and 0.05 g of sodium borohydride in 4 ml of ethanol and 1 ml of dimethylsulphoxide was stirred at room temperature for 1 hour, and then quenched with an excess of 4N hydrochloric acid. After removal of ethanol by evaporation in vacuo, the residue was rinsed with water, then with 3N sodium hydroxide and extracted with ethyl acetate. The organic layer was washed with water, dried on anhydrous sodium sulphate and evaporated to dryness in vacuo. The solid residue was crystallized from LV 10099 89 ethanol to give 0.22 g of the title compound, melting at 143-146 * C. 8-(N-methvlacrvlamido)-3-methvl-4-oxo-2-phenvl-4H-l--benzopvran (Intermediate L)
This compound was prepared in the same manner as Intermediate X, but using Intermediate XLIX instead of 8-amino-3-methyl-4-oxo-2-phenyl-4H-l-benzopyran. instead of diluting with water, THF was removed by evaporation in vacuo and the crude residue was dissolved in ethyl acetate and washed with water. The organic solution was dried on anhydrous sodium sulphate and evaporated to dryness in vacuo to give the title compound. A sample, purified by column chromatography on silica gel (eluting with ethyl acetate:petroleum ether 4:6) and crystallized from cyclohexane, melted at 136-137’C. 1-C2-(1,3-dihvdro-l,3-dioxo-2H-isoindol-2-yloxv)-ethvll --4-(2-methoxvphenvl)-piperazine (Intermediate LI) A mixture of 6.73 g of N-hydroxyphthalimide, 3.73 g of sodium acetate and 10 g of 1-(2-chloroethyl)-4-(2--methoxyphenyl) -piperazine in 100 ml of anhydrous dimethylsulphoxide was stirred at 100’C for 4 hours. The reaction mixture was then cooled to room temperature, poured into water and extracted with ethyl acetate. The collected organic layers were washed with IN sodium hydroxide, dried on anhydrous sodium sulphate and evaporated to dryness in vacuo to give 7.58 g of the title compound. A sample was crystallized from cyclohexane and found to melt at (76) 80-83*C. 1-(2-aminooxvethvl)-4-(2-methoxvphenvl)-piperazine hvdrochloride (Intermediate LII) A solution of 6.59 g of Intermediate LI and 1.10 ml of 85% hydrazine hydrate in 130 ml of 95% ethanol was refluxed for 4 hours. Ethanol was remowed by evaporation in vacuo. The residue was rinsed with water and then 90 with an excess of 37¾ hydrochloric acid and filtered. The acid agueous solution was made basie with 5¾ sodium hydroxide and extracted with chloroform. The organic layer was dried on anhydrous sodium sulphate and evaporated to dryness in vacuo to give 4.3 g of the title compound as an oil. A sample was converted to the hydrochloride by salification with ethanolic hydrogen chloride in dichloromethane. The solvents were removed by evaporation in vacuo and the crude residue was crystallized from ethanol, giving the title compound, m.p. 208-209*C. 8-(4-chlorobutvlthio)-3-methvl-4-oxo-2-phenvl-4H-1--benzopvran (Intermediate LIII)
The title compound was prepared in the same manner as Intermediate XXXIV, but using l-bromo-4-chlorobutane instead of l-bromo-3-chloropropane. M.p. 81-84’C (ethanol). 8- (4-chlorobutvlsulphinvl) -3-methvl-4-oxo-2-phenvl-4H-l--benzopvran (Intermediate LIV)
The title compound was prepared in the same manner as Intermediate XXVI, but using Intermediate LIII instead of Intermediate XXI. A sample, crystallized from cyclohexane:benzene 0.5:1, melted at 124-125*C. 8-carboxy-4-oxo-3-phenvl-4H-l-benzopvran (Intermediate LV) A solution of 38.22 g of silver nitrate in 75 ml of water was added dropwise, under stirring, at 20-25*C, to a solution of 22.5 g of 8-formyl-4-oxo-3-phenyl-4H-l--benzopyran (prepared as deseribed by G. Atassi et al., Eur. iJ. Med. Chem. - Chim. Ter., 2J1, 393, 1985) in 150 ml of 85% ethanol and 450 ml of dimethylformamide. Then, a solution of 32.67 g of 85% potassium hydroxide in 195 ml of water was added dropwise under stirring at 15-20*C. After additional stirring at room temperature, the LV 10099 91 reaction mixture was filtered by suction; the mother liqour was acidified with 37% hydrochloric acid and diluted with 1.2 litres of water. Piltration by suction and washing with water to neutrality gavē the title 5 compound as a crude product. This was suspended in 150 ml of ethyl acetate and stirred with 444 ml of 0.3M sodium carbonate until clear layers were obtained. The aqueous layer was washed with 75 ml of ethyl acetate, then made acidic with 37% hydrochloric acid, filtered 10 and dried at 60-65*C to give 19.12 g of the title compound, melting at (215) 218’C. A sample, crystallized from ethanol, had the same melting point. 8-chlorocarbonvl-4-oxo-3-phenvl-4H-l-benzopvran 15 (Intermediate LVI) A mixture of 15.97 g of Intermediate LV and 15.6 ml of thionyl chloride in 75 ml of anhydrous toluene was stirred at 80-85'C for 4 hours. After removal of the solvent under vacuo, the residue was rinsed twice with 20 20 ml of toluene and evaporating to dryness in vacuo to give, after drying, 16 g of the title compound melting at (126) 138-140*C which was used without further purification. M.p. (130) 138-140*C (toluene). 25 B-(N-acetvlc arbamovl)-3-methvl-4-oxo-2-phenvl-4H-1--benzopvran (Intermediate LVII) A mixture of 3.5 g of 8-carbamoyl-3-methyl-4-oxo-2--phenyl-4H-l-benzopyran (described in JP 61-238783), 4.8 ml of acetic anhydride and 0.25 ml of sulphuric acid 30 (d=l.Q98) was stirred at 140*C for 3 minūtes. The reaction mixture was cooled to ambient temperature, diluted with water and filtered by suction to give, after washing with water and desiccation, 3.88 g of the title compound. 35 (bs, 1H, imidic NH) NMK CDCL^ļ (5) 10.50 92 92 8.35-8.70 7.45-8.00 2.60 2.20 (Μ, 2Η, CH in position 5 and 7 of the benzopyran ring) (m, 6h, other aromatic CHs) (b, 3H, CH3CO) (s, 3H, CH3 in position 3 of the benzopyran ring). 2-(2-methvlthiophenoxv)-acetaldehvde diethvl acetal (intermediate LVin) A mixture of 15.2 ml of 97¾ 2-bromoacetaldehyde diethyl acetal, 14 g of 2-(methylthio)-phenol, 13.7 g of anhydrous potassium carbonate and 3.13 g of tricaprylmethylammonium chloride in 140 ml of anhydrous dimethylformamide was stirred at 95’C for 38 hours. At the end of this period, the reaction mixture was cooled to ambient tempera tūre, poured into 1 litre of water and extracted with diethyl ether. The organic layer was washed with water, dried on anhydrous sodium sulphate and evaporated to dryness in vacuo. The oily residue was purified by column chromatography on silica gel eluting with Petroleum ether:ethyl acetate 99:1. Evaporation in vacuo of the collected fractions yielded 12.9 g of pure title compound. A sample was crystallized from n-hexane and melted at 50-52*C. 2-(2-methvlthiophenoxv)-acetaldehvde (Intermediate LIX) A mixture of 10.5 g of Intermediate LVIII and 140 ml of 2N hydrochloric acid in 85 ml of anhydrous tetrahydrofuran was stirred at 50’C for 2 hours. The organic solvent was then removed by evaporation in vacuo, and the aqueous residue was extracted with ethyl acetate. The organic layer was washed with water, dried on anhydrous sodium sulphate and evaporated to dryness in vacuo giving 9.5 g of the title compound as a solid which was used without further purification. A sample was crystallized from cyelohexane yielding the pure title compound, m.p. 102-104*C. LV 10099 93 8-(4-chlorobutvlsulphonvl)-3-methvl-4-oxo-2-phenvl-4H-l--benzopvran (Intermediate LX)
The title compound was prepared by the same method as Intermediate XXV, but using Intermediate LIII instead of Intermediate XXI. It was crystallized from diisopropyl ether and melted at 112-115*C. 8-ethoxvcarbonvl-4-ΟΧΟ-4Η-1-benzopvran (Intermediate LXI)
4.35 g of sodium mētai was added in pieces at ambient temperature to a solution of 9.85 g of ethyl 3-acetyl-2-~hydroxy benzoate (synthesized from 3-acetyl-2--hydroxybenzoic acid (prepared as described in R.E. Ford, J. Med. Chem., 22.r 538, 1986) refluxing in 6N ethanolic hydrogen chloride for 1.5 hours, evaporating to dryness in vacuo and purifying the crude by column chromatography on silica gel (eluent ethyl acetate:Petroleum ether 8:2) - m.p. 47*C (hexane)) in 98 ml of ethyl formate.
The reaction mixture went spontaneously to reflux for 20 minūtes; then it was stirred at ambient temperature for 4 hours and the ethyl formate was removed by evaporation to dryness in vacuo. The crude solid obtained was rinsed with 120 ml of ethanol and 67 ml of 5.6M ethanolic hydrogen chloride. The mixture was stirred at reflux for 30 minūtes; after this period it was cooled to ambient temperature and evaporated to dryness in vacuo. The residue was purified by column chromatography on silica gel eluting with ethyl acetate:petroleum ether 3:7 to 6:4 to give 8.31 g of the title compound. A sample crystallized from cyclohexane melted at 88-89'C. 8-carboxv-4-oxo-4H-l-benzopvran (Intermediate LXII) 30 ml of 6N hydrochloric acid was added to a solution of 4.0 g of Intermediate LXI in 30 ml of dioxane and the resulting mixture was stirred at reflux for 5 hours. The 94 reaction mixture was cooled to ambient temperature and poured into 200 ml of water. After 12 hours at 0 to 5'C, the title compound was filtered off under suction. washing with water and diethyl ether yielded, after desiccation, 2.8 g of the title compound, uised without further purification. A sample washed with boiling acetonitrile:methanol 25:1, filtered and crystallized from acetic acid, melted at 253-254*C. 8-carboxy-6-hvdroxy-3-methyl-4-oxo-2-phenvl-4H-l--benzoovran (Intermediate LXIII) A mixture of 1.5 g of 8-carboxy-6-methoxy-3-methyl-4--oxo-2-phenyl-4H-l-benzopyran (prepared as described in JP 61-15880) and 28 ml of 57% hydroiodic acid in 47 ml of acetic acid was stirred at reflux for 18 hours. The reaction mixture was cooled to ambient temperature and poured into water; IN sodium hydroxide was added to adjust the pH to 4 to 5. 2 g of sodium thiosulphate was added and stirring was continued for 15 minūtes. After this period, the crude title compound was filtered off under suction and dissolved in 0.5M sodium hydroxide; the basie solution was washed with ethyl acetate and acidified to pH 1 by adding 37% hydrochloric acid. The title compound was collected under suction and desiccated. Yield: 1.12 g of the title compound, used without further purification and melting at 279-281*C after crystallization from 50% ethanol. 2-hvdroxv-5-nitro-3-propionvl-benzoic acid (intermediate LXIV)
97.1 g of 2-hydroxy-3-propionyl-benzoic acid, prepared as described in Brit 1, 343, 119 (1974), were added in 5 minūtes to 500 ml of sulphuric acid (d=1.84) stirred at -25*C. A mixture of 40 ml of 65% nitric acid and 100 ml of sulphuric acid (d=1.84) was added in 40 minūtes maintaining the temperature of the reaction mixture between -20 and -13’C. The mixture was stirred at -18*C LV 10099 95 for an additional 30 minūtes. After this period, it was cautiously poured into a mixture of 2.0 kg of crushed ice and 500 ml of water, stirred for 10 minūtes and filtered to give the title compound, after washing with water and drying at 50'C for 6 hours. Crystallization of this solid from 50% ethanol yielded 91.5 g of title compound melting at 186-189’C, used without further purification. A sample was recrystallized from 50% ethanol and melted at 189-191*C.
Ethvl 2-hydroxv-5-ņitro-3-propionvl-benzoate (Intermediate LXV) A solution of 93.3 g of Intermediate LXIV and 25 ml of sulphuric acid (d=1.84) in 490 ml of ethanol was refluxed for 17 hours. After cooling to ambient temperature, 47.7 g of sodium carbonate was added portionwise and the ethanol was evaporated off in vacuo. The residue was rinsed with 1.2 litres of water, made alkaline by adding 37% sodium hydroxide and stirred for 15 minūtes. 37% hydrochloric acid was added to this suspension to adjust the pH to 6. Filtration yielded 85.4 g of the title compound used without further purification (m.p. 75-77*0. A sample was crystallized twice from ethanol and melted at 76-77*C. a-ethoxvcarbonvl-3-methvl-6-nitro-4-oxo-2-phenvl-4H-l--benzonvran (Intermediate LXVI) A mixture of 48.1 g of Intermediate LXV, 63 ml of benzoyl chloride and 85.6 g of sodium benzoate was stirred at 180*C (bath temperature) for 8 hours. The pasty mixture was cooled to 60-70*C; 700 ml of 50% ethanol was added and the resulting mixture was stirred again at 50*C for 30 minūtes. 60 ml of 35% sodium hydroxide was added at 5*C, ensuring that the temperature did not rise above 15*C. Filtration by suction, followed by washing with 50% ethanol and water afforded a crude product, which was purified by double 96 passage on column chroxnatography on silica gel eluting first with dichloromethane:petroleum ether graduated 8:2 to 9:1/ then with dichloromethane and finally with dichloromethane:ethyl acetate 95:5. Evaporation in vacuo of the collected fractions gavē the title compound, which was washed with 140 ml of ethanol. Yield 43 g, m.p. 132-133*C (ethanol). 8-carboxy-3-methvl-6-nitro-4-oxo-2-phenvl-4H-l--benzoovran (Intermediate LXVII) A mixture of 15.9 g of Intermediate LXVI and 48 ml of 1N sodium hydroxide in 320 ml of ethanol was stirred at reflux for 30 minūtes. The organic solvent was removed by evaporation in vacuo and the resulting suspension was diluted with 200 ml of water and made acidic with 37% hydrochloric acid. Filtration and washing with diethyl ether yielded 11.1 g of the title compound melting at (258) 286-292’C and used without further purification. After crystallization from dimethylformamide:water 6:4 the title compound exhibited the same melting point. 8-chlorocarbonvl-3-methvl-6-nitro-4-0X0-2-phenvl-4H-l--benzopvran (Intermediate LXVIII) A mixture of 6.2 g of Intermediate LXVII, 5.2 ml of thionyl chloride and 0.1 ml of anhydrous dimethylformamide in 60 ml of toluene was stirred at 90*C for 2 hours. Evaporation to dryness in vacuo and desiccation yielded 6.5 g of the title compound, m.p. 161-162*C, used without further purification. A sample was crystallized from toluene and had the same melting point. 8-carboxv-7-methoxv-3-methvl-4-oxo-2-Phenvl-4H-l--benzoovran (Intermediate LXIX) 216 ml of a 0.3M solution of potassium permanganate in water was added dropwise over 40 minūtes to a mixture of 7.94 g of 8-formyl-7-methoxy-3-methyl-4-oxo-2-phenyl-4H- LV 10099 97 -l-benzopyran (prepared as described in Da Re et al.,J. Org. Chem., 21097, 1960) and 54 ml of 5% sodium dihydrogen phosphate in 162 ml of t-butanol, stirred at 7 5*C. After a further 21^ hours stirring at the same temperature, the reaction mixture was cooled to ambient temperatūra and 81 ml of 1M sodium dithionite was dropped slowly therein. The mixture was extracted with ethyl acetate. The organic layer was washed four times with 160 ml of 0.5N sodium hydroxide; the collected basie agueous layers were washed with diethyl ether and made acidic with 37¾ hydrochloric acid. The title compound precipitated. It was filtered off and washed with water, yielding after desiccation 3.3 g, used for further reactions without further purification and melting at 180-181’C after crystallization from 95¾ ethanol.
Ethvl 3-propionvl-2-(4-trifluoromethvlbenzovloxv)--benzoate (Intermediate LXX) A solution of 6.7 g of 4-trifluoromethylbenzoyl chloride (prepared from the corresponding benzoic acid and thionyl chloride in benzene at reflux and used vrithout purification) in 50 ml of chloroform was added dropwise to a solution of 7.13 g of ethyl 2-hydroxy-3-propionyl--benzoate and 4.9 ml of triethylamine in 50 ml of chloroform. The mixture was stirred at ambient temperature for 2 hours; the solvent was then evaporated off in vacuo and the residue was purified by column chromatography on silica gel, eluting with Petroleum ether:ethyl acetate 85:15. Evaporation in vacuo to dryness of the collected fractions yielded 7.4 g of the title compound as an oil. NMR soectrum at 60 MHz (CDClji. δ) 7.6-8.5 (m, 6H, aromatic CHs) 7.5 (t, 1H, phenol ring, CH in 5) 4.2 (q, 2H, COOCH2) 2.9 (q, 2H, COCH2) 98 1-1.3 (2t, 6H, 2xCH3). 8-ethoxvcarbonvl-3-methvl-4-0x0-2-(4-trifluoromethvl-phenvlī-4H-l-benzopvran (Intermediate LXXI) A mixture of 6.96 g of Intermediate LXX and 2.58 g of 5 potassium t-butoxide in 35 ml of pyridine was stirred at 100’C for 2 hours. After this period, the reaction mixture was cooled to ambient tenderatūre, poured into a solution of 50 ml acetic acid in 600 ml of water and extracted with ethyl acetate. The organic layer was 10 washed with 10% hydrochloric acid and with water, dried on anhydrous sodium sulphate and evaporated to dryness in vacuo to give 6.9 g of 1-(2-hydroxy-3--ethoxycarbonyl)-2-methyl-3-(4-trifluoromethylphenyl)--1,3-propanedione. A solution of the compound thus 15 prepared and 2.2 ml of 37% hydrochloric acid in 35 ml of glacial acetic acid was stirred at 100’C for lx/2 hours. After cooling to ambient temperature, the mixture was poured into 630 ml of IN sodium hydroxide and extracted with ethyl acetate. The organic layer was 20 washed with water, dried on anhydrous sodium sulphate and evaporated to dryness in vacuo. The crude was purified by column chromatography on silica gel eluting with petroleum ether:ethyl acetate 85:15. Evaporation in vacuo to dryness yielded 2.95 g of the title compound, 25 melting at 111-113’C after crystallization from cyclohexane. 8-carboxv-3-methvl-4-oxo-2-(4-trifluoromethvlphenvl)--4H-1-benzopvran (intermediate LXII)
30 A mixture of 2.95 g of Intermediate LXXI and 0.43 g of lithium hydroxide monohydrate in 12.5 ml of methanol and 12.5 ml of methanol and 12.5 ml of tetrahydrofuran comtaining 8 ml of water was stirred at ambient temperature for l1^ hours. The mixture was poured into 35 solution of 30 ml of IN hydrochloric acid in 300 ml of water and filtered by suction to give 2.47 g of the title compound used without further purification. A LV 10099
99 sample was crystallized from 60% ethanol and melted at 253-254’C. 8-ethoxvcarbonvl-2- (4-benzovlphenvl) -3-methvl-4-oxo-4H-5 -1-benzopvran (Intermediate LXXIII)
The title compound was synthesized following the procedure of intermediate LXX and LXXI in the established order but starting from 4-benzoylbenzoyl chloride, instead of 4-trifluoromethyl-benzo.yl chloride 10 and reacting this compound in 1,2-dichloro-ethane instead of chloroform and in the presence of 4-dimethyl-aminopyridine instead of triethylamine. After the usual work up, the residue was purified by column chromatography on silica gel eluting with 15 dichloromethane:ethyl acetate 9:1. Evaporation in vacuo to dryness of the collected fractions yielded the title compound used without further purification., A sample was crystallized from cyclohexane and melted at 125-136*C (dec.). 20 ... 8-carboxv-2- (4-benzovlphenvl) -3-methvl-4-oxo-4H-l--benzopvran (Intermediate LXXIV)
The title compound was prepared in the same manner as Intermediate LXXII but starting from Intermediate LXXIII 25 instead of Intermediate LXXI. It was purified by dissolving the crude .in 0.5M sodium hydroxide/ washing the agueous layer with ethyl acetate and precipitating the pure title compound by addition of 37% hydrochloric acid. A sample was crystallized from acetic acid and 30 melted at 260-262*C.
Ethvl 2-(4-phenoxvbenzovloxv)-3-propionvl-benzoate (Intermediate LXXV)
The title compound was prepared by the procedure 35 described for Intermediate LXX, but starting from 4-phenoxybenzoyl chloride instead of 4-trifluromethyl- 100 benzoyl chloride. Evaporation of the solvent yielded the pure title compound. NMR spectrum at 200 MHz (CDCl^. δ) 8.17 (dd, 3H, phenyl CHs in position ortho to the 5 carboxylate groups)
7.92 (dd, 1H, phenyl CH in position ortho to the CO group) 7.38-7.48 (m, 3H, phenyl CHs in position meta to the carboxylate groups) 10 7.25 (d, 1H, CH in position 4 of the phenoxy ring) 7.05; 7.10 (2d, 4H, other CHs of the phenoxy ring) 4.25 (q, 2H, CH20) 2.90 (q, 2h, CH2CO) 1.05-1.20 (m, 6H, 2xCH3). 15 8-ethoxvcarbonvl-3-methvl-4-oxo-2-(4-phenoxvphenvl)-4H--l-benzopyran (Intermediate LXXVI)
The title compound was prepared in the same manner as Intermediate LXXI, but starting from Intermediate LXXV 20 instead of Intermediate LXX. Purification was carried out by column chromatography on silica gel, eluting with Petroleum ether:ethyl acetate 6:4. Evaporation in vacuo yielded the pure title compound, m.p.98-100’C. 25 8-carboxv-3-methvl-4-oxo-2-(4-phenoxvphenvl)-4H-1--benzopvran (Intermediate IiXXVII)
This compound was obtained in the same manner as Intermediate LXXII, but starting from Intermediate LXXVI instead of Intermediate LXXI. M.p. 216-218*C. 30 8-carboxv-2- (t-butvl) -3-methvl-4-oxo-4H-l-benzopvran (Intermediate LXXVIII) 6 ml of pivaloyl chloride was added dropwise into a stirred solution of 8,9 g of ethyl 2-hydroxy-3-35 -propionyl-benzoate in 20 ml of anhydrous pyridine. The reaction mixture was stirred at 80’C for 6 hours, cooled at ambient temperatūre and poured into a mixture of 200 LV 100913 101 g of crushed ice and. 30 ml of 10N hydrochloric acid. After extraction with diethyl ether, the organic phase was washed with brine, dried on anhydrous sodium sulphate and evaporated to dryness in vacuo, yielding 5 11.4 g of crude ethyl 2-pivaloyloxy-3-propionyl- -benzoate. 2.4 g of this compound were dissolved in 4 ml of anhydrous pyridine and 1 g of anhydrous potassium t-butoxide was added. The resultant mixture was heated 10 for 15 minūtes at 100’C, cooled to ambient temperature and poured into 50 g of iced water containing 8 ml of 10N hydrochloric acid. After extraction with diethyl ether, the organic phase was washed with brine, dried on anhydrous sodium sulphate and evaporated to dryness in 15 vacuo, giving 2.1 g of crude ethyl 2-hydroxy-3-(2--pivaloylpropionyl)-benzoate, which was used without purification in the next step. 2 g of the compound thus prepared were heated at 100’C for 15 minūtes after dissolution in a mixture containing 20 15 ml of acetic acid and 1.5 ml of 37¾ hydrochloric acid. After cooling to ambient temperature, the mixture was poured into 100 ml of water and extracted with diethyl ether. The organic phase was washed with 5¾ aqueous sodium hydrogen carbonate £ollowed by water, 25 dried on anhydrous sodium sulphate and evaporated in vacuo, yielding 1.6 g of crude 8-ethoxycarbonyl-2-(t--buty1)-3-methy1-4-oxo-4H-1-benzopyran. 1.5 g of the above ester was dissolved in 20 ml of methanol. 3 ml of 10N sodium hydroxide was slowly added, 30 maintaining the temperature between 25 and 35’C. After l1/^ hours at ambient temperature, the reaction mixture was diluted with 100 ml of water and extracted with ethyl acetate. The aqueous layer was acidified with 3N hydrochloric acid. The precipitate was collected by 35 suction, washed with water and crystallized from ethanol, yielding 0.8 g of the title compound, melting at 225-228*C. 102 8-carboxv-2-cvclohexvl-3-methvl-4-oxo-4H-l-benzopvran LIntermediate lxxix)
This compound was prepared according to the reaction seguence and methods described for Intermediate LXXVIII, 5 but starting from cyclohexylcarboxylic acid chloride instead of pivaloyl chloride and with other minor differences. In particular, ethyl 2-cyclohexylcarbonyl--oxy-3-propionyl-benzoate was obtained after 8 hours stirring in pyridine at ambient temperature and 10 transposed to ethyl 2-hydroxy-3-(2-cyclohexylcarbonyl--propionyl)-benzoate upon heating with potassium t-butoxide for 21/2 hours at 100’C. Cyclization to 8-ethoxycarbonyl-2-cyclohexyl-3-methyl-4-oxo-4H-l--benzopyran was carried out by heating in a mixture of 15 acetic and hydrochloric acids at 100 *C for lx/2 hours and the hydrolysis to the title compound was performed in 20 minūtes at ambient temperature. The title compound melted at 224'C after crystallization from 40% ethanol. 20 8-ethoxvcarbonvl-2-(2-furvl)-3-methvl-4-oxo-4H-l--benzopvran (Intermediate LXXX) A mixture of 3.2 g of Intermediate XC and 1.3 g of anhydrous potassium t-butoxide in 8 ml of anhydrous pyridine was stirred at 60 *C for 15 minūtes, cooled to 25 ambient temperature and poured into 60 ml of iced water containing 15 ml of 10N hydrochloric acid. After extraction with ethyl acetate, the organic phase was washed with 5% aqueous sodium bicarbonate and water and dried on anhydrous sodium sulphate. Upon evaporation in 30 vacuo 2.5 g of crude ethyl 3-(2-furoyl-propionyl)-2--hydroxy-benzoate was obtained. 2.5 g of the compound so obtained was stirred at 100’C for 30 minūtes with 10 ml of acetic acid and 0.7 ml of 37% hydrochloric acid. After cooling to ambient 35 temperature, the mixture was poured into 180 ml of water. The title compound precipitated and was collected by suction filtration, washed with water and LV 10099 103 crystallized from isopropanol. Yield 1.5 g, m.p. 137-139 *C. 8-carboxv-2-(2-furvl)-3-methvl-4-oxo-4H-l-benzopyran 5 (Intermediate LXXXI) A mixture of 3.5 g of Intermediate LXXX and 6 ml of 10N sodium hydroxide in 4 0 ml of methanol was stirred at ambient temperature for 1 hour and poured into 500 ml of water, After extraction with ethyl acetate, the agueous 10 layer was acidified with 3N hydrochloric acid. The title compound precipitated and was collected by suction filtration, washed with water and crystallized from a 7:3 mixture of methanol:chloroform. Yield 2.55 g, m.p. 272-277'C. 15 8-ethoxvcarbonvl-3-methvl-4-oxo-2-(2-thienvl)-4H-1--benzopvran (Intermediate LXXXII)
This compound was prepared in two steps according to the methods reported for Intermediate LXXX, but using 20 Intermediate XCI instead of Intermediate XC. The title compound melted at 116-118*C after crystallization from isopropanol. 8-carboxv-3-methvl-4-oxo-2-(2-thienvl)-4H-l-benzopvran 25 (Intermediate LXXXIII1
This compound was prepared according to the method described for Intermediate LXXXI, but using Intermediate LXXXII instead of Intermediate LXXX. M.p. 287-294*C after crystallization from a 7:3 mixture of methanol and 30 chloroform. 8-carboxy-4-oxo-2-phenvl-4H-l-benzothiopvran (Intermediate LXXXIV) A mixture of 1 g of 8-methoxycarbonyl-4-oxo-2-phenyl-4H-35 -l-benzothiopyran (Intermediate XCII), 2.2 ml of 12.5N sodium hydroxide, 15 ml of methanol and 5 ml of dioxane was stirred at ambient temperature for 21/2hours. After 104 evaporation in vacuo, water was added until complete solution and this solution was extracted with chloroform. The separated agueous phase was acidified with dilute hydrochloric acid until complete 5 precipitation of the crude, which was filtered off and purified by crystallization from acetic acid. Yield 0.62 g, m.p. 302*C. (E)-8-ethoxvcarbonvl-3-methyl-4-oxo-2-(2-stvryl)-4H-1-10 benzopvran (Intermediate LXXXV)
This compound was prepared in three steps according to the methods described for Intermediate XC (first step) and Intermediate LXXX (second and third steps). In the first step, (E)-cinnamoyl chloride was used instead of 15 2-furoyl chloride and the obtained (E)-ethyl 2-hydroxy--3-(2-styryl-propionyl)-benzoate was used without purification for the second step. The title compound melted at 129-130’C after crystallization from isopropanol. 20 (E)-8-carboxv-3-methvl-4-oxo-2-stvrvl-4H-l-benzopvran (Intermediate LXXXVI)
This compound was prepared according to the method described for Intermediate LXXXI, but starting from 25 Intermediate LXXXV instead of Intermediate LXXX, and maintaining the reaction at ambient temperature for 10 hours. The title compound melted at 284-286’C after crystallization from ethanol. 30 8-carboxv-3-methvl-2-(4-methvlphenvl)-4-ΟΧΟ-4Η-1--benzopvran.(Intermediate LXXXVII) A mixture of 1.9 g of 2-hydroxy~3-propionyl-benzoic acid (prepared as described in Brit. 1, 343, 119, 1974), 5.2 g of anhydrous sodium 4-methylbenzoate and 3.9 ml of 35 4-methylbenzoyl chloride was stirred at 185-195’C for 8^2 hours. After cooling to ambient temperature, the solidified mass was stood overnight with 100 ml of LV 10099 105 chloroform. The mixture was then shaken with 5% aqueous sodium carbonate solution, added until the pH of the aqueous phase reached 8.9. The organic phaee was extracted again with 3¾ sodium carbonate and the aqueous phases were pooled, repeatedly extracted with diethyl ether and acidified with 10N hydrochloric acid. The precipitate was purified by flash chromatography on silica gel, eluting with chloroform:methanol 100:2 to 100:20. The title compound, obtained by evaporating in vacuo the pooled fractions containing it, melted at 249-251*C, after crystallization from ethanol. 8-ethoxycarbonvl-2-(4-fluorophenvl)-3-methvl-4-oxo-4H--1-benzopvran (Intermediate LXXXVIII)
This compound was prepared in three steps according to the methods described for Intermediate XC (first step) and Intermediate LXXX (second and third steps). In the first step, 4-fluorobenzoyl chloride was used instead of 2-furoyl chloride and the reaction lasted 20 hours at ambient temperature, yielding ethyl 2-(4-fluorobenzoyl-oxy)-3-propionyl-benzoate. This compound was used without purification for the second step. The title compound melted at 128-130*C after rinsing with diethyl ether and crystallization from ethanol. 8-carboxy-2- (4-fluorophenvl) ^-ιηθίίινΙ^-οχο-^Η-Ι-^οηζορν^η (Intermediate LXXXIX) A solution of 3.3 g of Intermediate LXXXVIII and 0.6 g of lithium hydroxide hydrate in 50 ml of tetrahydrofuran, 10 ml of methanol and 10 ml of water was maintained at ambient temperature for 5 hours and then poured into 300 ml of IN hydrochloric acid. The precipitate formed was collected by suction, washed with water and dried, yielding 2.3 g of the title compound, melting at 249-250'C after crystallization from 95¾ ethanol. 5 106 E_thvl__2^(2-furovlQxv) -3-propionvl-benzoate (Intermediate XC) 10 4.35 ml of 2-furoyl chloride were added dropwise at 10-15'C into a stirred mixture of 8.9 g of ethyl 2-hydroxy--3-propionyl-benzoate and 5.4 g of 4-dimethylamino-pyridine in 25 ml of dichloromethane. After 2 hours at ambient temperature, the reaction was quenched with 200 ml of water. The organic layer was washed with 5% sodium bicarbonate, dried on anhydrous sodium sulphate and evaporated in vacuo. The residue was purified by flash chromatography on silica gel eluting with Petroleum ether:ethyl acetate 4:1, obtaining 9.4 g of the title compound as a low melting solid, used without further purification in the next step. 15 NMR Spectrum at 60 MHz (CDCl^. δ) 20 8.2 8.0 7.7-7.8 7.43 7.45 6.6-6.8 4.3 2.9 25 0.95-1.35 (1H, dd,CH in position 4 of the benzene ring) (1H, dd, CH in position 6 of the benzene ring) (1H, dd, CH in position 5 of the furan ring) (1H, t, CH in position 5 of the benzene ring) (1H, s, CH in position 3 of the furan ring) (1H, m, CH in position 4 of the furan ring) (2H, q, COOCB2CH3) <2H, q, COCH2CH3) (6H, m, 2xCH3).
Ethvl 3-propionyl-2-(2-thienvlcarbonyloxv)-benzoate (Intermediate XCI)
This compound was prepared by the method described for 30 Intermediate XC, but using 2-thienylcarboxylic acid chloride instead of 2-furoyl chloride. NMR Soectrum at 60 MHz (CDCl^. 5) 7.1-8.35 (6H, m, aromatic CHs) 35. 4.25 (2H, q, COOCH2CH3) 2.9 (2H, q, COCH2CH3) 0.95-1.3 (6H, m, 2xCH3). LV 10099 107 8 -methoxvcarbonvl -4 -oxo-2 -phenvl -4H-1 - benzothiopvraii (Intermediate XCII) A mixture of 16.8 ml of thiosalicylate, 25.6 ml of ethyl benzoylacetate and 360 g of polyphosphoric acid was 5 stirred at 90‘C for 3 hours. After cooling to ambient temperature, the mixture was poured into crushed ice and the crude was collected by filtration, washed with water and purified by crystallization from ethanol. M.p. 170-171’C. 10
Elemental Analvsis for CjjHļaOjtSi-Calculated (%): C, 68.90; H, 4.08; S, 10.82.
Found (%): C, 68.59; H, 4.13; S, 10.69. 15 20 ŅMR Spectrum at 8.83-8.95 8.45- 8.53 7.68-7.80 7.55-7.65 7.45- 7.55 7.24 4.00 200 MHz (CDCIī, δ) (dd, 1H, benzothiopyran CH in 5) (dd, 1H, benzothiopyran CH in 7) (m, 2H, 2-phenyl CHs in 2 and 6) (t, 1H, benzothiopyran CH in 6) (m, 3H, 2-phenyl CHs in 3, 4 and (s, lH,benzothiopyran CH in 3) (s/ 3H, COOCH3). 5) 8 - e t hoxvc arbonvl - 3 -bromome thvl - 4 - 0x0 - 2 -phenvl-4H-1-25 -benzopvran (Intermediate XCIII) A mixture of 9.2 g of 8-ethoxycarbonyl-3-methyl-4-oxo-2--phenyl-4H-l-benzopyran (prepared as described by Da Re, P. et al., J. Med. Pharm. Chem., 2., 263, 1960), 6.4 g of N-bromosuccinimide and 0.04 g of benzoylperoxide in 80 30 ml of anhydrous carbon tetrachloride was stirred at reflux for ll/2honrs. After cooling to ambient temperature the formed succinimide was collected by suction and washed with cold carbon tetrachloride. The mother liguors were evaporated to dryness in vacuo and 35 the residue was rinsed with diethyl ether and collected by suction filtration yielding 9.2 g of the title.. 108 compound, melting at 133-134*c after crystallization from acetone:n-hexane. 8-ethoxvcarbonvl-3-acetoxvmethvl-4-oxo-2-phenvl-4H-1--benzopvran (Intermediate XCXV) A solution of 10.2 g of sodium acetate trihydrate in 30 ml of water was added dropwise at ambient temperature to a solution of 29 g of Intermediate XCIII in 300 ml of dimethylformamide. After stirring at 50*C for l^ahours, the reaction mixture was poured into 2 litres of water and the precipitated title compound was collected by suction filtration and crystallized from acetone yielding 20 g (two crops collected), m.p. 151-152*C. 8-carboxv-3-hvdroxvmethvl-4-oxo-2-phenvl-4H-1--benzopvran (Intermediate XCV) 116 ml of IN sodium hydroxide were added over 10 minūtes to a stirred suspension of 14.8 g of Intermediate XCIV in 300 ml of 95¾ ethanol. The rection mixture was then heated at 60-65*C for 15 minūtes, obtaining a clear solution which was maintained at ambient temperature for a further hour. After evaporation in vacuo, the residue was dissolved in 200 ml of ,water and the solution acidified by slow addition of 10 ml of hydrochloric acid (d=1.18). After stirring for 1 hour at ambient temperature the title compound was collected by suction filtration, washed with water and crystallized from isopropanol, yielding 9.3 g, m.p. (225) 237-240‘C.
Ethvl 2-(4-nitrobenzovloxv)-3-propjonvl-benzoate (Intermediate xcvi)
The title compound was prepared according to the procedure described for Intermediate XC, but using 4-nitrobenzoyl chloride instead of 2-furoyl chloride. The product was obtained as a low melting solid (m.p. (40) 78-80’C). LV 10099 109 NMR Soectrum at 60 MHz (CDClj*. δ ) 7.85-8.50 (m, 6H, aromatic CHs) 7.50 (t, 1H, CHs in position 5 of the phenol ring) 4.25 (q, 2H, CH2O) 3.95 (q, 2H, CH2) 0.95-1.30 (m, 6H, CH3). 8-ethoxvcarbonvl-3-methvl-2-(4-nitrophenvl)-4-oxo-4H-l--benzopvran (Intermediate XCVII> A mixture of 29.7 g of Intermediate XCVI and 10.18 g of anhydrous potassium t-butoxide in 89 ml of anhydrous pyridine was stirred at 100*C for 13 hours. The reaction mixture was cooled to ambient temperature, poured into 40 0 ml of 4N hydrochloric acid and extracted with dichloromethane. The organic layer was washed repeatedly with water, then with 2.5¾ sodium hydrogen carbonate, dried on anhydrous sodium sulphate and evaporated to dryness in vacuo. The crude product was purified by column chromatography on silica gel, eluting with hexane:ethyl acetate 7:3. Evaporation in vacuo of the collected fraction yielded 7 g of the title compound, melting at (130) 145-148*C. 8-carboxv-3-methvl-2-(4-nitrophenvl)-4-oxo-4H-l--benzoovran (Intermediate XCVIII) A suspension of 0.38 g of Intermediate XCVII in 4.75 ml of dioxane and 4.75 ml of methanol was stirred at 50*C. 1.29 ml of IN sodium hydroxide was added and stirring was continued for 3 hours at the same temperature. The reaction mixture was cooled to ambient temperature and 3N hydrochloric acid was added until the pH was 1. The suspension was filtered by suction giving 0.13 g of the title compound, which melted at 320-321*C after crystallization from dioxane. 110 8-ethoxycarbonyl-3-methvl-4-oxo-2-1ri fluoromethvl-4H-1--benzopvran (Intermedlate XCIX) 3.16 ml of 1,8-diazabicyclo[5.4.OJundec-7-ene was added dropwise at 0‘C by a syringe to a stirred mixture of 3 g of ethyl 2-hydroxy-3-propionyl-benzoate and 5.53 ml of trifluoroacetic anhydride. The rection mixture was stirred at 60'C for 4 hours; after this period it was cooled to ambient temperatūre and diluted with ethyl acetate and water. The organic layer was washed with 1N sodium hydroxide and water, dried on anhydrous sodium sulphate and evaporated to dryness in vacuo. The residue was purified by column chromatography on silica gel, eluting with Petroleum ether:ethyl acetate 95:5 yielding 0.8 g of the title compound. NMR Spectrum at 200 MHz (CDCr*. δ) 8.41;8.37 (2dd, 2H, CHs in position 5 and 7 of the benzopyran ring) 7.51 (t, 1H, CH in position 6 of the benzopyran ring) 4.46 (q, 2H, COOCH2) 2.22-2.27 (m, 3H, Jh-F=2.16Hz, CH3 in position 3 of the benzopyran ring) 1.39 (t, 3H, CH2CH3). 8-carboxv-3-methvl-4-0x0-2-trifluoromethvl-4H-l--benzopvran (Intermediate C)
The title compound was prepared by the same method as Intermediate LXII, but using Intermediate XCIX instead of Intermediate LXI and, after dilution with water, extracting with ethyl acetate instead of filtering. After drying on anhydrous sodium sulphate and evaporating the organic layer to dryness in vacuo, the title compound was obtained as a solid which melted at 175-178‘C. LV 10099 111 3- Γ4- (2-methoxvDhenvl) -l-piperazlovll -N-methvl--propvlamine (Intermediate CI) 42 ml of 35¾ acjueous methylamine was added to a solution of 8.2 g of 3-[4-(2-methoxypheny1)-l-piperazinyl]-propyl chloride in 48 ml of dimethylformamide. The mixture was heated at 60'C in a closed vessel for 5 hours, and then cooled to 30*c. The solvent was evaporated off in vacuo/ and the residue was stirred for 30 minūtes with 100 ml of diethyl ether. The solīds, collected by suction filtration, were dissolved in 200 ml of chloroform:5N methanolic ammonia 100:3. After 30 minūtes stirring at ambient temperature, the solution was adsorbed on a chromatographic column, which was eluted with chloroform:5N methanolic ammonia graduated 100:5 to 100:15. The fractions containing the title compound were pooled and evaporated in vacuo, yielding 3 g of intermediate CI as a thick oil. NMR Spectrum at 60 MHz (PMSO-d£, δ ) 6.80 (s, 4H, aromatic CHs) 3.75 (s, 3H, OCH3) 3.20-2.75 (m, 4H, piperazinic CH2S at pos. 3, 5) 2.75-2.10 (m, 8H, piperazinic CH2S at pos. 2, 6 and CB2CH2CH2) 2.40 (s, 1H, NH) 2.30 (s, 3H, NCH3) 1.80-1.40 (m, 2H, CH2CH2CH2).
Ethvl 2-benzovl-3-ethvlbenzo Tblfuran-7-carboxvlate (intermediate Q.H) A mixture of 11.1 g of ethyl 2-hydroxy-3-propionyl--benzoate, 9.9 g of phenacyl bromide, 6.9 g of anhydrous potassium carbonate and 200 ml of acetone was stirred at refluxing temperature for 7 hours. After cooling to ambient temperature, the inorganic salts were separated by filtration and the solution was evaporated in vacuo. The residue was purified by flash chromatography on 112 silica gel eluting wi.th toluene. The title compound, obtained by evaporating in vacuo the pooled fractions containing it, was crystallized from 90% ethanol. Yield 9.8 g, m.p. 64-66*C. 7-carboxv-2-benzovl-3-ethvl-benzo fblfuran (Intermediate Cili) A mixture of 7 g of Intermediate CII, 275 ml of 0.95N sodium hydroxide and 400 ml of dioxane was stirred at refluxing temperature for 4 hours. After cooling to ambient temperature, the dioxane was evaporated in vacuo and replaced with the same volume of water. After filtering with charcoal, the solution was acidified with dilute hydrochloric acid and the precipitate was filtered and purified by crystallization from acetone. Yield 4.94 g, m.p. 193-195'C.
Methvl 3-methvl-2-(4-methvlphenvl)-4-oxo-4H-l--benzopvran-8-carboxvlate (Intermediate CIV)
This compound was prepared in three steps according to the methods described for Intermediate XC (first step) and Intermediate LXXX (second and third steps).
In the first step, 4-methylbenzoyl chloride was used instead of 2-furanecarbonyl chloride and methyl 2-hydroxy-3-propionylbenzoate was used instead of ethyl 2-hydroxy-3-propionylbenzoate. The reaction 1asted 4 hours at room temperature, yielding methyl 2-(4-methyl-benzoyloxy)-3-propionylbenzoate. This compound was used without purification by column chromatography for the second step that lasted 1.5 hours at 100*C. In the third step 96% sulfuric acid was used instead of 37% hydrochloric acid.
The title compound melted at 174-175*C after crystallization from ethanol. LV 10099 113
Ethvl 2-(4-biphenvlvl)-3-methvl-4-oxo-4H-l-benzopvran-8--carboxvlate (Intermediate CV)
This compound was prepared in three steps according to the methods described for Intermediate XC (first step) 5 and Intermediate CIV (second and third steps).
In the first step 4-phenylbenzoyl chloride was used instead of 2-furanecarbonyl chloride and the reaction lasted 20 hours at room temperature and 13 hours at reflux. Purification was performed by column 10 chromatography on silica gel eluting with petroleum ether:ethyl acetate gradient 100:5 to 100:10/ yielding ethyl 2 - (4-biphenylyl)-3-propionylbenzoate.
The title compound melted at 165-167*C after rinsing with 95¾ ethanol. 15 2-(4-biphenvlvl)-3~methvl-4-oxo-4H-l-benzopvran-8--carboxvlic acid (Intermediate CVI) A mixture of 4.3 g of Intermediate CV and 35 ml of 35¾ hydrochloric acid in 50 ml of l,4-dioxane and 15 ml of 20 water was stirred at reflux for 16 hours. After cooling, the mixture was poured into 2 00 ml of water and extracted with ethyl acetate. The organic layer was separated and extracted with 20¾ agueous sodium carbonate. The precipitate formed after acidifying the 25 agueous layer with diluted hydrochloric acid, was collected by suction, washed with water and dried, yielding 2.5 g of the title compound, melting at 242.5-244*C. 30 2-(4-hvdroxvphenvl)-3-methvl-4-oxo-4H-l-benzopyran-8- -carboxvlic acid (Intermediate CVII) A mixture of 3 g of ethyl 2-(4-methoxyphenyl)-3-methyl--4-oxo-4H-l-benzopyran-8-carboxylate (prepared as described in JP 58-225083; C.A., 100, 19164h, 1984) and 35 60 ml of 48¾ hydrobromic acid in 80 ml of acetic acid was stirred at reflux for. 8 hours. After cooling, the mixture was poured into 500 ml of water and the 114 precipitate was collected by suction and washed with water. The crude was purified by flash chromatography on silica gel eluting with chloroform:isopropyl alcohol gradient 9:1 to 7:3 followed by methanol elution, 5 yielding 1 g the title compound, melting at 300*C. 1-(2-methoxvphenvl)-4-(4-methvlaminobutvl)pjperazine .(IņLennediatĢ ,cVI,II) 10 15 A solution of 3.8 ml of trifluoroacetic anhydride in 25 ml of anhydrous dichloromethane was added dropwise under stirring at 0*C to a solution of 2.53 g of 4-[4-(2--methoxyphenyl)-l-piperazinyl]butylamine in 25 ml of anhydrous dichloromethane. After 2 hours stirring at room temperatūre, the reaction mixture was diluted with dichloromethane and washed with water. The organic layer was dried on sodium sulphate and evaporated to dryness in vacuo, yielding 3.3 g of pure 1-(2-methoxyphenyl)-4--(4-trifluoroacetylamino)butylpiperazine as by NMR spectrum. 20 NMR Snectrum at 60 MHz 7.70-8.00 (bs , 1H) 6.80-7.20 (m, 4H) 3.85 (s, 3H) 2.90-3.80 (m, 12H) 1.50-2.05 (m, 4H) 25 (CDCl^, 6_)
NH
aromatic CHs CH3O piperazine CH2S, CH2N and ch^nhco
C-CH2CH2-C 0.88 g of 50¾ sodium hydride was added portionwise under 30 stirring at 0’C to solution of 3.3 g of the above intermediate in 46 ml of anhydrous dimethylformamide. After 1 hour stirring at the same temperature, 0.57 ml of methyl iodide was added. The reaction mixture was stirred at 0*C for additional 1.5 hours; then it was poured into water and extracted with ethyl acetate. The organic layer was washed with water, dried on sodium sulphate and evaporated to dryness in vacuo, yielding 35 LV 10099 115 1.13 g of crude l-(2-methoxyphenyl)-4-[4-(N-methyltri-fluoroacetylamino)butyl] piperazine used in the following step without further purification. 0.18 g of sodium borohydride was added to a solution of 1;13 g of this intermediate in 30 ml of ethanol and the resulting mixture was stirred at 60*C for 1 hour. After cooling to room temperature, the reaction mixture was poured into water, and extracted with dichloromethane. The organic layer was washed with water, dried on sodium sulphate and evaporated to dryness in vacuo, yielding 0.82 g of pure title compound. NMR Spectrum at 60 MHz (CDCl^. δ )
6.80-7.20 (m, 4H) aromatic CHs 3.85 (S, 3H) CH3 2.90-3.20 (m, 4H) piperazine CH2B, position 3 and 5 2.30-2.80 (m, 8H) piperazine CH2S, position 2 and 6; 2xCH2N 2.50 (s, 3H) CH3Ņ 1.80 (B, 1H) NH 1.40-1.80 (m, 4H) C-CH2CH2-C 1-(3-amino-2,2-dimethvlpropvl)-4-(2-methoxvphenvl)--piperazine
The title compound may be prepared by treating 1-(2-methoxyphenyl)-piperazine with isobutyraldehyde, 37¾ formaldehyde in water and acetic acid at 90-150'C or with the same in ethanolic hydrogen chloride (Mannich reaction) to give 1-(2-formyl-2-methylpropyl)-4-(2--methoxyphenyl)-piperazine, which is then aminated by treatment with excess ammonia under reducing conditions. The latter may be hydrogen and a catalyst (for example, palladium-on-charcoal, Raney nickel or platinum dioxide) in a solvent (for example, ethanol, methanol, isopropanol, dichloromethane, chloroform or dimethylformamide) at between ambient temperature and 80'C, or alternatively a mētai hydride (for example, 116 116 sodium or sodium borohydride, sodium or potassium cyanoborohydride) in a solvent (for example, methanol/ ethanol, benzene or 1,2-dichloroethane) in the presence of an acid (for example, gaseous hydrogeh chloride or acetic acid).
It may be reacted with 8-chlorocarbonyl-3-methyl-4-oxo--2-phenyl-4H-l-benzopyran in the manner described in Example 12 hereinbelow to give 8-(2,2-dimethyl-3-[4-(2--methoxyphenyl)-l-piperazinyl]-propylcarbamoyl)-3--methy1-4-oxo-2-pheny1-4 Η-1-benzopyran. 8-trifluoroacetamidomethvl-3-methvl-4-oxo-2-phenvl-4H--1-benzopvran
This compound can be prepared according to the procedure described for Intermediate XXIII but using Intermediate XXIV instead of 8-amino-3-methyl-4-oxo-2-phenyl-4H-l--benzopyran. It can be used as starting material, instead of Intermediate XXIII, in the reaction described in Example 32 to yield 8-(2-[4-(2-methoxyphenyl)-1--piperazinyl]-ethylaminomethyl}-3-methyl-4-oxo-2-phenyl--4 Η-1-benzopyran. 8-(2-chloroethvlureidomethvl)-3-methvl-4-oxo-2-Phenvl--4H-l-benzopvran
This intermediate can be prepared by the method described for the preparation of Intermediate XLIV, but using Intermediate XXIV instead of 8-amino-3-methyl-4--oxo-2-phenyl-4H-l-benzopyran. It can be reacted with a compound of formula H-B, according to Path (a) to give the described final compounds. 8-ethenvlsulphonvlaminomethvl-3-methvl-4-oxo-2-phenvl·--4H-l-benzopyran
This compound can be prepared by reacting Intermediate XXIV with 2-chloroethylsulphonyl chloride in a halogenated solvent such as dichloromethane in the presence of triethylamine at 0-40’C, according to A.A. LV 10099 117
Goldberg,J. Chem. Soc., 464, 1945. It can be reacted with the appropriate compounds H-B, according to Path (m) to yield the corresponding final compounds. Operating as described above, but starting from 8-amino-5 -3-methyl-4-oxo-2-phenyl-4H-l-benzopyran the final compounds Fl'-Y36-(CH2)2-B can be obtained. 8 -chloroBulphonvlme thvl - 3 -methvl - 4 -oxo-2 -phenvl -4H-1 --benzopvran 10 This intermediate can be prepared by reacting 8-amidino-t hiome thy 1 - 3 -me t hy 1 - 4 - oxo - 2 -pheny 1 - 4H-1 -benzopyran (whose synthesis is described in Intermediate XXI) with chlorine gas in water at -10 to +10 *C according to T.B. Johnson et al., J. Chem. Soc., £1, 2548, 1939. By 15 reaction of this intermediate with the appropriate compounds A-NH-Z-B according to Path (n), the desired final compounds can be obtained. 20 EXAMPLBS Example 1 8-{2- [4-(2-methoxyphenyl)-l-piperazinyl]-l-oxoethyl}-3--methyl-4-oxo-2-phenyl-4H-l-benzopyran hydrochloride 25 A solution of 11.5 g of 1-(-2-methoxyphenyl)-piperazine in 30 ml of methanol was added dropwise at 20-25*C to a stirred mixture consisting of 21.4 g of Intermediate VI and 4.1 g of potassium carbonate in 120 ml of methanol. 30 After 4 hours stirring at the same temperature, the reaction mixture was stripped in vacuo. The residue was extracted with chloroform and the organic solution was washed with water, dried on anhydrous sodium sulphate/calcium chloride, filtered and stripped in 35 vacuo. The obtained crude product was dissolved in acetone and a slight excess of ethanolic hydrogen chloride was added. After collection by suction 118 filtration and recrystallization from 95% ethanol, 16.3 g of the title compound was obtained, m.p. (189) 195-199 *C. RTcamnlft 2 8-{2-[4-(2-methylphenyl)-l-piperazinyl]-l-oxoethyl}-3--methy1-4-oxo-2-pheny1-4Η-1-benzopyran hydrochloride
This compound was prepared according to Example 1, but using 1-(2-methylphenyl)-piperazine instead of 1- (2 — -methoxyphenyl)-piperazine and carrying out the reaction in dimethylformamide for 1 hour instead of in methanol for 4 hours. M.p. (194) 203-206’C (isopropanol).
ExaTOle .3 8-{2-[4-(2-ethoxyphenyl)-l-piperazinyl]-l-oxoethyl}-3--methyl-4-oxo-2-phenyl-4H-1-benzopyran hydrochloride
This compound was prepared according to Example 1 but using 1-(2-ethoxyphenyl)-piperazine instead of l-(2--methoxyphenyl)-piperazine and carrying out the reaction in dimethylformand.de for 2 hours instead of in methanol for 4 hours. M.p. 208-210*C (isopropanol).
Example 4 8-{3-[4-(2-methoxyphenyl)-1-p iperaz inyl]-1-oxopropyl}-3--methyl-4-oxo-2-pheny1-4H-1-benzopyran hydrochloride A solution of 10 ml of 37% formaldehyde in 15 ml of methanol was dropped, over a period of 3 minūtes at 0*C, into a solution of 5.75 g of 1-(2-methoxyphenyl)--piperazine in 10 ml of methanol. After 12 hours at 0*C, the mixture was stripped in vacuo and redissolved in 15 ml of methanol. 20 ml of 3.6N hydrogen chloride in diethyl ether was added at 0*C. After stripping in LV 10099 119 vacuo, the residue· was suspended in 15 ml of l,4-dioxane. A solution of 8.3 g of Intermediate V in 100 ml of l,4-dioxane was added under stirring at 20-25*C. After stirring for 8 hours at reflux the reaction mixture was cooled to 30-40’C. 50 ml of methanol was added and the mixture was refluxed for a further 2 hours. After cooling to 20-25*C, the resultant solution was diluted with 300 ml of diethyl ether. Stirring was continued for a further 3 hours at the same temperatūra. The title compound was collected by suction filtration and recrystallized from ethanol. Yield 4 g, m.p. 209-210'C.
Example 5 8-{3- [4-(2-methoxyphenyl)-l-piperazinyl]-l-propoxy-carbonyl} - 3 -methyl - 4 -oxo-2 -phenyl -4H-l-benzopyran dihydrochloride A mixture of 4.24 g of 8-carboxy-3-methyl-4-oxo-2--phenyl-4H-l-benzopyran and 6.3 g of anhydrous potassium carbonate in 60 ml of dimethylformamide was stirred at 80‘C for 30 minūtes. 5.23 g of 1-(3-chloropropyl)-4-(2--methoxyphenyl)-piperazine was then added and stirring was continued at 80’C for 3.5 hours. The reaction mixture was cooled to ambient temperature, poured on to iced water and extracted with ethyl acetate. The organic extracts were washed with aqueous sodium chloride solution, dried on anhydrous sodium sulphate, and evaporated to dryness in vacuo. The residue was taken up in ethanol and excess ethanolic hydrogen chloride was added to the solution. Yield: 8.16 g of the title compound, m.p. 198-203*C.
Example 6 8-{2- [4- (2-methoxyphenyl) -1 -piperazinyl] -ethoxycarbo-ny 1}-3-me thy1-4-oxo-2-pheny1-4H-1-benzopyran dihydrochloride 120
Operating as described in Example 5, but using 1-(2-chloroethyl)-4-(2-methoxyphenyl)-piperazine instead of 1-(3-chloropropyl)-4-(2-methoxyphenyl)-piperazine, the title compound was obtained, m.p. 200-203'C from ethanol.
Sxgmp3,g „? 8-{3-[4-(2-chlorophenyl)-l-piperazinyl]-propoxycarbo-nyl>-3-methy1-4-oxo-2-phenyl-4H-1-benzopyran dihydrochloride A mixture of 2.8 g of 1-(2-chlorophenyl)-piperazine hydrochloride and 4.2 g of anhydrous potassium carbonate in 25 ml of dimethylformamide was stirred at ambient temperature for 15 minūtes. 4.81 g of Intermediate I was added, and stirring was continued for 2 days. The reaction mixture was then poured into 200 ml of cold water, and extracted with diethyl ether and ethyl acetate. The organic extracts were washed in turn with aqueous sodium chloride solution, 0.1N acetic acid, agueous sodium chloride solution, agueous 4% sodium carbonate solution and water, and were then dried on anhydrous sodium sulphate. After evaporation to dryness in vacuo, the residue was dissolved in 160 ml of acetonitrile and excess hydrogen chloride in diethyl ether was added. The insoluble title compound was recrystallized from acetonitrile. Yield 3.6 g, m.p. 138-143’C.
Rxamnlfl 8 8-[3-(4-phenyl-l-piperazinyl)-propoxycarbonyl]-3-methyl--4-oxo-2-pheny1-4H-1-benzopyran dihydrochloride
The title compound was prepared by the method described in Example 7, but using l-phenyl-piperazine in place of 1-(2-chlorophenyl)-piperazine hydrochloride. Recrys- LV 10099 121 tallization was from methanol; the melting point was 229-231*C.
Example 9 8-{3- [4-(2-methoxyphenyl)-l-piperazinyl]-propoxy-carbony1>-3-methyl-4-oxo-2-pheny1-4Η-1-benzopyran dihydrochloride
Operating as described in Example 7, but using l-(2--methoxyphenyl)-piperazine hydrochloride instead of 1-(2-chlorophenyl)-piperazine hydrochloride, the title compound was obtained. This represents an alternative route to the product of Example 5. fctample 10 8-(3- [4-(2-methoxyphenyl)-l-piperazinyl]-2-methyl-2--propoxycarbonyl}-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran dihydrochloride 5.29 g of Intermediate XXVIII in. 25 ml of 1/2-dichloroethane was added dropwise at 60 *C to a solution of 6 g of 8-chlorocarbonyl-3-methyl-4-oxo-2--phenyl-4H-l-benzopyran in 22 ml of 1,2-dichloroethane. The reaction mixture was refluxed for 16 hours, and then cooled to ambient temperature and poured into cold 0.5N sodium hydroxide solution. Water and dichloromethane were added. The organic phase was separated off, washed with agueous sodium chloride solution and dried on anhydrous sodium sulphate. The solvents were evaporated off and the oily residue was purified by flash chromatography on silica gel, eluting with Petroleum ether:ethyl acetate 85:15. The collected fractions vrere evaporated to dryness in vacuo and the residue was dissolved in ethanol. Excess ethanolic hydrogen chloride was added to give 6.71 g of the title compound, m.p. 203-204*C. 122
Example 11 8-(3-[4-(2-methoxyphenyl)-1-piperaz inyl]-propylcarba-moyl}-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran dihydrochloride hemihydrate A mixture of 6.28 g of 1-(2-methoxyphenyl)-piperazine and 5.34 g of Intermediate XXXVII was heated at 180*C for 5 hours. After cooling/ the dark mass was purified by flash chromatography on silica gel, eluting with di chloromethane:methanol 100:3. The f ractions containing the title compound were pooled. The solvents were removed In vacuo and the resldue was dissolved in boiling ethanol. The solution was filtered, acidified with ethanolic hydrogen chloride, and stood overnight at 20-25'C. The crude product was collected by filtration and crystallized from ethanol to give 5 g of the title compound, m.p. (177)182-186*0. gx3mpļe_12 8-(3-(4-(2-methoxyphenyl)-1-piperaz inyl]-propylcarba-moyl)-3-me thy1-4-oxo-2-phenyl-4H-1-benzopyran dihydrochloride hemihydrate A solution of 4.48 g of 8-chlorocarbonyl-3-methyl-4-oxo--2-phenyl-4H-l-benzopyran in 40 ml of chloroform was added dropwise over a period of 10 minūtes at ambient temperature to a solution of 3.74 g of 3-(4-(2--methoxyphenyl)-l-piperazinyl]-propylamine, prepared as described in GB 2161807, and 1.97 g of triethylamine in 50 ml of chloroform. After stirring for 2 hours, the solution was washed first with 0.5N hydrochloric acid, secondly with a saturated aqueous sodium bicarbonate solution and finally with water. The chloroform solution was dried on anhydrous sodium sulphate and the solvent was evaporated off in vacuo. The residue was worked up as described in Example 11 to give 6.67 g of the title LV 10099 123 compound, m.p. (177). 182-186’C. This represents an alternative route to the product of Example 11.
The following salts were also prepared: monohydrochloride hydrate, m.p. 151-154*C, monomethanesulphonate, m.p. 162-164 *C, and (±)-hemimalate hydrate, m.p. 110-112‘C.
This example has described the condensation of the amine, 3-[4-(2-methoxyphenyl)-l-piperazinyl]-propylami-ne, with the carbonyl chloride, 3-methyl-4-oxo-2-phenyl--4H-l-benzopyran-8-carbonyl chloride. It should be noted that the amine can be condensed with the corresponding free acid or the corresponding ethyl ester by heating eguimolar amounts thereof with or without a solvent. If a solvent is used, a high boiling point hydrophilic or hydrophobic solvent is appropriate. The amine can also be condensed at ambient temperature with an equimolar amount of the corresponding free acid in the presence of N,N'-dicyclohexylcarbodiimide and 4-dimethylaminopyri-dine in a solvent such as dichloromethane, chloroform, tetrahydrofuran or dimethylformamide.
Bacample ,..13 8-{2- [4-(2-methoxyphenyl)-l-piperazinyl]-ethylcarba-moy1)-3-methy1-4-oxo-2-phenyl-4H-1-benzopyran monohydrochloride hemihydrate
The title compound was prepared by the method described in Example 16, but using Intermediate XIV instead of Intermediate XV and heating at 55-60’C for 32 hours. Also, work up was varied as follows. After collecting the base by filtration, purification was by flash chromatography on silica gel, eluting with chloroform:methanol 100:0.5 and then 100:1. The fractions containing the title compound were pooled and the solvents were removed in vacuo. The residue was 124 crystallized from ethanol. After filtration, the solids were taken up in boiling water and sufficient dilute hydrochloric acid was added to effect solution. The crystalline salt separated on cooling and was collected by suction filtration. M.p. 119-123*C.
Examole 14 8-{3- [2- (2-methoxyphenoxy) -ethylamino] -propylcarbamoyl}--3-methyl-4-oxo-2-phenyl-4H-1-benzopyran hydrochloride
Operating as described in Example 11, but using 2-(2--methoxyphenoxy)-ethylamine (prepared according to Augstein, J. et al., J. Med. Chem., £., 356, 1965) instead of 1-(2-methoxyphenyl)-piperazine, heating for 2 hours instead of 5 hours, and using dichloromethane:methanol 100:5 as eluant, the title compound was obtained. M.p. 200-202*C (ethanol). gxasple ..15 8- [3- (4-phenyl-l-piperazinyl) -propylcarbamoyl] -3-methyl--4-oxo-2-pheny1-4 Η-1-benzopyran monohydrochloride hemihydrate
Operating as described in Example 11, but using l-phenylpiperazine instead of l-(2-methoxyphenyl)--piperazine, heating for 2 hours instead of 5 hours, and using dichloromethane:methanol 100:4 as eluant, the title compound was obtained. M.p. (251) 255-258*C with decomposition (87% ethanol). ;Exaaple .16 8-{N-methyl-2-[4-(2-methoxyphenyl)-1-piperaz inyl]--ethylcarbamoyl)-3-methyl-4-oxo-2-phenyl-4H-l-benzopyran monohydrochloride A mixture of 3.56 g of Intermediate XV, 2.35 g of l-(2--methoxyphenyl)-piperazine, 2.76 g of anhydrous LV 10099 125 potassium carbonate and 1.66 g of potassium iodide in 25 ml of dimethylformamide was stirred at 100’C for 6 hours. After cooling, the solvent was removed in vacuo and the residue was taken up in 50 ml of water, stirred for 1 hour at ambient temperature, collected by filtration, washed with water and crystallized from 95¾ ethanol in the presence of a small amount of activated charcoal (for decolouring). The base was dissolved in 105 ml of boiling 0.086N hydrochloric acid. After cooling, the crystallized salt was collected by filtration, giving 4.3 g of the title compound, m.p. 201-203 *C.
SkafflPlfi-l? 8-{l-hydroxy-2-[4-(2-methoxyphenyl)-l-piperazinyl]--ethyl}-3-methyl-4-oxo-2-phenyl-4H-l-benzopyran hydrochloride 1.36 g of sodium borohydride was added portionwise at 0 to 5’C to a solution of 15.5 g of the compound prepared in Example 1 in 1500 ml of methanol. After stirring for 90 minūtes at 0 to 5’C, 3N hydrochloric acid was added in order slightly to acidify the reaction mixture, which was then stripped in vacuo. The residue was shaken with 2N aqueous sodium hydroxide solution and extracted with chloroform. The organic layer was dried on anhydrous sodium sulphate/calcium chloride, filtered, acidified with ethanolic hydrogen chloride and stripped in vacuo. After washing with diethyl ether, the crude product was crystallized from ethanol to give 9.5 g of title compound, m.p. 248-249*C. gxample 13 8-{l-hydroxy-2-[4-(2-methylphenyl)-l-piperazinyl]--ethy1}-3-methy1-4-oxo-2-pheny1-4Η-1-benzopyran hydrochloride 126
This compound was prepared according to Example 17, but starting from the compound prepared in Example 2 rather than that prepared in Example 1. M.p. 257-258*C.
Examole 19 8-{l-hydroxy-2-[4-(2-ethoxyphenyl)-l-piperazinyl]--ethyl}-3-me thy1- 4-oxo-2-pheny1-4 Η-1-benzopyran hydrochloride
This compound was prepared according to Example 17, but starting from the compound prepared in Example 3 rather than that prepared in Example 1. M.p. 241-241’C (methanol).
Examr>lft 20 8- {l-hydroxy-3- [4- (2-methoxyphenyl) -l-piperazinyl] --propyl>-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran hydrochloride
This compound was prepared according to Example 17, but starting from the compound prepared in Example 4 rather than that prepared in Example 1. The crude base wa-s purified by flash chromatography (silica gel, eluant -ethyl acetaterchloroform 4:1). The fractions containing the pure base were pooled, acidified with ethanolic hydrogen chloride and stripped in vacuo. The residue was crystallized from ethanol. M.p. (126) 156-160’C. ,Example 21 8-{l-hydroxy-4-[4-(2-methoxypheny1)-l-piperazinyl]--butyl)-3-methyl-4-0x0-2-pheny1-4 Η-1-benzopyran hydrochloride monohydrate A solution of 3.04 g of Intermediate XXXVIII and 2.45 g of l-(2-methoxyphenyl)-piperazine in 21 ml of anhydrous dimethylformamide was stirred for 5 hours at ambient temperature. A further 1.22 g of 1-(2-methoxyphenyl)- LV 10099 127 -piperazine was added,.and the mixture was stirred for 4 hours, poured into 300 ml of water, and extracted with ethyl acetate. The combined organic extracts were washed with aqueous sodium bicarbonate solution and then with agueous sodium chloride solution, and evaporated to dryness in vacuo. The residue was purified by flash chromatography on silica gel, eluting with ethyl acetate:methanol 95:5. The collected fractions were stripped on a rotary evaporator, and the residue was dissolved in 0.81M ethanolic hydrogen chloride and stripped again in vacuo. The solid residue was crystallized from waterrethanol 9:1 to give 2.43 g of the title compound, m.p. 144-146*C. gxaro.le.....22 8-{l-ethoxy-2-[4-(2-methoxyphenyl)-l-piperazinyl]--ethyl}-3-me thy1-4-oxo-2-pheny1-4 Η-1-benzopyran hydrochloride 6 ml of anhydrous dimethylsulphoxide was added to 6.55 g of sodium hydride (50¾ in mineral oil, repeatedly washed with hexane) under nitrogen. A solution of 3 g of the compound prepared in Example 17 in 50 ml of anhydrous dimethylsulphoxide was added to the mixture at 20-25*C. After stirring for 1 hour at 20*C, 0.66 g of ethyl bromide was added. The reaction mixture was stirred for an additional 20 minūtes at the same temperature and then poured into iced water. The crude product obtained after suction filtration was purified by flash chromatography (silica gel, eluant - chloroform:ethyl acetate 8:2). The fractions containing the pure title compound were pooled, acidified with ethanolic hydrogen chloride, and stripped in vacuo. The residue was crystallized from chloroform:diethyl ether and dried in vacuo at 140’C to give 1.6 g of the title compound, m.p. (155) 209*C. 128
Example 33 8-{N-methyl-2-[4-(2-methoxyphenyl)-l-piperazinyl]--ethylaminomethyl > - 3 -methy 1 - 4 -oxo - 2 -p.henyl -4H -1 -benzopyran dihydrochloride hemihydrate A mixture of 5.2 g of Intermediate XXVII, 3.1 g of 1-(2-methoxyphenyl)-piperazine and 2.2 g of anhydrous potassium carbonate in 50 ml of dimethylformamide was stirred at 70*C for 7 hours. After cooling to 20-25*C, the reaction mixture was poured into 500 ml of water, and extracted with dichloromethane. The organic phase was washed with water and dried on anhydrous sodium sulphate. The solvent was removed in vacuo. The residue was purified by flash chromatography on silica gel, eluting with ethyl acetate:petroleum ether 98:2. The title compound was obtained by salification with ethanolic hydrogen chloride. M.p. 217-219*C.
Bxample ..24 8-{N-acetyl-2- [4-(2-methoxyphenyl)-l-piperazinyl]--ethylaminomethyl}-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran hydrochloride A mixture of 5 g of Intermediate XXXIII and 5.3 g of 1-(2-methoxyphenyl)-piperazine in 75 ml of dimethyl-formamide was stirred at 95'C for 2 hours. After cooling to 20-25*C, the reaction mixture was poured into 200 ml of water, made alkaline with potassium carbonate and extracted with ethyl acetate. The organic phase was washed with water and dried on anhydrous sodium sulphate. The solvent was removed in vacuo. The residue was purified by flash chromatography on silica gel, eluting with dichloromethane:methanol 100:0.2. Salification of the pure base with ethanolic hydrogen chloride and recrystallization from methanol gavē 4.4 g of the title compound, melting at (200) 227-228’C and containing one eguivalent of methanol. LV 10099 129 sxampl.e. 2.5 8-[4-(2-methoxyphenyl)-l-piperazinylacetamidomethyl]-3--methyl-4-oxo-2-phenyl-4H-l-benzopyran hydrochloride A mixture of 3.42 g of Intermediate XXXII, 2.74 g of 1-(2-methoxyphenyl)-piperazine and 0.71 g of anhydrous potassium carbonate in 34 ml of anhydrous dimethyl-formamide was stirred at 0*C for 2 hours. The reaction mixture was poured into water and filtered under suction. The resultant solid was purified by flash chromatography on silica gel, eluting with ethyl acetate:Petroleum ether 6:4. The collected fractions were evaporated to dryness in vacuo, and the residue was crystallized from ethyl methyl ketone. The base obtained was treated in ethanolic solution with a molar equivalent of aqueous 2.25N hydrochloric acid to give the tītie compound, m.p. 168-170*C. 8-{N-methyl-N- [4- (2-methoxyphenyl) -l-piperazinyl] --ac et amidome thyl>-3-methyl-4-oxo-2-pheny1-4H-1-benzopyran hydrochloride hydrate A mixture of 5 g of Intermediate XXXI, 2.9 g of 1-(2-methoxyphenyl)-piperazine and 2 g of anhydrous potassium carbonate in 50 ml of dimethylformamide was stirred at 20-25*C for 3 hours. The reaction mixture was then poured into 500 ml of water and extracted with dichloromethane. The organic phase was washed with water and dried on anhydrous sodium sulphate. The solvent was removed in vacuo. The residue was purified by flash chromatography on silica gel, eluting with ethyl acetate:petroleum ether 6:4, and crystallized from acetone to give 3.6 g of the base of the title compound, melting at 144-145'C. The base was dissolved in ethanol and 8N hydrochloric acid and water were added, yielding 130 the title compound, m.p. 218-220*C, after drying at 100‘C in vacuo.
Example 27 8-{2-[4-(2-methoxyphenyl)-l-piperazinyl]-ethoxymethyl}--3-methyl-4-oxo-2-phenyl-4H-1-benzopyran dihydrochloride A mixture of 4 g of Intermediate XVIII, 2.4 g of 1- (2-methoxyphenyl)-piperazine, 1.96 g of potassium iodide and 1.65 g of anhydrous potassium carbonate in 40 ml of anhydrous dimethylformamide was stirred at 90 *C for 7 hours. After cooling to ambient temperature, the mixture was poured into water and extracted with dichloromethane. The combined extracts were washed with aqueous sodiura chloride solution, dried on anhydrous sodium sulphate and evaporated to dryness in vacuo. The residue vras crystallized from ethyl acetate and the collected crystals were dissolved in ethanol and treated with exce8s ethanolic hydrogen chloride to give 5.21 g of the title compound, m.p. 199-201’C.
Examole 28 8-{2-[2-(2-ethoxyphenoxy)-ethylamino]-ethoxymethyl}-3--methy1-4-oxo-2-phenyl-4Η-1-benzopyran hydrochloride
Operating as described in Example 27, but using 2- (2-ethoxyphenoxy)-ethylamine in place of 1 - (2- -methoxyphenyl)-piperazine and including a purification step of flash chromatography on silica gel eluted with ethyl acetate :methanol 97 :3, 4.25 g of the title compound was obtained. M.p. 191-193’C.
Exampie, 23 8-{2-[4-(2-methoxyphenyl)-l-piperazinyl]-ethylthio-methy1}-3-me thyl-4 -oxo-2-phenyl-4 Η-1-benzopyran hydrochloride LV 10099 131 2.5 g of potassium carbonate, 2.13 g of potassium iodide and 3.15 g of 1-(2-methoxyphenyl)-piperazine were added to a solution of 5 g of Intermediate XXI in 50 ml of dimethylformamide/ and the mixture was stirred at 90 *C for 4.5 hours. After cooling to ambient temperature, the reaction mixture was poured into 450 ml of water and extracted with ethyl acetate. The organic extracts were washed with water, dried on anhydrous sodiumsulphate and evaporated to dryness in vacuo. A solution of the residue in acetone was treated with a molar equivalent of 3.8N hydrogen chloride in diethyl ether, filtered and recrystallized from ethanol to yield 6.15 g of the title compound, m.p. (218) 223-224’C.
Example 30 8-{2- [4-(2-methoxyphenyl)-l-piperazinyl]-ethylsulphinyl-methyl}-3-methyl-4-oxo-2-phenyl-4H-l-benzopyran dihydrochloride hemihydrate
The title compound was prepared by the method described in Example 29, using Intermediate XXVI instead of Intermediate XXI and stirring for 2.5 hours rather than for 4.5 hours. After the usual work up, the residue was purified by flash chromatography on silica gel, eluting with ethyl acetate:methanol 97:3. The collected fractions were acidified with excess ethanolic hydrogen chloride, evaporated to dryness in vacuo. The residue was crystallized from ethanol, giving 5.2 g of the title compound, m.p. 170-172*C. This compound contains 1 ecjuivalent of ethanol.
Example 31 8- {2- [4-(2-methoxyphenyl)-l-piperazinyl]-ethylsulphonyl-methyl}-3-methyl-4-oxo-2-phenyl-4H-l-benzopyran hydrochloride 132 A mixture of 4.5 g of Intermediate XXV, 2.36 g of 1-(2-methoxyphenyl)-piperazine and 0.84 g of potassium carbonate in 45 ml of anhydrous dimethylformamide was stirred at ambient temperature for 2.5 hours. The 5 reaction mixture was poured into 300 ml of water and filtered under suction, washing with water. The solid base was crystallized from ethanol and had a melting point of 143-146’C. The crystallate was dissolved in 1,2-dichloroethane and acidified with ethanolic hydrogen 10 chloride. 4.4 g of the title compound, m.p. 229-233*C, was obtained by recrystallization from methanol :water 1:3.5.
Exaffple 32 15 8-{2- [4- (2-methoxyphenyl) -l-piperazinyl] -ethylamino}-3- -methy1-4-oxo-2-pheny1-4Η-1-benzopyran dihydrochloride A solution of 3.7 g of Intermediate XXIII in 10 ml of dimethylformamide was added dropwise at 0’C to a 20 suspension of 0.9 g of sodium hydride (50% in mineral oil) in 9 ml of dimethylformamide. The cooling bath was removed, and after 30 minūtes at 20-25*C a solution of 4.1 g of 1-(2-chloroethyl)-4-(2-methoxyphenyl)--piperazine in 10 ml of dimethylformamide was added. The 25 mixture was stirred at 90’C for 5 hours and then cooled to 20-25*C. A further addition of 0.25 g of sodium hydride (50% in mineral oil) followed by 1.36 g of l-(2--chloroethyl)-4-(2-methoxyphenyl)-piperazine in 5 ml of dimethylformamide was made. The mixture was stirred at 30 90*C for 8 hours and again cooled to 20-25*C. 200 ml of water was cautiously added, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and dried on anhydrous sodium sulphate. The solvent was evaporated off in vacuo and the residue was purified by flash chromatography on silica gel, eluting with n-hexane:ethyl acetate 3:2. 35 LV 10099 133
This gavē a mixture of the base of the title compound and the corresponding N-trifluoroacetyl compound. 3.8 g of this mixture was dissolved in 35 ml of ethanol and 35 ml of dimethylsulphoxide. To this solution, 0.55 g of sodium borohydride was added portionwise at 20-25 ’C. The mixture was stirred for 3 hours at this temperatūra, and then poured into 200 ml of water and extracted with ethyl acetate. The organic extracts were washed with water, dried on anhydrous sodium sulphate and evaporated to dryness in vacuo. The residue was dissolved in dichloromethane. 2 equivalents of ethanolic hydrogen chloride were added to give the title compound, which was recrystallized from ethanol. Yield 3.8 g, m.p. 231-234 *C.
Example 33 8-{3- [4-(2-methoxypheny1)-l-piperazinyl]-propylamino}-3--methy 1 -4 -oxo-2 -pheny 1 -4H-1 -benzopyran hydrochloride 2.75-hydrate
Using 1- (3-chloropropyl) -4- (2-methoxyphenyl) -piperazine instead of 1-(2-chloroethyl)-4-(2-methoxyphenyl)--piperazine, but otherwise operating as described in Example 32, the title compound was obtained. M.p. 206-208'C (10¾ ethanol).
Example 34 8-{4- [4-(2-methoxyphenyl) -l-piperazinyl] -butylamino}-3--methyl - 4 - oxo-2 -phenyl -4H-1 -benzopyran hydrochloride hemihydrate A mixture of 4.5 g of Intermediate XXXIX, 3.9 g of 8-amino-3-methyl-4-oxo-2-phenyl-4H-l-benzopyran, 8.3 g of sodium triacetoxyborohydride and 3.4 ml of acetic acid in 40 ml of 1,2-dichloroethane was stirred for 6 hours at 20-25*C. 15 ml of 5¾ agueous sodium bicarbonate 134 solution was then added, and the mixture was stirred for 10 minūtes. The mixture was then made alkaline by addition of 0.5N sodium hydroxide solution and extracted with dichloromethane. The organic extracts were washed with water and dried on anhydrous sodium sulphate. The solvent was evaporated off in vacuo and the residue was purified by flash chromatography on silica gel, eluting with ethyl acetate:petroleum ether 9:1. The base obatined was dissolved in dichloromethane and 1 eguivalent of ethanolic hydrogen chloride was added. After removing the solvent in vacuo, the residue was crystallized from 50¾ ethanol to give 1.6 g of the title compound, m.p. (140) 151-153*C.
Example 35 8-{N-methyl-3-[4-(2-methoxyphenyl)-l-piperazinyl]--propy lamino} - 3 -methyl - 4-oxo-2 -phenyl - 4 Η-1 -benzopyran hydrochloride A mixture of 4 g of the compound prepared in Example 33, in the form of its base, 4.35 ml of 37% aqueous formaldehyde and 1.15 g of sodium cyanoborohydride in 25 ml of acetonitrile was stirred at 20-25*C, maintaining the pH in the range 5-6 by the addition of acetic acid during the reaction. After 4 hours the solvent was evaporated off in vacuo. 80 ml of ethyl acetate and 200 ml of ice cooled IN sodium hydroxide solution were added to the residue. The organic phase was washed with water, dried on anhydrous sodium sulphate and evaporated to dryness in vacuo. The residue was purified by flash chromatography on silica gel, eluting with ethyl acetate :petroleum ether 3:1. The pure base which was obtained was dissolved in diethyl ether. 1 eguivalent of ethanolic hydrogen chloride was added and the solvent was removed in vacuo. The residue was crystallized from water to give 2 g of the title compound, m.p. 186-187*C. LV 10099 135
Example 36 8-{N-acetyl-3-[4-(2-methoxyphenyl)-l-piperazinyl]--propylamino}-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran hydrochloride hydrate A mixture of 4.8 g of the compound prepared in Example 33, in the form of its base, 2.8 ml of acetic anhydride and 33 ml of pyridine was stirred at 80’C for 4 hours. After cooling to 20-25*C, the reaction mixture was poured into 200 g of iced water, acidified with 10N hydrochloric acid and extracted with dichloromethane. The organic extracts were washed with water, dried on anhydrous sodium sulphate and evaporated to dryness in vacuo. The residue was purified by flash chromatography On silica gel, eluting with ethyl acetate:methanol 95:5. The pure base which was obtained was dissolved in dichloromethane. 1 equivalent of ethanolic hydrogen chloride was added and the solvent was removed in vacuo. The residue was crystallized from acetonitrile to give 3 g of the title compound containing 0.33 equivalents of acetonitrile, m.p. 208.5-210.5*C.
Example 37 8-{3- [4-(2-methoxyphenyl)-l-piperazinyl]-propionamido}--3-methyl-4-oxo-2-phenyl-4H-1-benzopyran hydrochloride A mixture of 3.97 g of īntermediate X and 3.07 g of 1-(2-methoxyphenyl)-piperazine in 40 ml of dimethylformamide was stirred at 60 *C for 6 hours. The reaction mixture was then cooled to ambient temperature and poured into water. Following extraction with dichloromethane, the organic phase was washed with water and dried on anhydrous sodium sulphate. The solvent was removed in vacuo. The crude residue was crystallized from ethanol to give the base of the title compound, which was then dissolved in hot ethanol. 1 molar eguivalent of 0.81M ethanolic hydrogen chloride was 136 added to the solution,-4 g of the title compound, m.p. 255-257*C, was obtained.
Sxample 38 5 8-{2-[4-(2-methoxyphenyl)-l-piperazinyl]-ethylureido}-3- -methyl-4-oxo-2-phenyl-4H-l-benzopyran methanesulphonate A mixture of 3.34 g of Intermediate XLIV and 7.22 g of 1-(2-methoxyphenyl)-piperazine was stirred at 100*C for 10 5 hours. An additional 1.8 g of 1-(2-methoxyphenyl)- -piperazine was then added and stirring was continued for a further 2 hours at 100*C. After cooling to ambient temperature, the reaction mixture was poured into water and extracted with ethyl acetate. The organic phase was 15 washed with agueous sodium hydroxide solution, dried on anhydrous sodium sulphate and evaporated to dryness in vacuo. The crude residue was purified by flash chromatography on silica gel, eluting with ethyl acetatejmethanol 98:2. The collected fractions were 20 evaporated to dryness in vacuo and crystai1izēd from water:ethanol 4:6. The crystals were redissolved in dichloromethane and treated with 1 molar eguivalent of methanesulphonic acid. The crude methanesulphonate obtained by evaporation in vacuo was crystallized from 25 ethyl acetate:ethanol 1:1 to yield 2.35 g of the title compound, melting at 191-193*C. dampis .39 8-{2- [4-(2-methoxyphenyl)-1-piperazinyl]-ethoxy}-3-30 -methyl-4-oxo-2-phenyl-4H-l-benzopyran hydrochloride hydrate A mixture of 6.61 g of the Intermediate XI, 8.34 g of 1-(2-methoxyphenyl)-piperazine and 1.26 g of sodium iodide in 70 ml of dimethylformamide was stirred at 80*C for 17 hours. After cooling to 20-25*C, the reaction mixture was poured into 600 ml of water, made alkaline 35 LV 10099 137 with 5% a<iueous sodium bicarbonate and extracted with dichloromethane. The organic extracts were washed with aqueous sodium chloride solution, dried on anhydrous sodium sulphate and evaporated to dryness in vacuo. The 5 residue was purified by flash chromatography on silica gel, eluting with dichloromethanermethanol 99:1, then 98:2. The fractions containing the base of the title compound were pooled, and the solvent was removed in vacuo. The residue was dissolved in ethanol and 10 ethanolic hydrogen chloride was added. The title compound crystallized and was collected by suction filtration. It was recrystallized from 95% ethanol. Yield 6.5 g, m.p. 224-225*C. 15 Elemental analvsis:
Found % : C=*66.38, H=6.34, N=5.35, Cl=6.76, H20=3.35
Calculat.%: 66.34, 6.14, 5.33, 6.75, 3.43 NMR Spectrum at 60 MHz (CDCl^-CD^OD) 20 7.8-7.1 (m, 8H, aromatic protons of the benzopyran ring) 7.1-6.6 (m, 4H, aromatic protons of the 2-methoxyphenyl group) 4.8-4.4 (m, 2H, OCH2) 4.4-4.1 (m, 3H, H2O and N+H) 25 3.9-3.0 (m, 10H, 5xCH2N) 3.8 (s, 3H, OCH3) 2.1 (s, 3H, CH3)
Example 40 30 8-{3-[4-(2-methoxyphenyl)-l-piperazinyl]-propoxy}-3- -me thy1-4-0x0-2-pheny1-4Η-1-benzopyran dihydrochloride
This compound was prepared by the method described in Example 39, but using Intermediate IX instead of intermediate XI. Purification by flash chromatography was omitted as unnecessary in this case. M.p. 226-227’C. 35 138 ΡΧΜΒΡίβ, 42 8-{4- [4-(2-methoxyphenyl)-l-piperazinyl]-butoxy}-3--methyl-4-oxo-2-phenyl-4H-l-benzopyran dihydrochloride A mixture of 7.75 g of Intermediate XVI, 4.7 g of 1-(2-methoxyphenyl)-piperazine, 3.3 g of potassium iodide and 2.8 g of anhydrous potassium carbonate in 78 ml of dimethylformamide was stirred at 75*C for 2 hours. After cooling to 20-25*C, the reaction mixture was poured into 600 ml of water and extracted with dichloromethane. The organic extracts were washed with water and dried on anhydrous sodium sulphate, and the solvent was then evaporated off in vacuo. The residue was purified by column chromatography on silica gel, eluting with ethyl acetate. The pure title compound thus obtained as its base was transformed into its dihydrochloride by treatment with ethanolic hydrogen chloride. After crystallization from ethanol, 6.5 g of the title compound was obtained, m.p. 217-219*C.
Examole 42 8-{5-[4-(2-methoxyphenyl)-l-piperazinyl]-pentyloxy}-3--methyl-4-oxo-2-phenyl-4H-l-benzopyran hydrochloride
This compound was prepared by the method described in Example 41, but using Intermediate XVII instead of Intermediate XVI. M.p. 173*C (ethanol). The corresponding base melts at 117-118*C (ethanol).
Ejamie 4.3 8-{3- [4-(2-methoxyphenyl)-l-oxo-piperazinyl]-propoxy)-3--methyl-4-oxo-2-phenyl-4H-l-benzopyran 1.75-hydrate 2.93 g of magnesium monoperoxyphthalate in 10 ml of water was added dropwise at -15‘C to a solution of 4.34 g of the compound prepared in Example 40 and 0.1 g of benzyl(triethyl)ammonium chloride in 20 ml of LV 10099 139 dichloromethane and 20. ml of methanol. The mixture was stirred for 2 hours at 0*C and then warmed to ambient temperature. It was poured into water and made basie by addition of aqueous sodium hydroxide solution. 5 Extraction with dichloromethane gavē, after the usual work up, a solid which was purified by flash chromatography, eluting with dichloromethane:methanol 9:1. The collected fractions containing the pure compound were evaporated to dryness in vacuo and the 10 residue was crystallized from acetonitrile to give 0.5 g of the title compound, m.p. 89-92’C.
Example 44 8-(2- [2-(2,6-dimethoxyphenoxy)-ethylamino]-ethoxy}-3-15 -methyl-4-oxo-2-phenyl-4H-l-benzopyran hydrochloride A mixture of 4.5 g; of intermediate XII, 3.7 g of triphenylphosphine and 2.85 g of 2,6-dimethoxyphenoxy-acetaldehyde (prepared according to Nelson, W.L. et al., 20 17. Med. Chem., 22.i 1125, 1979) in 45 ml of benzene was stirred at 20-25*C for 18 hours and at reflux for 5 hours. The solvent was evaporated off in vacuo and the residue was dissolved in 80 ml of anhydrous methanol. 3A molecular sieve was added. Next, 0.61 g of sodium 25 borohydride was added at 0*C. The mixture was stood for 1 hour at 0’C and for 1 hour at 20-25'C, and then poured into iced water and extracted with dichloromethane. The organic extracts were washed with water and dried on anhydrous sodium sulphate. The solvent was removed in 30 vacuo and the residue was purified by flash chromatography on silica gel, eluting with dichloromethane:methanol 49:1. The base obtained was treated with ethanolic hydrogen chloride. After crystallization from ethanol, the title compound was 35 obtained. Yield 40%, m.p. 200-202*C. 140 gxamplĢ A3 8-(2-hydroxy-3- [4-(2-methoxyphenyl)-l-piperazinyl] -propoxy >-3-methyl-4-oxo-2-pheny1-4 Η-1-benzopyran hydrochloride A solution of 3.7 g of Intermediate XL and 4.64 g of 1-(2-methoxyphenyl)-piperazine in 40 ml of dimethyl-formamide was stirred at 80*C for 3 hours. After cooling to 20-25C, the reaction mixture was poured into 400 ml of water and extracted with dichloromethane. The aqueous phase was made alkaline with 1N sodium hydroxide solution and extracted with ethyl acetate. The combined organic extracts were washed with water and dried on anhydrous sodium sulphate. The solvents were evaporated off in vacuo. The residue was purified by flash chromatography on silica gel, eluting with ethyl acetate. The fractions containing the title compound in the form of its base were pooled, and stripped in vacuo. the residue was dissolved in dichloromethane and one equivalent of ethanolic hydrogen chloride was added. The solvents were removed and the residue was crystallized from ethanol. 5 g of the title compound containing one molar eguivalent of ethanol vrere obtained. M.p. (122) 126-128*C with decomposition.
Example 46 8-{3-[4-(2-methoxyphenyl)-1-piperaz inyl]-propy1thio} - 3 --me thyl - 4 - oxo - 2 -pheny 1 - 4 Η -1 -benzopyran A mixture of 4.4 g of Intermediate XXXIV, 2.5 g of 1-(2-methoxyphenyl)-piperazine, 1 g of potassium iodide and 1.8 g of anhydrous potassium carbonate in 40 ml of dimethylformamide was stirred at 100*C for 3 hours. After cooling to 20-25'C, the reaction mixture was poured into 350 ml of water and extracted with dichloromethane. The organic extracts were washed with water and dried on anhydrous sodium sulphate, and the LV 10099 141 solvent was then evaporated off in vacuo. The residue was purified by columii chromatography on sillca gel, eluting with ethyl acetate: Petroleum ether 3:2, and by crystallization from ethanol, yielding 3.9 g of the 5 title compound, m.p. (70) 96-99*C.
Example 47 8-{3- [4-(2-methoxyphenyl)-l-piperazinyl]-propylsulpho-nyl}-3-methy1-4-oxo-2-phenyl-4H-1-benzopyran 10 hydrochloride A solutlon of 3.8 g of Intermediate XXXV and 4 g of 1-(2-methoxyphenyl)-piperazine in 40 ml of dimethylform-amide was heated at 60*C for 7 hours. After cooling to 15 20-25’C, the reaction mixture was poured into 500 ml of water and extracted with dichloromethane. The organic extracts were washed with water and dried on anhydrous sodium sulphate, and the solvent was then evaporated off in vacuo. The residue was purified by flash 20 chromatography on silica gel, eluting with ethyl acetateipetroleum ether 1:1. The base of the title compound was obtained. It was dissolved in ethanol and one equivaleņt of ethanolic hydrogen chloride was added to give 4.5 g of the title compound, m.p. (215) 226-25 228 *C.
Example 48 8-(2-[4-(2-methoxyphenyl)-l-piperazinyl]-ethylsulpha-moyl}-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran 30 hydrochloride A solution of 4.5 g of Intermediate XLII and 3.8 g of 1-(2-methoxyphenyl)-piperazine in 40 ml of dimethylform-amide was heated at 70‘C for 7 hours. After cooling to 35 20-25'C, the reaction mixture was poured into 150 ml of water and extracted with dichloromethane. The organic solution was washed with water and dried on anhydrous 142 sodium sulphate, and the solvent was then evaporated off in vacuo. The residue was purified by flash chromatography on silica gel, eluting with ethyl acetate:Petroleum ether 3:7, and the title compound was obtained by salification with ethanolic hydrogen chloride. Yield 2.9 g, m.p. 236-238*C.
Examole 49 8- {N-methyl-2- [4- (2-methoxyphenyl) -l-piperazinyl] -ethyl-sulphamoyl }-3-methyl-4 -oxo-2-phenyl-4H-1-benzopyran hydrochloride
The title compound was obtained by the method described in Example 48, but using Intermediate XLI instead of Intermediate XLII. M.p. 194-198‘C (ethanol).
Example 50 8-{N-carbamoyl-3-[4-(2-methoxyphenyl)-l-piperazinyl]-propylamino >-3-methy1-4-oxo-2-pheny1-4H-1-benzopyran methanesulphonate hemihydrate A mixture of 4.06 g of the compound of Example 33 and 1.5 g of potassium cyanate in 42 ml of glacial acetic acid was stirred at 50*C for 4 hours. The reaction mixture was poured into iced water and made alkaline. The precipitate was collected by suction filtration, dried and purified by flash chromatography using a silica gel column, eluting with ethyl acetate:methanol 98:2. The fractions, containing the title product as a base, were evaporated to dryness in vacuo and one eguivalent of methanesulphonic acid was added to the residue after dissolution in 30 ml of dichloromethane. The solvent was evaporated off in vacuo and the residue was crystallized from ethanol to give 3.1 g of the title compound, m.p. 157-160*C, with decomposition. This compound contained one molar eguivalent of ethanol. LV 10099 143
Example 51 8-<4- [4-(2-methoxyphenyl)-l-piperazinyl]-l-oxobutyl}-3--methyl-4-0X0-2-phenyl-4H-1-benzopyran methanesulphonate A solution of 1.33 ml of anhydrous dimethylsulphoxide in 9 ml o£ dichloromethane was added at -70*C to a solution of 0.74 ml of oxalyl chloride in 6 ml of dichloromethane. After stirring at -70*C for 15 minūtes, a solution of 2.8 g of the compound of Example 21 (as a base) in 14 ml of dichloromethane was added. After 15 minūtes at the same temperature, 4.7 ml of anhydrous triethylamine was added and the temperature was raised to -30'C over a period of 30 minūtes. Stirring was continued at -30*C for another 30 minūtes. After letting the temperature rise to O'C, the mixture was diluted with 120 ml of water and extracted with dichloromethane. The organic phase was washed with water, dried on anhydrous sodium sulphate and evaporated to dryness in vacuo. The residue was purified by flash chromatography in a silica gel column, eluting with ethyl acetate:dichloromethane 9:1. The fractions, containing the title product as a base, were evaporated to dryness in vacuo and one equivalent of methanesulphonic acid was added to the residue after dissolution in 30 ml of dichloromethane. The solvent was evaporated off in vacuo and the residue was crystallized from ethanol to give 2.9 g of the title compound, m.p. 194-195*C. gxample 52 8-{3-[2-(l,4-benzodioxanyl)methylamino]propylcarbamoy1}-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran methanesulphonate
A mixture of 5.56 g of Intermediate XLIII, as a base, 4.58 g of 2-(p-toluenesulphonyloxymethyl)-1,4-benzodi-oxane and 1.9 g of anhydrous potassium carbonate in 80 ml of anhydrous dimethylformamide was stirred at 110*C for 5 hours. The reaction mixture was cooled to ambient temperature, poured into water and extracted with dichloromethane. The organic phase was washed with water, dried on anhydrous sodium sulphate, filtered and 5 evaporated to dryness in vacuo. The residue was purified by flash chromatography using a silica gel column, eluting with ethyl acetate:methanol 95:5. The fractions containing the title compound as a base were evaporated to dryness in vacuo. The residue was dissolved in 10 ethanol and one equivalent of methanesulphonic acid dissolved in ethyl acetate was added. The crystallized product was filtered off and recrystallized from ethanol to give 2.4 g of the title compound, m.p. 172-174*C. 15 Bxample 53 8-{4-[4-(2-methoxyphenyl)-1-piperaz inyl]-butyl}-3- -methyl-4 -oxo-2 -pheny 1 -4H-1 -benzopyran methanesulphonate A solution of 2.8 g of Intermediate XLVI and 0.13 g of 20 p-toluenesulphonic acid in 150 ml of methanol was refluxed for 5 hours. After cooling to 20-25*C, 0.8 g of anhydrous potassium carbonate was added and stirring was continued for 3 hours. After filtration, the reaction mixture was evaporated to dryness in vacuo to give 2.5 g 25 of 8-(4,4-dimethoxybutyl)-3-methyl-4-oxo-2-phenyl-4H-l--benzopyran. NMR (CDCU, δ) 1.6-1.9 (4h, m, CHCH2CH2CH) 30 2.2 (3H, s, flavone CH3) 2.9 (2H, t, Fl'-CH2) 3.3 (6H, s, 2xOCH3) 4.4 (1H, t, CH(OCH3)2) 7.3 (1H, dd, flavone CH in 6) 35 7.5-7.8 (6H, m, flavone CH in 7, and 5 x phenyl CH) 8.1 (1H, dd, flavone CH in 5) LV 10099 A solution of 2.5 g of.the compound thus prepared in 10 ml of water and 30 ml of acetic acid was heated at 50*C for 2.5 hours. The reaction mixture was cooled to ambient temperature, diluted with iced water, basified 5 with agueous sodium carbonate, and extracted with chloroform. The organic phase was dried on anhydrous sodium sulphate, filtered and evaporated to dryness in vacuo. The residue was purified by flash chromatography on silica gel, eluting with Petroleum ether:ethyl 10 acetate 3:1. 2.1 g of 8-(4-oxobutyl)-3-methyl-4-oxo-2--phenyl-4H-l-benzopyran was obtained (>75% yield) and was used with no further purificationin the next step. NMR (CDClļ, 5) 15 1.9-2,1 (2H, dd, CH2C32CH2CHO) 2.2 (3H, s, flavone CH3) 2.5 (2H, t, CH2CHO) 2.9 (2H, t, F1'-CH2) 7.3 (1H, dd, flavone CH in 6) 20 7.5-7.7 (6H, m, flavone CH in 7, and 5 x phenyl CH) 8.1 (1H, dd, flavone CH in 5) 9.7 (1H, s, CHO) 2.3 ml of 6N hydrochloric acid in ethanol, a solution of 2.1 g of the compound thus prepared in 40 ml of methanol 25 and 0.45 g of sodium cyanoborohydride vere added in succession to a solution of 8 g of 1-(2-methoxyphenyl)--piperazine in 30 ml of methanol. After stirring the reaction mixture at ambient temperature for 24 hours, it was poured into 500 ml of iced water and extracted with 30 dichloromethane. The organic phase was washed with water, dried on anhydrous sodium sulphate and evaporated to dryness in vacuo. The residue was purified by flash chromatography using a silica gel column, eluting with ethyl acetate:petroleum ether 9:1. The fractions, 35 containing the title product as a base, were evaporated to dryness in vacuo. The residue was dissolved in 30 ml of dichloromethane and one eguivalent of 146 methanesulphonic acid was added. The solvent was evaporated off in vacuo and the residue was crystallized from acetone to give 2.35 g of the title compound, m.p. 141-143’C. . .
Example 54 8- [3- (4-phenyl-l-piperidinyl) -propylcarbamoyl] -3-methyl--4 -oxo-2-pheny1-4H-1-benzopyran methanesulphonate
This compound was prepared by the method described in Example 11, using 4-phenylpiperidine instead of 1-(2-methoxyphenyl)-piperazine and conducting the reaction for 1 hour Instead of 5 hours. Purification was carried out by flash chromatography using a silica gel column, eluting with dichloromethanermethanol 100:5. M.p. 157-159‘C (ethyl acetate). The respective base melted at (127) 147-149’C (ethanol). 8-[3-(4,4-diphenyl-l-piperidinyl)-propylcarbamoyl]-3--methyl-4-oxo-2-phenyl-4H-l-benzopyran methanesulphonate
This compound was prepared by the method described in Example 11, using 4,4-diphenylpiperidine instead of 1-(2-methoxyphenyl)-piperazine and conducting the reaction for 2 hours instead of 5 hours. M.p. 221-223*C (ethyl acetate).
Examole 56 8-{3- [4-(4-fluorobenzoyl)-l-piperidinyl]-propyl-carbamoy1}-3-methyl-4-oxo-2-pheny1-4H-1-benzopyran
This compound was prepared by the method described in Example 11, using 4-(4-fluorobenzoyl)-piperidine instead of 1-(2-methoxyphenyl)-piperazine and conducting the reaction for 30 minūtes instead of 5 hours. Purification was carried out by flash chromatography using a silica LV 10099 147 gel column, eluting with dichloromethane:5N methanolic ammonia graduated 100:1 to 100:20. M.p. 181-183*C (ethanol). 5 Example 57 8-{3- [4-(2-oxo-l-benzimidazolinyl)-l-piperidinyl]--propylcarbamoyl}-3-methyl-4-oxo-2-phenyl-4H-l--benzopyran 10 This compound was prepared by the method described in Example ll,using 4-(2-oxo-l-benzimidazolinyl)-piperidine instead of 1-(2-methoxyphenyl)-piperazine. Purification was carried out by flash chromatography using a silica gel column, eluting with chloroform:5N methanolic 15 ammonia 100:3. M.p. 238-241*C (ethanol).
Exgfliple 58 8-{3- [4-(2-pyrimidinyl)-l-piperazinyl]-propylcarbamoyl} --3-methy1-4-oxo-2-pheny1-4 Η-1-benz opyran 20 methanesulphonate
The title compound was prepared by the method described in Example 11, using 1-(2-pyrimidinyl)-piperazine instead of l-(2-methoxyphenyl)-piperazine and conducting 25 the reaction for 2 hours. The product was purified by flash chromatography using a silica gel column, eluting with chloroform:methanol 100:3. The desired fractions were dissolved in dichloromethane and one eguivalent of methanesulphonic acid was added to the solution. After 30 evaporation of the solvent in vacuo, the residue was boiled for 1 hour with ethyl acetate and then collected by filtration. M.p. 209-210’C. The product contained 0.2 equivalents of ethyl acetate and 0.1 equivalent of water. The respective base melted at 178-180‘C (ethanol). 35 148
Example 59 8-{3-[4-(2-hydroxyphenyl)-1-piperaz inyl]-propylcarba-moy1}-3-methy1-4-oxo-2-pheny1-4H-1-benzopyran
Operating as described in Example 11, but using l-(2--hydroxyphenyl)-piperazine instead of 1-(2-methoxy-phenyl)-piperazine, heating for 1.5 hours instead of 5 hours, and using dichloromethaneimethanol 100:3 to 100:10 as eluant for column chromatography, the title compound was obtained. M.p. 118-120’C (ethanol 95%).
Example 60 8-{4- [4-(2-methoxyphenyl)-l-piperazinyl]-butylcarba-moyl} - 3 -methyl - 4-oxo - 2 -pheny 1 - 4H-1 -benzopyran methanesulphonate
This compound was prepared by the method used in Example 12, but using 4-[4-(2-methoxyphenyl)-l-piperazinyl]--butylamine instead of 3-[4-(2-methoxyphenyl)-l-pipera-zinyl]-propylamine. The reaction mixture was stirred at room temperature for 22 hours, diluted with water and filtered by suction, washing the insoluble solids with water. The crude residue was dried and purified by column chromatography on silica gel, eluting with ethyl acetate:methanol 9:1. The fractions containing the pure product as a base were collected, evaporated to dryness in vacuo and dissolved in dichloromethane. Methanesulphonic acid was added to the solution and the salt was precipitated by adding 2 volumes of ethyl acetate, filtered and recrystallized from ethanol to give the title compound, m.p. 230-232'C. This product contained 0.3 molar ecjuivalent of ethanol. LV 10099 149
Example 61 8-{3-[4-(2-methoxyphenyl)-l-piperazinyl]-propylsulpha-moyl}-3-methyl-4-oxo-2-phenyl-4H-l-benzopyran methanesulphonate 5 This compound was obtained operating as described in Example 12, but using intermediate VIII instead of 8-chlorocarbonyl-3-methyl-4-oxo-2-pheny1-4H-1-benzopyran and stirrlng for 24 hours instead of 2.5 hours. The crude product was purified by column chromatography on 10 silica gel, eluting with ethyl acetate:methanol 98.5:1.5. The collected fractions containing the pure product as a base were evaporated to dryness in vacuo and dissolved in dichloromethane. Methanesulphonic acid was added to the solution and the solvent was removed by 15 evaporation in vacuo. The crude salt was crystallized from ethanol to give the title compound, m.p. (196) 198-200 *C.
Example 62 20 8-(3- [N-methyl-2-(2-methoxyphenoxy)-ethylamino]-propyl- carbamoyl)-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran hydrochloride A solution of 10.5 ml of 40% formaldehyde in water was 25 added to a suspension of 6.66 g of the compound prepāred in Example 14 in 55 ml of acetonitrile and 20 ml of water. After stirring for 15 minūtes at room temperature, 2.70 g of sodium cyanoborohydride 95% was added to the red solution, and after an additional 15 30 minūtes in the same conditions 1.38 ml of acetic acid was added. After stirring for 3 hours, the solvents were removed in vacuo and the residue was rinsed with 250 ml of water and 250 ml of chloroform. After addition of 3N sodium hydroxide, the organic phase was separated off 35 and the aqueous phase was extracted twice with chloroform. The solvent was removed from the collected organic phases by evaporation in vacuo and the residue 150 was purufied by flash chromatography on silica gel, eluting with chloroform:5.2N methanolic ammonia 100:0.5 to 100:2. The collected fractions containing the pure title compound as a base were evaporated to dryness in vacuo and the residue was dissolved in hot ethanol. The solution was acidified with ethanolic hydrogen chloride and, after evaporation of the solvent in vacuo, the residue was rinsed with diethyl ether and stirred at room temperatūra. The crude product was collected by filtration and crystallized from acetonitrile to give 3.1 g of the title compound, m.p. 146-148*C. K-ramnlfl 63 8-{N-methyl-3-[4-(2-methoxyphenyl)-l-piperazinyl]- -propionamido}-3-methyl-4-oxo-2-phenyl-4H-l-benzopyran methanesulphonate
Operating as described in Example 37, but using Intermediate L instead of Intermediate X and stirring at 90*C for 4 hours instead of 60*C for 6 hours, the title compound was obtained as a crude base. After purification by column chromatography on silica gel, eluting with ethyl acetate:methanol 95:5, a crude methanesulphonate was obtained as described in Example 61 and crystallized from acetone to give the title compound, m.p. 200-202*C.
Example 64 8-{3-[4-(2-methoxyphenyl)-l-piperazinyl]-propylcarba-moy1}-3-methy1-4-oxo-2-pheny1-4H-1-benzopyran dimethanesulphonate
The title compound was prepared operating as described in Example 12, but using Intermediate LVI instead of 8-chlorocarbonyl-3-methyl-4-oxo-2-pheny1-4H-1-benzopyran and stirring for 24 hours instead of 2.5 hours. The crude product was purified by column chromatography, LV 10099 151 eluting with ethyl acetate:methanol 92:8, and the pure base, obtained by evaporation in vacuo of the collected fractions, was dissolved in dichloromethane. Two equivalents of methanesulphonic acid were added. The crude dimethanesulphonate, obtained after evaporating off the solvent, was recrystallized from acetone, m.p. 153-156 (200) *C. ΒυαιππΙβ 65 8 - {3 - [ (3,4-dihydro-l-oxo-2H-naphthyl) -methylamino] --p ropy1carbamoy1}-3-methyl-4-oxo-2-pheny1-4H-1--benzopyran methanesulphonate A mixture of 6 g of Intermediate XLIII, 2.4 g of 2-methylene-a-tetralone (prepared as described in Org. Synth.r SSL/ 88, 1981) and 3.14 ml of triethylamine in 48 ml of anhydrous dimēthylformamide was stirred at room temperature for 6 hours, and then at 50*C for 1 hour. The reaction mixture was diluted with water and extracted with dichloromethane. The organic layers were washed with water, dried on anhydrous sodium sulphate and evaporated to dryness in vacuo. The crude residue was purified twice by column chromatography eluting first with dichloromethaneimethanol 95:5 and then with dichloromethane:methanol:5.8N methanolic ammonia 98:2:0.2, to give 1.74 g of the title compound as a base. The base was converted into the methanesulphonate by the procedure described in Example 61. The salt was recrystallized first from acetone and then from acetonitrile to give the title compound, m.p. (69) 157-159 *C.
Example 66 8-{2-[4-(2-methoxyphenyl)-l-piperazinyl]--ethoxycarbonylmethyl}-3-methyl-4-oxo-2-phenyl-4H-1--benzopyran dihydrochloride 152
The title compound was prepared by the method described in Example 5, but using Intermediate XLVII in place of 8-carboxy-3-methyl-4-oxo-2-phenyl-4H-l-benzopyran and 1-(2-chloroethyl)-4-(2-methoxyphenyl)-piperazine instead of 1-(3-chloropropyl)-4-(2-methoxyphenyl)-piperazine. M.p. 193-196 *C from ethanol:diethyl ether. ]gxgjņpļg $7 8-{4- [4-(2-methoxyphenyl)-l-piperazinyl]--butylsulphamoyl}-3-methyl-4-oxo-2-phenyl-4H-l--benzopyran dimethanesulphonate
The title compound was prepared as described in Example 61 but using 4-[4-(2-methoxyphenyl)-l-piperazinyl]--butylamine instead of 3-[4-(2-methoxyphenyl)-l--piperazinyl]-propylamine. The crude dimethanesulphonate was crystallized first from acetonitrile and then from ethanol. M.p. 172-174 *C.
Example 68 8-{N-(2-tetrahydropyranyloxy)-3- [4-(2-methoxyphenyl)-1--piperazinyl]-propylcarbamoyl}-3-methyl-4-oxo-2-phenyl--4H-l-benzopyran methanesulphonate hemihydrate A solution of 3.6 g of l-(3-chloropropyl)-4-(2-methoxy-phenyl)-piperazine in 30 ml of anhydrous dimethylformamide was added dropwise, under stirring at O’C, to a mixture of 3.92 g of 0-(2-tetrahydropyranyl)--hydroxylamine (prepared as described by R.N. Watrener et al., Angevrandte Chem. Int. Ed., jL, 511, 1966). Stirring was continued for 2 hours at 0‘C, and then for 12 hours at 110*C. The reaction mixture was cooled to room temperature and dimethylformamide was removed by distillation in vacuo. The residue was rinsed with water and extracted with ethyl acetate. The combined organic layers were washed with water and dried on anhydrous sodium sulphate, The solvent was evaporated off in vacuo LV 10099 153 to give 4.39 g of 1- [3-(2-tetrahydropyranyloxyand.no) --propyl]-4-(2-methoxyphenyl)-piperazine. 3-H-NMR (CDCl^. δ) 6.50-6.75 (m, 4H, aromatic protons) 5.20 (bs, 1H, NH) 4.60 (m, 1H, O-CH-O) 3.30-4.00 (m, 5H, OCH3 and tetrahydropyran CH20) 2.80-3.20 (m, 6H, piperazine 2 x CH2, alkyl Chain CH2N) 2.20-2.80 (m, 6H, piperazine 2 x CH2, alkyl Chain CH2N) 1.30-2.00 (m, 8H, tetrahydropyran 3 x CH2, alkyl Chain C-CH2-C) 15 A solution of 2.79 g of 8-chlorocarbonyl-3-methyl-4-oxo--2-phenyl-4H-l-benzopyran in 47 ml of chloroform was added dropwise at room temperatūre to a mixture of 3.26 g of the compound thus prepared and 1,42 g of potassium carbonate in 47 ml of chloroform. The reaction mixture 20 was stirred for 3 hours, and then diluted with 75 ml of chloroform and washed three times with 1M sodium hydroxide. The organic layer was washed with water, dried on anhydrous sodium sulphate and evaporated to dryness in vacuo. The crude residue was purified by 25 column chromatography on silica gel eluting with ethyl acetate:methanol 98:2. The collected fractions were evaporated to dryness in vacuo to give 2.99 g of pure title compound as a base. The base was dissolved in dichloromethane, and methanesulphonic acid was added to 30 the solution. The solvent was removed by evaporation in vacuo and the crude salt was crystallized from ethyl acetate to yield the title compound, m.p. 159-160*C.
Example 69 35 8-<4- [4- (2-methoxyphenyl) -l-piperazinyl] -butyramido}-3- -methyl-4-oxo-2-phenyl-4H-l-benzopyran methanesulphonate hemihydrate 154
The title compound was prepared by the method described in Example 38, but using Intermediate XLVIII instead of Intermediate XLIV and stirring for 1 hour at 70*C and 2 hours at 130*C instead of 7 hours at 100*C. After the 5 usual work up, the crude residue was purified by column chromatography on silica gel eluting with ethyl acetateimethanol 95:5. The fractions containing the pure title compound as a base were collected and evaporated to dryness in vacuo. The residue was dissolved in 10 dichloromethane and one eguivalent of methanesulphonic acid was added to the solution. After evaporation of the solvent to dryness in vacuo, the crude salt was crystallized from acetone, m.p. 175-176’C. 15 gx«ipļe.-lfl E-8-{2- [4-(2-methoxyphenyl)-l-piperazinyl]-ethoxyimino--methyl}-3-methyl-4-oxo-2-phenyl-4H-l-benzopyran A solution of 5.4 g of 8-formyl-3-methyl-4-oxo-2-phenyl-20 -4H-l-benzopyran and 5.13 g of Intermediate LII in 10 ml of chloroform, containing 3 A molecular sieve, was stirred at reflux for 6 hours. The molecular sieve was removed by filtration and the solution was evaporated to dryness in vacuo. The crude product was purified by 25 column chromatography on silica gel, eluting with ethyl acetate:petroleum ether 7:3. Two groups of fractions were collected and evaporated to dryness in vacuo. The first eluted group of fractions (less polar) contained almost pure title compound; the second group (more 30 polar) was a 1:1 mixture of the E and Z diastereomers, as determined by NMR. ļĶ-NMR (CDCl^, δ). 8.75 8.65 35 8.30 (dd, 0.5H, benzopyran CH in 7, Z) (s, 0.5H, iminic CH, E) 8.158.00 (dd, 1H, benzopyran CH in 5, E+Z) (dd, 0.5H, benzopyran CH in 7, E) (s, 0.5H, iminic CH, Z) 5 LV 10099 155 (m, 2H, phenyl CH in 2' and 6', E+Z) (m, 3H, phenyl CH in 3', 4' and 5', E+Z) (dd/ 0.5H, benzopyran CH in 6, Z) (dd, 0.5H/ benzopyran CH in 6, E) (m, 4H, phenyl protons, E+Z) (t, 2H, CH20, E+Z) (S, 3H, CH3O, E+Z) (m, 4H, piperazine 2 x CH2, E+Z) 10 7.60-7.75 7.50-7.60 7.45 7.41 6.70- 7.10 4.41 3.86 3.05-3.20 2.70- 2.90 2.20 2.18 (m, 6H, piperazine 2 x CH2 and CH2N, E+Z) (s, 1.5H, benzopyran CH3 in 3, Z) (s, 1.5H, benzopyran CH3 in 3, E)
The E diastereomer was crystallized from ethanol:water 2:1 to give 2.5 g of pure title compound, m.p. 107-109’C. 15
Example 71
8-{N-hydroxy-3-[4-(2-methoxyphenyl)-l-piperazinyl]--propylcarbamoy1}-3-methyl-4-0x0-2-phenyl-4H-1--benzopyran methanesulphonate 0.25 H2O 20 25 30 A solution of 2.04 g of the compound of Example 68 as a base in 104 ml of 1.6 N ethanolic hydrogen chloride was stirred for 12 hours at ambient temperature. Ethanol was removed by evaporation in vacuo and the residue was rinsed with IN sodium hydroxide and dichloromethane. The organic layer was collected, washed with water, dried on anhydrous sodium sulphate and evaporated to dryness in vacuo. One molar equivalent of methanesulphonic acid was added to a solution of the residue in dichloromethane. The solvent was removed and the crude methanesulphonate crystallized from acetone to give 1.02 g of the title compound, m.p. 211-213*C. The product contained 0.25 mole of water. 35 156
Bxample, .22 E-8-<2-{2-[4-(2-methoxyphenyl)-l-piperazinyl]--ethylcarbamoyl}-etheny1>-3-methy1-4-oxo-2-pheny1-4H-1--benzopyran methanesulphonate 1.2 H20 5
The title compound was obtained by the method described in Example 61 but using Intermediate IV instead of Intermediate VIII and 2-[4-(2-methoxyphenyl)-1--piperazinyl]-ethylamine instead of the corresponding 10 propylamine, in 1,1,2,2-tetrachloroethylene as solvent. At the end, the reaction mixture was diluted with water and chloroform and washed with IN agueous sodium hydroxide# then with water. To the organic layer, after drying on anhydrous sodium sulphate# was added 15 methanesulphonic acid and the solvents were evaporated off in vacuo. The crude product was crystallized twice from isopropanol to give the title compound containing 1.2 molar equivalents of water. M.p. 124-127*C. 20 Example 73 8-{4-[4-(2-methoxyphenyl)-1-piperaz inyl]--butylsulphinyl}-3-methyl-4-oxo-2-phenyl-4H-l-benzopyran methanesulphonate 25 The title compound was prepared according to Exaniple 38/ but using Intermediate LIV instead of Intermediate XLIV/ stirring at 70 *C for 3 hours and again at 90 *C for 3 hours after adding a catalytic quantity (0.01 eguivalents) of potassium iodide. Purification by column 30 chromatography on silica gel, eluting with ethyl acetateimethanol 9:1# gavē the title compound as a base.To the crude base, dissolved in dichloromethane, was added one molar eguivalent of methanesulphonic acid. After removal of the solvent by evaporation in vacuo# 35 the resulting salt was crystallized from acetone to give the title compound, m.p. 183-184'C. LV 10099 157
Example 74 8- {3- [3- (2-methoxyphenoxy) -propylamd.no] --propylcarbamoyl > - 3 -me thyl -4 -oxo- 2 -phenyl -4H-1 --benzopyran methanesulphonate hemihydrate 5
The title compound was prepared according to the method described in Example 76 but using 3-(2-methoxyphenoxy)--propyl chloride (prepared as described in B. willhalm, Tetrahedron, 2J}., 1185, 1964) instead of 2-(2,6- 10 -dimethoxyphenoxy)-ethyl bromide. The residue from dichloro-methane extraction was purified by column chromatography on silica gel eluting with dichloromethanermethanol:5N methanolic ammonia 9:1:0.3; the pure base was converted into the methanesulphonate, 15 which was crystallized twice from ethyl acetate:acetonitrile 9:1 to give the title compound, melting at (60) 87-90’C.
Example 75 20 8-{3- [2- (2-methylthiophenoxy) -ethylamino] - -propylcarbamoyl} -3 -methyl-4 -oxo-2 -phenyl-4H-l--benzopyran methanesulphonate 1.85 g of 95 % sodium borohydrate was added to a 25 solution of 7 g of Intermediate LIX in 70 ml of methanol stirred at 0 *C. After stirring for 1 hour at the same temperatūre, the solvent was removed by evaporation in vacuo. The residue was diluted with water and 2 N hydrochloric acid and extracted with ethyl acetate. The 30 organic layer was washed with water, dried on anhydrous sodium sulphate and evaporated to dryness in vacuo, giving 6.6 g of pure 2-(2-methylthiophenoxy)-ethanol as an oil. 8.57 g of p-toluenesulphonyl chloride was added portionwise to a solution of the compound thus prepared 35 in 35 ml of pyridine stirred at 0*C. After stirring for 14 hours at ambient temperature, the reaction mixture was poured into cold 2 N hydrochloric acid and extracted 158 with dichloromethane. The organic layer was washed twice with water, dried on anhydrous sodlum sulphate and evaporated to dryness in vacuo yielding 7.8 g of a 3:1 mixture of 2-(2-methylthiophenoxy)ethyl p-toluenesul-phonate and 2-(2-methylthiophenoxy)-ethyl chloride (assessed by NMR) as a low melting solid which was used without further purification. A homogeneous mixture of 3.3 g of the above mixture and 8 g of Intermedlate XLIII was ķept in an oil bath at 140 *C for 20 minūtes. After this period the molten mass was cooled to ambient temperatūra and solidified. The solid residue was rinsed with dichloromethane and 4N sodium hydroxide. The organic layer was washed with water, dried on anhydrous sodium sulphate and evaporated to dryness in vacuo.
The crude product was purified by column chromatography on silica gel eluting with dichloromethane:methanol 9:1 giving 2.07 g of the title compound as a base. This was converted by the usual method into a crude methanesulphonate, which was crystallized first from acetone and then from acetonitrile. M.p. 143-146*C.
Example 76 8-{3-[2-(2,6-dimethoxyphenoxy>-ethylamino]--propylcarbamoyl}-3-methyl-4-oxo-2-phenyl-4H-l--benzopyran hydrochloride A homogeneous mixture of 3.3 g of 2-(2,6--dimethoxyphenoxy)-ethyl bromide (prepared as described in J.Augstein et al., J. Med. Chem., &, 356, 1965) and 8.4 g of Intermedlate XLIII was heated in an oil bath at 150 *C for 10 minūtes. The molten mašs was cooled to ambient temperature and solidified. The solid residue was rinsed with ethyl acetate and 2N sodium hydroxide. The organic layer was washed with water, dried on anhydrous sodium sulphate and evaporated to dryness in vacuo. The oily residue was purified twice by column LV 10099 159 chromatography on silica gel eluting firstly with ethyl acetate:methanol:5N methanolic ammonia 97:3:0.3 and then with dichloromethane:methanol:triethylamine 90:10:0.3. This gavē 3.3 g of the pure title compound as a base. The cmde hydrochloride, obtained by the usual method, was crystallized from acetone followed by acetonitrile. M.p. 179-181'C.
Bxaaple 11 8- {3- [4- (5-chloro-2-methoxyphenyl) -l-piperazinyl] --propylcarbamoyl>-3-methyl-4-oxo-2-pheny1-4H-1--benzopyran
This compound was prepared by the method described in Example 11, but using 1-(5-chloro-2-methoxyphenyl)--piperazine instead of 1-(2-methoxyphenyl)-piperazine and carrying out the reaction for 6 hours instead of 5 hours.
Purification was carried out by flash chromatography on silica gel, eluting with chloroform:5N ammonia in methanol (100:1). The title compound melted at 163-166 *C after crystallization from 95% ethanol.
Bxample..78 (E) -8-{4-[4-(2-methoxyphenyl)-l-piperazinyl]-l-butenyl>--3-methyl-4- oxo - 2 -pheny 1 - 4 Η -1 -benzopyr an 33.4 ml of a 1 molar solution of lithium bis(trimethylsi- lyl)amide in anhydrous tetrahydrofuran was added dropwise over a period of 15 minūtes to a suspension of 6.4 g of 3-hydroxypropyltriphenyl-phosphonium bromide in 60 ml of anhydrous tetrahydrofuran cooled to -15*C. Then a solution of 4 g of 8-formyl-3-methyl-4-oxo-2-phenyl-4H-l-benzopyran in 4 0 ml of tetrahydrofuran was added dropwise. The reaction mixture was stirred at 0'C for 30 minūtes, then at ambient temperature for 1.5 hours. 160
Quenching with methanol, followed by evaporation to dryness in vacuo, gavē a residue which was purified by column chromatography on silica gel eluting with ethyl acetate:Petroleum ether 6:4. The collected fractions were evaporated in vacuo giving 4.17 g of 8-(4-hydroxy--l-butenyl)-3-methyl-4-oxo-2-phenyl-4H-l-benzopyran as a E-Z diastereoisomer mixture having a 3.5:1 ratio determined by NMR. 1H-NMR. 200 MHz (CDCljļ. S) 8.10-8.20 (d, 1H, benzopyran CH in 5, E+z) 7.30-7.80 (m, 7H, other aromatics, E+Z) cn • 00 o *· • o © (2d, 1H, aryl-CH=, E+Z) 6.41 (dt, 0.78H, CH-CH2, B) 5.90 (dt, 0.22H/ CJJ-CH2/ Z) 3.60-3.80 (m, 2H, CH20, E+Z) 2.45-2.60 (m, 2H, CH-CU2/ E+Z) 2.18 (s, 3H, benzopyran CH3 in 3 1.60-1.90 (sa, 1H, OH, E+Z) 1.65 g of p-toluenesulphonyl chloride was added to a solution of 2.2 g of the above mixture in 24 ml of anhydrous pyridine was stirred at 0*C. stirring was continued for 48 hours at the same temperatūre, and the reaction mixture was then poured into cold IN hydrochloric acid and filtered by suction. The guauny solid was washed with water and rinsed with dichloromethane. The solution was dried on anhydrous sodium sulphate and evaporated to dryness in vacuo to give 2.30 g of (E,Z)-4-{8-[3-methyl-4-oxo-2-phenyl-4H-l--benzopyranyl)-3-butenyl p-toluenesulphonate having the same diastereoisomer composition as the above Intermediate. A solution of 2.85 g of the p-toluenesulphonic acid ester above and of 2.98 g of 1-(2-methoxyphenyl)--piperazine in anhydrous dimethylformamide was stirred at ambient temperature for 48 hours. After this period/ the mixture was poured into 250 ml of water and LV 10099 161 extracted with ethyl acetate. The organic layer was washed with water, dried on anhydrous sodium sulphate and evaporated to dryness in vacuo giving a residue which was purified by column chromatography on silica gel, eluting with ethyl acetate:petroleum ether 6:4. The collected fractions were evaporated to dryness in vacuo and the crude product was crystallized from 70% ethanol yielding 1.48 g of the title compound that melted at 119-121*C. J-H-NMR. 200 MHz 8.14 7.85 7.41-7.70 7.34 6.70-7.10 6.30-6.50 3.86 3.00-3.15 2.50-2.80 2.18 (CDCl^. 5) (dd, 1H, benzopyran CH in 5) (dd, 1H, benzopyran CH in 7) (m, 5H, phenyl CHS) (dd, 1H, benzopyran CH in 6) (m, 5H, aryl-CH= and methoxyphenyl CHs) (dt, 1H, Jtrans=16-5 Hz, CB-CH2) (s, 3H, CH3O) (m, 4H, 2 piperazine CH2) (m, 8H, 2 piperazine CH2, CHCB2CH2N) (s, 3H, benzopyran CH3 in 3)
Example 79 (E)-8-<2-{2-[4-{2-methoxyphenyl)-l-piperazinyl]--ethoxycarbonyl}-ethenyl>-3-methyl-4-oxo-2-phenyl-4H-1--benzopyran methanesulphonate
The title compound was prepared according to Example 6, but using Intermediate III instead of 8-carboxy-3--methyl-4-oxo-2-phenyl-4H-l-benzopyran. After the usual work up, the residue was crystallized twice from ethanol; the solid obtained was purified by column chromatography on silica gel eluting with chloroform:ethyl acetate 8:2 to give the pure base, which was dissolved in chloroform:ethanol 1:1. Methanesulphonic acid was added to the solution and the solvents were removed by evaporation in vacuo. The crude salt was crystallized from isopropanol yielding the 162 title compound, melting at 193-195*C. This compound contains 0.33 equivalents of isopropanol and 0.25 eguivalents of H2O. 5
Bxample 80 8-{2-[4-(2-methoxyphenyl)-l-piperazinyl]- -ethy lcarbamoylmethyl} -4 -oxo-2 -phenyl -4H-1 -benzopyran methanesulphonate hydrate 10 A mixture of 2.8 g of Intermediate XLVII and 1.28 g of l-hydroxybenzotriazole in 20 ml of anhydrous dimethyl-formamide was stirred at 0-5*C for 15 minūtes. A solution of 1.96 g of dicyclohexylcarbodiimide in 20 ml 15 of anhydrous dimethylformamide was added dropwise to the mixture over a period of about 40 minūtes. After stirring for 8 hours at ambient temperatūre, a solution of 2.24 g of 1-(2-aminoethyl)-4-(2-methoxyphenyl)--piperazine in 15 ml of anhydrous dimethylformamide was 20 added. After 5 hours stirring and ovemight standing at the same temperatūre, the insoluble matter was filtered off and the filtrāte was poured into about 300 ml of water and made alkaline by addition of IN sodium hydroxide. The mixture was extracted with 25 dichloromethane and the organic layer was separated, dried on anhydrous sodium sulphate and evaporated in vacuo. The crude product was purified by flash chromatography on silica gel eluting with chloroform:methanol 95:5. One molar eguivalent of 30 methanesulphonic acid was added to the solution of the crude base in ethanol. Diethyl ether was added until the salt crystallized. The salt was then filtered off and recrystallized from ethanol:diethyl ether 1:2 to give 1.15 g of the title compound, m.p. 160-162’C. 35 LV 10099 163
Bxample 81 8 - { N- ace tyl—3— [4— (2 -me thoxypheny 1) -1 -piperaz iny 1 ] --propylcarbamoyl} - 3 -methyl -4 -oxo- 2 -phenyl-4H-1--benzopyran 5 A solution of 2.86 g of Intermediate LVII, 5.04 g of 1-(3-chloropropyl)-4-(2-methoxyphenyl)-piperazine and 2.58 g of anhydrous potassium carbonate in 50 ml of dimēthy1formamlde was stirred at 90*C for 7 hours. After 10 cooling to ambient tempera tūre, the reaction mixture was poured into 500 ml of water and extracted with dichloromethane. The organic layer was washed with water, dried on anhydrous sodiun sulphate and evaporated to dryness in vacuo. The residue was purified by column 15 chromatography on silica gel . eluting with ethyl acetate:Petroleum ether 7:3 to give 1.89 g of the title compound melting at (55) 62-63'C.
Bxample .82 20 8-{2-[4-(2-methoxyphenyl)-1-p ipera z iny1]- -ethy1sulphony1amino}-3-methyl-4-oxo-2-pheny1-4H-1--benzopyran methanesulphonate 1.05 ml of 2-chloroethanesulphonyl chloride was added 25 dropwise to a solution of 5 g of 8-amino-3-methyl-4-oxo--2-phenyl-4H-l-benzopyran and 1.4 ml of triethylamine stirred at 0*C. The reaction mixture was stirred at ambient temperature for 2 days. After filtering off the precipitated solids, the solution was evaporated to 30 dryness in vacuo to give a crude residue containing 8- (ethenylsulphonylamino) -3-methyl-4-oxo-2-phenyl-4H-l--benzopyran used without further purification. A mixture of 7.54 g of this residue and 5.8 g of l-(2--methoxyphenyl)-piperazine and 4.15 g of potassium 35 carbonate in 100 ml of dimethylformamide was stirred at ambient temperature for 4 hours, poured into 600 ml of water and extracted with ethyl acetate. The organic 164 layer was evaporated to dryness in vacuo and the residue was purified by column chromatography on silica gel, eluting with Petroleum ether:acetone 8:2. The collected fractions were evaporated to dryness in vacuo and crystallized from 70¾ ethanol to give 0.75 g of the title compound as a base. This solid was dissolved in dichloromethane and one eguivalent of methanesulphonic acid was added to the solution. The crude methanesulphonate, obtained by evaporation in vacuo, was crystallized from acetone, yielding 0.6 g of the title compound melting at 202-203*C. 8-{3- [4-(2-methoxyphenyl)-l-piperazinyl]--propylthiocarbamoyl}-3-methyl-4-oxo-2-phenyl-4H-l--benzopyran methanesulphonate A stirred mixture of 0.8 g 8-formyl-3-methyl-4-oxo-2--phenyl-4H-l-benzopyran, 0.75 g of 1-(3-aminopropyl)-4--{2-methoxyphenyl)-piperazine and 0.14 g of sulphur in 5 ml of pyridine was refluxed for 6 hours. After solvent evaporation in vacuo, the residue was purified by flash chromatography on silica gel, eluting with chloroform. The obtained title compound (as the base) was dissolved in dichloromethane and one equivalent of methanesulphonic acid was added. The title compound was obtained by evaporation in vacuo and crystallization of the residue from acetonitrile. Yield 0.7 g, m.p. 189-190 *C. 1
Bxampla...8i
8-{4-[4-(2-methoxyphenyl)-1-piperazinyl]-butylsuphonyl}--3-me thy1-4-oxo-2-pheny1-4H-1-benz opyran methanesulphonate H2O
The title compound was prepared according to Example 73, but using Intermediate LX instead of Intermediate LIV. LV 10099 165
Its purification was performed by column chromatography on silica gel, eluting with ethyl acetate:Petroleum ether 7:3. One molar equivalent of methanesulphonlc acid was added to a Bolution of the crude base in 5 dichloromethane. After removal of the solvent by evaporation in vacuo, the resulting salt was crystallized from acetone to give the title compound, m.p. 212-214’C. 10 Example 85 8-{3 - [4-(2-methoxyphenyl)-l-piperazinyl]--propylcarbamoyl}-3-hydroxymethyl-4-oxo-2-phenyl-4H-l--benzopyran * 0.4 ethanol 15 A mixture of 3.6 g of Intermediate XCV and 1.65 g of l-hydroxybenzotriazole in 35 ml of anhydrous dimethylformamide was stirred at 0-5’C for 15 minūtes. A solution of 2.5 g of dicyclohexylcarbodiimide in 35 ml of anhydrous dimethylformamide was added dropwise. After 20 stirring for 1 hour at the same temperatūra, a solution of 1-(3-amino-propyl)-4-(2-methoxyphenyl)-piperazine was added. After stirring for 2 hours at the same temperature and standing overnight at ambient temperatūre, the reaction mixture was evaporated to 25 dryness in vacuo. The residue was purified by flash chromatography eluting with a mixture of dichloromethane jmethanol 100:3, followed by crystallization from ethanol. 2.5 g of the title compound was obtained, m.p. 152-154 *C. 30
Example 86
8-{3-[4-(2-methoxyphenyl)-l-piperazinyl]--propylcarbamoyl)-4-oxo-2-pheny1-4H-1-benzopyran methanesulphonate *0.25 H2O 3.6 ml of diethyl cyanophosphonate were added dropwise at 0-5*C into a stirred solution of 4 g of 8-carboxy- 35 166 -4-oxo-2-phenyl-4H-l-benzopyran (prepared as described in Da Re et al.,Ber., ū, 1962, 1966) and 3.75 g of 1-(3-aminopropyl) -4-(2-methoxyphenyl) -piperazine in 35 ml of anhydrous dimethylformamide. Immediately afterwards, 2.5 ml of triethylamine was added dropwise at the same temperature. After 30 minūtes stirring at 0-5*C and 1 hour at ambient temperature, the reaction mixture was poured into 350 ml of 2.5% agueous sodium carbonate. The precipitate formed was stirred for 1 hour at ambient temperature, collected by suction filtration and crystallized from ethanol. The base of the title compound, thus obtained, was dissolved in dichloromethane and one equivalent of methanesulphonic acid was added. After evaporation in vacuo, a glassy solid was obtained, which was crushed and refluxed for 1 hour in acetone, yielding 5 g of the title compound melting at 191-194*C. gxample ,87 8-{3- [4-(2-methoxyphenyl)-1-piperazinyl]--propylcarbamoyl) -2,3-dihydro-4-oxo-4H-l-benzopyran methanesulphonate A solution of 0.84 ml of thionyl chloride in 17 ml of anhydrous dichloromethane was added dropwise to a solution of 2.0 g of 8-carboxy-2,3-dihydro-4-oxo-4H-l--benzopyran (prepared according to Lichtenberger et al., Buli. Chem. Soc. Fr., 275, 1963) and 1.75 ml Of triethylamine in 17 ml of dichloromethane stirred at ambient temperature. Stirring was continued for 1.5 hour at the same temperature; after this period the reaction mixture was evaporated to dryness in vacuo to give crude 8-chlorocarbonyl-2,3-dihydro-4-oxo-4H-l-benzopyran. This was used in the method of Example 10 instead of 8 -chlorocarbonyl-3 -methyl-4 -oxo-2 -phenyl-4H-l-benzopyran to prepare the base of the title compound, which was purified by column chromatography eluting with ethyl LV 10099 167 acetate:methanol 85:15i The yield was 1.91 9 of the pure base. After dissolution in dichloromethane, acidification with methanesulphonic acid, and evaporation to dryness in vacuo, the resultant crude salt was crystallized from acetonitrile giving 1.57 g of the title compound, melting at 175-177’C. fisarol.fl ....8,8
8-{3- [4-(2-methoxyphenyl)-l-piperazinyl]--propylcarbamoy1}-4-0x0-4 Η-1-benzopyran methanesulphonate * 1.25 H2O
The title compound was prepared by the method described in Example 87 but using Intermediate LXII instead of 8-carboxy-2,3-dihydro-4-oxo-4H-l-benzopyran. The crude methanesulphonate was rinsed with diethyl ether, filtered and repeatedly crystallized from acetonitrile. M.p. 155-157 *C.
ExafflPlQ.fi9 8- {3- [4-(2-methoxyphenyl)-l-piperazinyl] --propylcarbamoyl}-6-bromo-3-methyl-4-oxo-2-phenyl-4H-1--benzopyran
This compound was prepared according to Example 86 but using 8-carboxy-6-bromo-3-methyl-4-oxo-2-phenyl-4H-l--benzopyran (prepared as described in EP 107804) instead of 8-carboxy-4-oxo-2-phenyl-4H-l-benzopyran. It was purified as a base by flash chromatography on silica gel, eluting with dichloromethane:methanol 100:3/ and crystallized from 95% ethanol. M.p. (150) 154-159‘C.
Example 90 8-{3-(4-(2-methoxyphenyl)-l-piperazinyl]--propylcarbamoyl}-6-methoxy-3-methyl-4-oxo-2-phenyl-4H--l-benzopyran methanesulphonate 168 1.01 ml of diethyl cyanophosphonate and 0.85 ml of triethylamine were added to a solution of 1.7 g of 8-carboxy-6-methoxy-3-methyl-4-oxo-2-phenyl-4H-l-benzo-pyran (prepared as described in JP 61-15880) and 1.51 g 5 1-(2-methoxyphenyl)-4-(3-aminopropyl)-piperazine in 20 ml of anhydrous dimethylformamide stirred at O’C. After stirring for 1 hour at O'C to ambient temperature, the reaction mixture was poured into a mixture of 100 ml of water and 10 ml of IN sodium hydroxide. The base of the 10 title compound precipitated; it was filtered off and washed with water. After desiccation it was converted in the usual way to the methaneeulphonate, which was crystallized from acetonitrile. Yield 1.7 g; m.p. 185-186 *C. . 15
Example 91 8-{3-[4-(2-methoxyphenyl)-1-piperaz inyl]- -propylcarbamoyl}-6-hydroxy-3-methyl-4-oxo-2-phenyl-4H- -l-benzopyran methaneeulphonate 20 0.8 g of the compound prepared in Example 114 and 5.8 ml of IN sodium hydroxyde in 10 ml of methanol were stirred at ambient temperature for 4 hours. After standing overnight, 15 ml of IN sodium hydroxide and 15 ml of 25 methanol were added and the mixture was stirred at ambient temperature for 1 hour. Methanol was evaporated off in vacuo and water was added to the residue. The suspension was filtered by suction to give 0.48 g of the base of the title compound. This was converted by the 30 usual procedure into its methaneeulphonate salt, recrystallized from acetonitrile. M.p. 200-202’C.
Example 92 8-{3-[4-(2-methoxyphenyl)-l-piperazinyl]-35 -propylcarbamoyl}-3,6-dimethyl-4-oxo-2-phenyl-4H-l--benzopyran methaneeulphonate LV 10099 169
The title compound was' prepared according to Exaxnple 90 but using 8-carboxy-3,6-dimethyl-4-oxo-2-phenyl-4H-l--benzopyran (prepared as described in Da Re et al., Arch.Pharm., 296. 714, 1963) instead of 8-carboxy-6--methoxy-3-methyl-4-oxo-2-phenyl-4H-l-benzopyran. The crude methanesulphonate was crystallized from acetonitrile and melted at 196-197*C.
Example 93 8-{3-[4-(2-methoxyphenyl)-1-pipera z iny1]--propylcarbamoyl)-3-methyl-6-nitro-4-oxo-2-phenyl-4H-1--benzopyran
This product was obtained operatlng as described in Example 12 but using Intermediate LXVIII instead of 8-chloro-carbonyl-3-methyl-4-oxo-2-phenyl-4H-l-benzopy-ran and 1,1,2-trichloroethane instead of chloroform. After the usual work up, the crude product was purified by column chromatography eluting with dichlorome-thaneimethanol 98:2. Evaporation in vacuo to dryņess of the collected fractions and crystallization from ethanol yielded the title compound, m.p. 159.5-161*C.
Example 94 8-{3-[4-(2-methoxyphenyl)-1-piperazinyl]--propylcarbamoyl}-6-amino-3-methyl-4-oxo-2-phenyl-4H-1--benzopyran A mixture of 33 g of the compound prepared in Example 93, 109 ml of IN hydrochloric acid, 105 ml of water and 8.7 8 g of Raney-Nickel in 9 50 ml of ethanol was hydrogenated in a Parr apparatus, hydrogen pressure 2 atmospheres, stirring at 40*C for 12 hours. After this period, the catalyst was filtered off and washed with 80¾ ethanol. The mother liguors were evaporated in vacuo to a volume of 80 ml and filtered. The crude product was washed with water, and suspended in water; 37¾ 170 hydrochloric acid was added untll the pH was 1. The insoluble matter was filtered off by suction and the filtrate was alkalinized by adding 35% sodium hydroxide. The title compound precipitated. It was recovered by filtration and washed with water. Desiccation yielded 26 g melting at (108) 215-217.5*C for use in Example 95 without further purification. For characterization/ 4.7 g of the product were crystallized first from ethanol and then from 85% ethanol giving 3 g of the title compound, m.p. 218-219*C. F,xainr>1 e 9¾ 8-{3- [4-(2-methoxyphenyl)-l-piperazinyl]--propylcarbamoyl}-6-acetamido-3-methyl-4-oxo-2-phenyl--4 Η-1-benzopyran
The title compound was obtained according to the procedure described in Example 36, but using the compound prepared in Example 94 instead of that prepared in Example 33. The reaction mixture was diluted with water and filtered by suction, washing the solid with water. After desiccation at 80*C, this solid was purified by column chromatography on silica gel eluting with chloroform:methanol 95:5. Evaporation in vacuo of the collected fractions and crystallization from 95% ethanol of the residue gavē the title compound, m.p. (150) 218-220*C.
Example 96 8-{3-[4-(2-methoxyphenyl)-l-piperazinyl]--propylcarbamoyl} - 6 -e thylamino - 3 -methyl - 4 -oxo- 2 -pheny 1 --4Η-1-benzopyran A mixture of 8.42 g of the compound of Example 94, 0.45 ml of acetaldehyde, 0.59 g of 85% sodium cyanobo-rohydride and 3.3 ml of 4.85 N ethanolic hydrogen chloride in 73 ml of methanol was stirred at ambient LV 10099 171 temperature for 5 days.. After this period, the reaction mixture was poured into cold 1.5N sodium hydroxide; the suspenslon was diluted wlth water and flltered by suction. After desiccation, the resldue was purified by column chromatography on sllica gel eluting with chloroform:methanol 100:3. Evaporation in vacuo of the collected fractions yielded 6 g of the compound of Example 94 and 2.67 g of the title compound, which melted at 198-201*C after recrystallization from ethanol.
SxaffiPle 97 8-{3-[4-(2-me t hoxypheny 1)-1-pipera z iny1]--propylcarbamoyl)-6-dimethylamino-3-methyl-4-oxo-2--pheny1-4H-1-benzopyran
The title compound was prepared according to Example 35 but using the compound prepared in Example 94 instead of that prepared in Example 33, reacting 10 molar equivalents of 40% formaldehyde instead of 7 molar equivalents and 3 moles of sodium cyanoborohydride instead of 2 moles and stirring at ambient temperature for 18 hours instead of 4.5 hours. After the usual work up and purification by column chromatography on silica gel eluting with chloroform:methanol 97:3, evaporation in vacuo of the collected fractions and crystallization of the residue from ethanol yielded the title compound which melted at 183-186*C.
Bxample ,98 8-{3-[4-(2-methoxyphenyl)-l-piperazinyl]- -propylcarbamoy1}-7-methoxy-3-me thy1-4-oxo-2-pheny1-4 H- -l-benzopyran
The title compound was prepared according to the procedure described in Example 87 but using Intermediate LXIX instead of 8-carboxy-2,3-dihydro-4-oxo-4H-l- 172 -benzopyran. After the usual work up, the solid residue was purified by column chromatography on silica gel, eluting with ethyl acetatejmethanol 8:2. The collected fractions were evaporated to dryness in vacuo and the 5 residue was crystallized from acetonitrile to give the title compound, melting at 151-152*C.
SxafflBle .13 8-{3-[4- (2-methoxyphenyl)-l-piperazinyl]-10 -propylcarbamoyl}-3-methyl-4-oxo-2-(4-trifluoro-methylphenyl)-4H-l-benzopyran methanesulphonate
The title compound was prepared following the procedure described in Example 90, but starting from Intermediate 15 LXXII instead of 8-carboxy-6-methoxy-3-methyl-4-oxo-2--phenyl-4H-l-benzopyran. The methanesulphonate melted at (85) 90-120*C (dec), after crystallization from acetonitrile. 20 Example 100 8-{3—[4—(2-methoxypheny1)-1-p ipera z inyl]--propylcarbamoyl}-2-(4-benzoylphenyl)-3-methyl-4-oxo-4H--l-benzopyran methanesulphonate hemihydrate 25 The title compound was prepared following the procedure described in Example 90, but starting from Intermediate lxxiv instead of 8-carboxy-6-methoxy-3-methyl-4-oxo-2--phenyl-4H-l-benzopyran. The crude methanesulphonate was crystallized from acetonitrile. M.p. 208-210*C. 30
EyaPPļg 3L,Q1
8-{3-[4-(2-methoxyphenyl)-l-piperazinyl)--propylcarbamoyl}-3-methyl-4-oxo-2-(4-phenoxyphenyl)-4H--l-benzopyran methanesulphonate*0.25 H2O
The title compound was prepared following the procedure described in Example 90, but starting from Intermediate 35 LV 10099 173 LXXVII instead of 8-carboxy-6-methoxy-3-methyl-4-oxo-2--phenyl-4H-l-benzopyran. The crude methanesulphonate was crystallized from acetonitrile. M.p. 200-202*C.
Exaapļfl 1D2 8-{3 - [4-(2-methoxyphenyl)-l-piperazinyl]-propylcarbamoyl}- -2,3-dimethyl-4-oxo-4H-l-benzopyran This compound was prepared according to Example 86, but using 8-carboxy-2,3-dimethyl-4-oxo-4H-l-benzopyran (prepared according to Da Re, Farmaco Ed. Sci., 678, 1956) instead of 8-carboxy-4-oxo-2-phenyl-4H-l--benzopyran and carrying out the reaction at ambient temperature for 5 hours. It was purified by flash chromatography on silica gel eluting with chloroform:methanol 98:2, and crystallized from acetone. M.p. 155-158.5*C.
Example lfl.3 8-{3- [4-(2-methoxyphenyl)-l-piperazinyl]--propylcarbamoyl}-2-(t-butyl)-3-methyl-4-oxo-4H-l--benzopyran dihydrochloride dihydrate
This compound was prepared according to Example 86, but using Intermediate LXXVIII instead of 8-carboxy-4-oxo-2--phenyl-4H-l-benzopyran. The base was purified by flash chromatography on silica gel eluting with chloro-form:methanol 49:1 and converted into the dihydrochloride in methanol:diethyl ether. It melted at 226-229.5*C after recrystallization from methanol:di-ethyl ether 1:1.
Example 104 8-{3-[4-(2-methoxyphenyl)-l-piperazinyl]--propylcarbamoyl} -2 -cyc lohexyl -3 -me thyl - 4 -oxo- 4H-1 --benzopyran 174
This compound was prepared accordlng to Example 86, but using Intermediate LXXIX instead of 8-carboxy-4-oxo-2--phenyl-4H-l-benzopyran, and carrying out the reaction for 5 hours at ambient temperature. It was purified by flahs chromatography on silica gel, eluting with chloroform :methanol 49:1, and crystallized from acetonitrile (m.p. 155-157’C).
Example 105 8-{3-[4- (2-methoxyphenyl)-l-piperazinyl]--propylcarbamoyl}-2-(2-furyl)-3-methyl-4-oxo-4H-l--benzopyran
This compound was prepared accordlng to Example 86, but using Intermediate LXXXI instead of 8-carboxy-4-oxo-2--phenyl-4H-l-benzopyran, and completing the reaction at ambient temperature for 5 hours. After quenching, the title compound was isolated by extraction with chloroform and purified by flash chromatography on silica gel eluting with chloroform:methanol 49:1, followed by crystallization from acetonitrile. M.p. 151-153 *C.
Example 106 8-{3-[4-(2-methoxyphenyl)-l-piperazinyl]- -propylcarbamoy1}-3-methyl-4-oxo-2-thieny1-4H-1- -benzopyran
This compound was obtained according to Example 86, but using Intermediate LXXXIII instead of 8-carboxy-4-oxo-2--phenyl-4H-l-benzopyran. It was purified by stirring in water (completely to remove dimethylformamide), folloved by column chromatography on silica gel eluting with chloroform:methanol 49:1, and crystallized from acetonitrile. M.p. 174-175*C. LV 10099 175
Example 107 8-{3-[4-(2-me thoxypheny 1)-1-pipera z iny1]- -p ropy1carbamoy1}-4-oxo-2-pheny1-4Η-1-benz o thi opyran 5 A mixture of 2.8 g of Intermediate LXXXIV and 3.4 g of 1,1'-carbonyldiimidazole in 60 ml of anhydrous dimethylformamlde was stlrred under nitrogen at amhient temperature for 1.5 hours. 2.7 g of l-(3-aminopropyl)-4--(2-methoxyphenyl)-piperazine were then added. After 10 further 2 hours stirring at ambient temperature, the reaction mixture was poured into 300 ml of water and extracted with chloroform. The organic layer was dried on anhydrous sodium sulphate and evaporated in vacuo. The resldue was purlfied by flash chromatography on 15 silica gel eluting with chloroform:methanol 49:1, washed with water and crystallized from acetonitrlle, yielding 2 g of the tītie compound melting at 144-146*C.
Bxample ļfl.8 20 (E)-8-{3-[4-(2-methoxyphenyl)-l-piperazinyl]- -propylcarbamoyl}-3-methy1-4-oxo-2-(2-s tyry1)-4H-1--benzopyran
This compound was prepared according to Example 86, but 25 using Intermediate LXXXVI instead of 8-carboxy-4-oxo-2--phenyl-4H-l-benzopyran. It was purified by crystallization from acetonitrlle. M.p. 191-194*C.
Example 109 30 8-{3-[4-(2-methoxyphenyl)-1-piperazinyl]- -propylcarbamoyl}-3-methyl-2-(4-methylphenyl)-4-oxo-4H--1-benzopyran
This compound was prepared according to Example 86, but 35 using Intermediate LXXXVII instead of 8-carboxy-4-oxo--2-phenyl-4H-l-benzopyran and completing the reaction at ambient temperature for 4 hours. After guenching, the 176 title compound was isolated by extraction with ethyl acetate, drylng on anhydrous sodium sulphate and evaporation in vacuo, followed by rinsing with diethyl ether and crystallization from acetonitrile. M.p. 161-163 *C.
Example 110 8-{3-[4-(2-methoxyphenyl)-l-piperazinyl]--propylcarbamoyl)-2-(4-methoxyphenyl)-3-methyl-4-oxo-4H--1-benzopyran
This compound was prepared according to Example 86, but using 8-carboxy-2-(4-methoxyphenyl)-3-methyl-4-oxo-4H-l--benzopyran (prepared as described in EP 108986) instead of 8-carboxy-4-oxo-2-phenyl-4H-l-benzopyran, and completing the reaction at ambient temperature for 3.5 hours. It was purified by flash chromatography on silica gel eluting with chloroform:methanol 49:1, followed by crystallization from acetonitrile. M.p. 158-161'C.
Examp.le 111 8-{3-[4-(2-methoxypheny1)-l-piperazinyl]--propylcarbamoyl}-2-(4-fluorophenyl)-3-methyl-4-oxo-4H--1-benzopyran
This compound was prepared according to Example 86, but using Intermediate LXXXIX instead of 8-carboxy-4-oxo-2--phenyl-4H-l-benzopyran. It was purified by flash chromatography on silica gel eluting with chloroform:methanol 100:2 to 100:6 and crystallized from 95% ethanol. M.p. 166-168’C.
Example 112 8-{3-[4-(2-methoxyphenyl)-1-piperazinyl]--propylcarbamoyl}-6-methanesulphonylamino-3-methyl-4--oxo-2-phenyl-4H-1-benzopyran hydrochloride LV 10099 177 0.032 ml of methanesulphonyl chloride in 1 ml of dimethylformamide was added dropwise over a period of 10 minūtes to a solution of 0.21 g of the compound of Example 94 and 0.062 ml of triethylamine in 4 ml of dimethylformamide, stirred at -20’C. Stirring was continued at the same temperature for 3.5 hours. After this period, the reaction mixture was poured into water and the suspension was filtered by suction, yielding 0.1 g of the title compound which was recrystallized from 80% ethanol. M.p. 272-275*C.
Example 113 8-{3- [4-(2-methoxyphenyl)-1-piperazinyl]--propylcarbamoyl}-3-methyl-2-(4-nitrophenyl)-4-oxo-4H-l--benzopyran
The title compound was prepared following the procedure described in Example 90 but starting from Intermediate XCVIII instead of 8-carboxy-6-methoxy-3-methyl-4-oxo-2--phenyl-4H-l-benzopyran. After stirring for 1 hour at ambient temperature, the reaction mixture was poured into cold 2% sodium carbonate solution and the precipitated solid was collected by suction filtration. After desiccation and crystallization from ethanol, the title compound melted at (60) 185-187’C.
Example 114 8-{3-[4-(2-methoxyphenyl)-1-piperazinyl]- -propy lcarbamoy 1} - 6 -diethoxyphosphonyloxy- 3 -methy 1 - 4 - -oxo-2-pheny1-4Η-1-benzopyran
The title compound was prepared following the procedure described in Example 90, but starting from Intermediate LXIII instead of 8-carboxy-6-methoxy-3-methyl-4-oxo-2--phenyl-4H-l-benzopyran and using 2 equivalents of diethyl cyanophosphate instead of 1.1 equivalents. Filtration from water yielded the title compound melting 178 at 48-80*C (dec). The title compound may be regarded as a prodrug of 8-{3-[4- -(2-methoxyphenyl)-1-piperaziny1]--propylcarbamoyl}-6-hydroxy- 3-methyl-4-oxo-2-pheny1-4H--1-benzopyran. fižaspJle -115
8-{3-[4-(2-methoxyphenyl)-1-piperaz inyl]--propylcarbamoyl}-3-methy1-4-oxo-2-trifluoromethyl-4H-1--benzopyran methanesulphonate · 2/3 H2O
Operating as described in Example 90, but starting from Intermediate C instead of 8-carboxy-6-methoxy-3-methyl--4-oxo-2-phenyl-4H-l-benzopyran, the crude base of the title compound was obtained. After the usual work up by extraction with ethyl acetate, the residue was purified by column chromatography on silica gel eluting with ethyl acetatejmethanol 9:1. It was converted into its methanesulphonate by the usual procedure and recrystallized from ethyl acetate. M.p. 145-148*C.
Example 116 8-{N-methyl-3-[4-(2-methoxyphenyl)-1-piperazinyl]--propylcarbeunoyl}-3-methyl-4-oxo-2-phenyl-4H-l--benzopyran hydrochloride
This compound was prepared according to Example 12, but using Intermediate CI instead of 3-[4-(2-methoxypheny1)--l-piperazinyl-propylamine. The crude base was purified by flash chromatography on silica gel, eluting with chloroform:5N methanolic ammonia 100:1, and transformed into the hydrochloride in the usual way. M.p. 195-198*C, after crystallization from acetone.
Eacaapļg 117 7-{3- £ 4-(2-methoxyphenyl)-1-piperazinyl]--propylcarbamoyl}-2-benzoyl-3-ethyl-benzo[b]furan LV 10099 179
This compound was prepared according to Example 86 but using Intermediate Cili instead of 8-carboxy-4-oxo-2--phenyl-4H-l-benzopyran-8-carboxylic acid, and comple-ting the reaction at ambient temperature for 4 hours. It 5 was purifled by crystallization from ethanol. M.p. 165-166*C.
Bxaaple-118 2-(4-biphenyļyl)-8-{3-[4-(2-methoxyphenyl)-Ι-ΙΟ -piperazinyl]-propylcarbamoyl)-3-methyl-4-oxo-4H-l--benzopyran
The tītie compound was prepared according to Example 86 but using Intermediate CVI instead of 4-oxo-2-phenyl-4H-15 -l-benzo-pyran-8-carboxylic acid. The reaction lasted 20 hours at room temperature. The base waa purified by crystallization from ethanol (m.p. 164-166'C).
Sxaiņplg U? 20 8-{3-[4-(2-methoxyphenyl)-l-piperazinyl]- -propylcarbamoyl}-3-methyl-4-oxo-2-(3-pyridyl)-4H-1--benzopyran A mixture of 6.2 g of methyl 3-propionylsalicylate and 25 5.8 g of nicotionyl chloride hydrochloride in 18 ml of anhydrous pyridine was stirred and heated at 100*C for 2 hours under nitrogen. After that, 16 ml of triethylamine was added and heating was continued for 1 hour at the same temperature. The reaction mixture was cooled to 30 room temperature, poured into 600 ml of water and the precipitate was collected by suction and washed with water, yielding 5.4 g of methyl 2-hydroxy-3-(2--nicotinoyl)propionylbenzoate, which was used without purification in the next step. 35 3.4 g of this Intermediate was heated at 100*C for 1,5 hours after dissolution in a mixture containing 15 ml of acetic acid and 1 ml of 37¾ hydrochloric acid. After 180 cooling to room temperature, the mixture was poured into 150 ml of water and extracted with ethyl acetate. The organic phase was washed with 5¾ aqueous sodium hydrogen carbonate followed by water, dried on sodium sulphate 5 and evaporated in vacuo, yielding 1.3 g of crude methyl 3- methyl-4-oxo-2-(3-pyridyl)-4H-1-benzopyran-8-carboxy-late. 1 g of the above ester was dissolved in 9 ml of methanol and 15 ml of l/4-dioxane and slowly added with 1.7 ml of 10N sodium hydroxide# maintaining the 10 temperatūra between 20 and 25*C. After 1 hour at 50‘C, the reaction mixture was poured into 150 ml of water and extracted with ethyl acetate. The aqueous layer was acidified with IN hydrochloric acid. The precipitate was collected by suction, yielding 0.6 g of 3-methyl-4-oxo-15 -2-(3-pyridyl)-4H-l-benzopyran-8-carboxylic acid, which was used without purification in the next step. The title compound was prepared according to Example 86 but using the above Intermediate instead of 4-oxo-2-phenyl--4H-l-benzopyran-8-carboxylic acid and carrying out the 20 reaction for 2 hours at room temperature. The base was purified by flash chromatography on silica gel/ eluting with a mixture of chloroform:methanol 98:2, followed by crystallization from acetone, yielding 0.15 g (m.p. 134.5-137*0. 25
Example 120 8-{3-[4-(2-acetoxyphenyl)-1-piperaz inyl]--propylcarbamoyl}-3-methyl-4-oxo-2-phenyl-4H-l--benzopyran 30 1 g of compound of Example 59 and 0.32 g of 4- dimethylaminopyridine were dissolved in 10 ml of dichloromethane and slowly added with 0.15 ml of acetyl chloride, maintaining the temperature between 8 and 35 10*C. After 2 hours at room temperature, the reaction ... mixture was poured into 7 0 ml of water and extracted with dichloromethane. The organic layer was washed with LV 10099 181 5¾ agueous sodium hydrogen carbonate followed by water, dried on anhydrous sodium sulphate and evaporated in vacuo. The crude base was purified by flash chromatography on silica gel, eluting with a mixture of ethyl acetate:methanol 9:1, followed by crystallization from ethanol, yielding 0.74 g of the title compound (m.p. 120-123*0.
Example 121 3-methyl-8-{3-[4-(2-methylaminocarbonyloxyphenyl)-1--piperazinyl]-propylcarbamoyl}-4-oxo-2-phenyl-4H-l--benzopyran 3 g of compound of Example 59 and 1.8 ml of methylisocyanate were dissolved in 30 ml of dry N, N-dimethylformamide and stirred at room temperature for 24 hours. The mixture was diluted with water, stirred for 2 hours, then filtered by suction. The crude base was purified by flash chromatography on silica gel eluting with chloroform:5 N ammonia in methanol 100:3. The title compound melted at 132-135*C after crystallization from ethanol.
Example 122 6-acetoxy-8-{3-[4-(2-methoxyphenyl)-l-piperazinyl]--propylcarbamoyl}-3-methyl-4-oxo-2-phenyl-4H-1--benzopyran O. 17 ml of acetyl chloride was added dropwise during 5 minūtes, under stirring at O'C, into a solution of 1 g of the compound of Example 91 and 0.32 ml of triethylamine in 36 ml of chloroform. After 2 hours stirring at the same temperature, the reaction mixture was diluted with dichloromethane and water; the organic layer was separated, washed with water, dried on sodium sulphate and evaporated to dryness in vacuo. 182
Crystallization of the.residue from acetonitrile yielded 0.8 g of the title compound, melting at 148-149*C. gxamp.ļ,e 12.3 (R,S)-2,3-dihydro-4-hydroxy-8-{3-[4-(2-methoxyphenyl) -1 --piperazinyl] -propylcarbamoyl} -4H-l-benzopyran methanesulphonate
The title compound was prepared by the same method as described in Example 17 but starting from compound of Example 87, instead of compound of Example 1. The reaction mixture was diluted with water and stirred for 15 minūtes; then it was extracted with ethyl acetate. Usual work up gavē a crude, which was purified by flagh chromatography on silica gel eluting with dichloromethane:methanol 95:5. Evaporation in vacuo of the collected fraction yielded the pure base, wich was converted into the methanesulphonate and crystallized from acetonitrile (m.p. 172-175*0.
Example 124 2-(4-aminophenyl)-8-{3-[4-(2-methoxyphenyl)-1--piperazinyl]-propylcarbamoyl}-3-methyl-4-oxo-4H-l--benzopyran 2.22 g of compound of Example 113 and 0.56 g of Raney-Nickel in 96 ml of ethanol and 4.8 ml of acetic acid was hydrogenated in a Parr apparatus (pH2 = 1 atm) at room temperature. After 6 hours shaking, the catalyst was filtered off and the filtrate was alkalinized with 3N sodiiim hydroxide and diluted with water. After 2 days resting, the precipitated title compound was collected by suction, washed with water, desiccated and recrystallized firstly from ethyl acetate then from ethanol yielding 1.5 g (m.p. 192-194*0. LV 10099 183
Example 125 2-(4-acetylaminophenyl)-8-{3-[4-(2-methoxyphenyl)-1--piperazinyl]-propylcarbamoyl}-3-methyl-4H-l-benzopyran 5 The title compound was prepared by the same method as described for compound of Example 36, but using the compound prepared in Example 124 instead of compound of Example 124 Instead of compound of Example 33. It was purified by crystallization from 95% ethanol (m.p. 207-10 209*C).
Example 126 2-(4-hydroxyphenyl)-8-{3-[4-(2-methoxyphenyl) -1 --piperazinyl]-propylcarbamoyl}-3-methyl-4H-l-benzopyran 15 dihydrochloride monohydrate
The title compound was prepared by the method described in Example 86 but using Intermediate CVII instead of 4-oxo-2-phenyl-4H-l-benzopyran-8-carboxylic acid, and 20 carrying out the reaction for 14 hours at room temperatūra also in the presence of hexamethyl-phosphoramide as co-solvent. The isolated diethyl-phosphonyl ester of the title compound was hydrolized by alkaline treatment followed by neutralization with 25 diluted hydrochloric acid. The crude base was extracted with chloroform and the organic layer washed with water and evaporated in vacuo. The salt was prepared by ethanolic hydrogen chloride addition to an acetone solution of the base, evaporating to dryness and rinsing 30 with acetone (m.p. 193-205*0 .
Bxample 127 8-{3-[4-(2-methoxyphenyl)-l-piperazinyl]--propylcarbamoyl > - 2 -phenyl-4, Ni, N4 -trioxo-4H-l-35 -benzothiopyran monohydrate 184 0.8 g of compound of Example 107 and 15 ml of acetic acid were added with 0.32 ml of 30% hydrogen peroxide and stirred at 50*C for 3 hours. Then 0.48 ml of 30% hydrogen peroxide (3x0.16 ml portions every 2 hours of heating) was added to the mixture. After cooling, the mixture was poured into 240 ml of water, neutralized at pH 7 with 5% agueous sodium hydrogen carbonate and extracted with chloroform. The organic layer was washed with water, dried on anhydrous sodium sulphate and evaporated in vacuo, yielding 0.18 g of the title compound, melting at 172-175*C after crysrallization from acetonitrile.
Example 128 7- 3-[4-(2-methoxyphenyl)-l-piperazinyl]--propylcarbamoyl}-2-phenylbenzo[b]furan
The title compound was prepared by the method described in Example 86 but using 2-phenylbenzo[b]furan-7--carboxylic acid (prepared as described in EP 306226, 1989) instead of 4-oxo-2-phenyl-4H-l-benzopyran-8--carboxylic acid, and carrying out the reaction for 1.5 hours at room temperature. It was purified by crystallization from carbon tetrachloride (m.p, 132-136*C).
Example 129 8- {3-[4-(2-methoxyphenyl)-l-piperazinyl]-propyl-N--methylsulfamoyl)-3-methyl-4-oxo-2-phenyl-4H-l--benzopyran methanesulphonate 2.29 g of Intermediate VIII was added portionwise under stirring at 0*C to a solution of 1.5 g of Intermediate CI and 0.95 ml of triethylamine in 30 ml of chloroform. After 2 additional hours stirring at room temperature, the reaction mixture was diluted with dichloromethane, water and 0.5N sodium hydroxide. The organic layer was LV 10099 185 washed wlth water, dried on sodium sulphate and evaporated to dryness in vacuo. The residue was purified by flash chromatography on silica gel, eluting with ethyl acetatermethanol 96:4. Evaporation in vacuo of the 5 collected fractions, yielded of the pure title compound as a base. This one was converted by the usual method into the methanesulphonate salt, which was crystallized from ethyl acetate yielding 2,75 g, melting at 135-141*C (dec.). 10 . .
Example 130 8-{3-[4-(2-methoxyphenyl)-1-piperazinyl]-butyl-N--me thy1sulphamoy1-3-methyl-4-oxo-2-pheny1-4H-1--benzopyran methanesulphonate 15
The title compound was obtained by the same method described in Exeuaple 129 but using intermediate CVIII instead of Intermediate CI. The title compound was crystallized from acetonitrile (m.p. 173-175’C). 20 186 PHARMACOLOGICAL DATA .
Methodologv
Male Sprague Dawley rats [Crl: CD' BR] of 200-300 g 5 b.w., female Albino Swiss mice [Crl: CD-I (ICR) BR] 20-30 g b.w., and male Beagle dogs (10-12 kg b.w.) were obtained from Charles River, Italy and Nossan (Correzzana, Milan, Italy), respectively. Animals were housed with free access to food and water and maintained 10 on forced light-dark cycle at 22-24’C until the day of experiments.
Asute tpxlfilty
The acute toxicity of synthesized compounds was 15 evaluated in female albino Swiss mice after intraperitoneal and oral administration. Four logarithmic scaled doses of the compounds were dissolved or suspended in 0.5 % Methocel and administered in a volume of 10 ml/kg to groups of 4 mice/dose. Mortality 20 was recorded 7 days after the administration. Data analysis: the LD50 values and their fiducial limits were calculated according to the method of Weil (Biometrice, £, 249, 1952). 25 Receotor Binding studies: - C3H]prazosin binding (ai receotors)
Rat cerebral cortices were homogenized in 50 volumes of original wet weight of ice-cold 50 mM Tris-HCl buffer pH 30 7.4. The homogenates were centrifuged at 48,000 x g for 10 minūtes, and the pellets were resuspended in the same volume of ice-cold buffer, centrifuged and resuspended two more times. The final pellets obtained were resuspended in the same volume of buffer and incubated 35 according to the conditions reported in the table below. The foregoing receptor binding studies, as well as the experimental data on dogs reported below, establish LV 10099 187 compounds of the invention as αι-blockers, i.e. to be within a class of substances widely used as antihypertensive and anti-BPH aģents. See, e.g., Frishman, W.H. et al.,Medical Clinice of N. America, 12. 427, 1988 and references cited therein. -_[3H18-OH-DPAT bindinc (5HTia receptūra)
Rat hippocampi were homogenized in 50 volumes of original wet weight of ice-cold 50 mM Tris-HCl buffer pH 7.4. The homogenates were centrifuged at 48,000 x g for 10 minūtes, and the peliets were resuspended in the same volume of ice-cold buffer, incubated for 10 minūtes at 37*C, centrifuged and resuspended two more times. The final pellets obtained were resuspended in the same volume of buffer and incubated according to the conditions reported in the table below.
These receptor binding studies serve to establish compounds of the present invention as ligands for the SHTia receptor. As previously reported, compounds that are 5HTia ligands exert anxiolytic and antidepressant effects in animals and humāns (Hamon, M. et al., Ann. Ν.Υ. Acad. Sci., 600. 114, 1990; Traber J. et al., T.I.P.S., £, 437, 1987).
Receptor bindino studies ai adrenergic l3HlprazĢgiņ
RECEPTOR/LIGAND
Conditions
5-HTia serotonergic Γ3Η1 8-OH-DPAT 1 2 3 [nM] ligand 0.35 1.0 188 1 2 3 preparat ion (c.m.p.) 1 ml 1 ml 10 mg/ml 10 mg/ml incubation buffer* Tris HCl Tris HCl 50 mM 50 mM pH 7.4 pH 7.4 non-specific binding prazosin 5-HT 2 μΜ 10 μΜ incubation 25 *C 25 *C 30 min 30 min c.m.p. = crude membranes preparation; * = containing ascorbin acid 1 % and pargyline 10 μΜ
The incubations were terminated after the appropriate time (see table) by rapid filtration through Whatman GF/B filters using a Brandel celi harvester. The filters were washed twice with 15 ml of ice-cold buffer (see table). The radioactivity retained on the filters was determined by liguid scintillation counting. Nonspecific binding (which amounted generally to 10-30%) was evaluated by adding high concentrations of the specific displacers (see table). Ali the compounds were initially tested at 1x10"^ M concentration, and in the presence of significant displacing activity, a complete competition curve was generated (down to a concentration of 10 M). Ali the samples were run in triplicate.
The competition curves were always analyzed (to evaluate the IC50 values) by non linear curve fitting of the logistic equation according to the method reported by De Lean et al. (Am.J. Phy9iol., 235/ E97, 1978), utilizing LV 10099 189 the ALLFIT program ,[publically available from the National Institutes of Health (N.I.H.) Bethesda, Maryland, USA] written for the IBM PC. 5 K+-induced contractions of rat bladder strips:
The whole bladder of the rat was removed and immediately placed in Krebs solution warmed at 37 ’C. Strips of detrusor muscle (20-30 mm long, 1-2 mm wide), were cut from the dome of the bladder. Each strip was placed in a 10 10 ml organ bath and connected, under a constant load of 1 g, to an isometric strain gauge (DY-1 Basile, Comerio, Varese, italy). Contractions were recorded by means of a Basile 7070 polygraph. After a 60 minūtes equilibration period the strips were exposed to 80 mM KC1 (final 15 concentration). This produced a rapid phasic contraction followed by a slow ensuing and sustained tonic component. When the tonic contraction was stable, the strips were washed and 30 minūtes later a new contraction was induced. After having recorded two or 20 more reproducible responses, one concentration of the tested drugs was added to the bath and 30 minūtes later a new contraction was induced. The experimental groups consisted of at least two preparations taken from different animals for each concentration of drug tested. 25 The IC50 values of inhibition of agonist-induced contractions were evaluated by linear regression analysis.
Effects on ūrethral Contractions and Blood Pressure in 30 Dogs
The experiments were performed according to the method of Imagawa et al. (J. Pharmacol. Methods, 22, 103-111, 1989), with substantial modifications, as follows: Adult male beagle dogs, weighing 8-10 Kg, were anaesthetized 35 with pentobarbital sodium (30 mg/Kg i.v. and 2 mg/Kg/h i.v.), intubated and spontaneously ventilated with air room. In order to monitor systemic blood pressure (BP), 190 a PE catheter was introduced into the aortic arch through the right common carotid artery. A collateral of the left femoral vein was cannulated for infusion of anaesthetic, and the right femoral vein was 5 cannulated for ādministration of drugs. For intrarterial (i.a.) injection of noradrenaline (NA), a PE catheter was introduced into the lower portion of abdominal aorta via the right external iliac artery. Through such procedure, NA was selectively distributed to the lower 10 urinary tract. Via a midline laparotomy, the urinary bladder and proximal urethra were exposed. In order to prevent the filling of the bladder, the two ureters were cannulated and the urine led outside. In order to record the prostatic urethra1 pressure, a Mikro-tip catheter (6 15 F) was introduced into the bladder via the external urethral meatus, and withdrawn until the pressure transducer was positioned in the prostatic urethra. A ligature was secured between the neck of the bladder and urethra to isolate the response of the latter and avoid 20 any interaction with the bladder. Another ligature was put around the Mikro-tip catheter at the external urethral meatus, to secure the catheter itself. After a stabilizing period following surgical procedure (30 min), in which arterial and prostatic urethral pressure 25 were continuously monitored as basai values, i.a. administration of NA was made at intervāls of 10 min. The dose of NA chosen was such to producē an increase of at least 100¾ in urethral pressure. The tēst compounds were administered i.v. in a cumulative manner with 30 intervāls of 15-2 0 min betv/een administrations. I.a. injections of NA were repeated approximately 5 min. after every dosing of tēst compound.
Dose response curves were constructed computing the percentage inhibition to the increase in urethral 35 pressure (NA induced), and the percentage drop in blood pressure produced by the tēst compound. ED25 for diastolic blood pressure (dose inducing a 25% decrease) LV 10099 191 and ID50 (dose inducing a 50¾ inhibition of NA-induced increase in urethral pressure) were computed by means of linear regression analysis. 5 Results
Compounds as prepared in the Examples were tested according to the methods reported above, and the results are given in the Tables below, together with comparative results for the reference standards used. Compounds 10 having receptor a£finity (IC50 values) lower than about 500 nM are generally considered to have good affinity. Compounds with IC50 values less than 100 nM are generally preferred. 192
. TABLE I
ComDound ReceDtor Bindino Acute Toxicitv K+ Stimulation Example No. IC50 ai (nM) 5-HTia in Mice of Rat Bladder LD50 i.p. (mg/kg) P · 0. IC50 (μΜ) Contractions Phasic Tonic 4 550 55 346 1732 5 20 19 621 >3000 6 107 1000 233 7 86 155 384 1915 8 66 111 >500 1915 11 29 9 247 297 2.9 3.0 13 68 229 >1000 >3000 10.0 10.0 14 61 6 140 559 15 8 131 306. 496 16 220 1050 345 778 1.6 2.2 17 59 910 299 608 8.8 3.8 18 270 >1000 457 3000 19 165 340 >1000 >3000 20 169 85 297 594 2.7 2.5 21 17 33 297 566 22 117 48 >500 >2000 24 690 212 >1000 >3000 26 270 >1000 >500 >2000 27 23 124 399 >3000 1.0 0.8 28 120 96 203 1127 29 86 45 730 >3000 10.0 10.0 32 119 46 301 >2000 10.0 >10 33 17 38 399 >2000 10.0 10.0 34 30 34 >500 2.8 3.6 35 15 8 329 959 36 18 54 >500 >2000 37 32 77 >500 >2000 38 20 344 >500 >2000 39 90 170 >1000 >3000 40 75 83 140 349 0.5 0.9 41 43 53 399 2241 0.7 1.4 42 111 39 459 2163 10.0 10.0 43 166 >1000 44 685 201 84 399 0.6 0.5 45 15 106 329 1727 46 86 23 47 36 23 330 1047 2.7 5.2 48 104 5 500 1914 49 152 9 432 >2000 50 39 300 211 299 51 22 84 >500 >2000 52 89 2 127 224 53 7 41 127 1020 54 35 143 106 421 55 291 >1000 128 >2000 56 25 748 >500 [N.B. Table 1 is continued on the next page] LV 10099 193 TABLE I (continued)
ComDound Example No Receutor Bindina Acute Toxicitv K + Stimulation IC50 ai (nM) 5-HTia in Mice LDsp (mg/kg) i.p. p.o. of Rat Bladder IC50 (μΜ) Contractions Phasic Tonic 57 69 >1000 500 >200 58 *1000 126 258 0 59 5 9 >500 508 60 25 45 203 278 61 36 11 315 329 62 252 278 128 592 63 194 99 309 344 64 40 11 479 65 113 26 66 57 56 67 4 4 508 601 68 29 13 1868 69 16 87 344 70 53 85 >500 71 108 69 1868 72 145 111 479 73 6 89 202 >200 74 178 482 0 75 147 15 462 78 18 116 79 77 141 >500 80 28 162 81 13 81 >200 83 30 5 0 84 5 2 85 16 14 86 48 20 87 119 107 237 88 216 11 93 47 38 94 39 66 >500 98 103 12 99 44 5 102 56 18 104 9 15 107 37 16 110 26 15 Flavox- ate »1000 >>1000 385 808 13 13 194
TABLE II 5 Effects on Urethral Contractllitv and Blood Pressure in
Doga
Compound Example No. Urethra ED50 (mg/kg) DBP ED25 (mg/kg) DBP / Urethra ratio 5 37.0 1074 29.0 13 16.0 215 13.4 17 10.0 6.2 0.6* 21 6.6 126 19.2 27 3.2 9.8 3.1* 40 11.0 152 13.8 41 57.0 745 13.1 42 31.0 404 13.0 45 16.4 186 11.3 47 35.0 530 15.1 Prazosin 3.6 6.6 1.8* Terflavoxate >10000 6060 10 Urethra: active dose in inhibiting by 50% the noradrenaline induced contraction of urethra DEP: 15 active dose in lowering diastolic blood pressure by 25% DBP/urethra: ratio between the active doses (selectivity index)
* non-selective: substantial effect on 20 both urethra and DBP
Effective Amounts
The following represent guidelines to effective oral, parenteral or intravenous dose ranges expressed in mg/kg of body weight per day for the following uses: LV 10099 195 (a) In obstructive disorders of the lower urinary tract: General 0.001 - 20 Preferred 0.05 - 1 Most Preferred** 0.3 (b) AS antihypertensives; General 0.01 - 20 Preferred 0.1 - 5 Most Preferred** 1 (c) As anxiolytics - antidepressants: General 0.01 - 20 Preferred 0.05 - 5 Most Preferred** 0.5 (d) As bladder spasmolyticss General 0.01 - 20 Preferred 0.02 - 10 Most Preferred** 2 ** Most preferred values refer to oral dosing. Intravenous dosages should be 10 to 100 fold lower. Patients in need of treatment by the present compounds and compositions also include humāns that have one or more depression symptoms (as defined, e.g. in Harrison's Principles of Internai Medicine, XII Ed., McGraw-Hill, Inc., p.2124) or humāns that display anxiety symptoms (Harrison's/ Bupra, pp.2131-2134).
Selective use dosages, l.e. dosages that are actlve in the lower urinary tract without a substantial effect on the blood pressure depend on the particular compound employed but, generally, up to four times the ED50 of a selective compound can be administered without substantial effect on blood pressure. Further refinements and optimization of dosages are possible using no more than routine experiments.
The active compounds of the invention may be orally administered, for example, with an inert diluent or with an edible carrier, or they may be enclosed in gelatin capsules, or they may be compressed into tablets. For 196 the purpose of oral therapeutic administration, the active compounds of the invention may be incorporated with excipients and used in the form of tabletS/ troches, capsules, elixirs, suspensions, syrups, wafers, 5 chewing gum and the like. These preparations should contain at least 0.5¾ of active compounds, but the amount of active ingredient may be varied depending upon the particular form and may conveniently be between 5¾ to about 70¾ of the weight of the unit. The amount of 10 active compound in such compositions is such that a suitable dosage will be obtained although the desired dosage can be obtained by administering a plurality of dosage forms. Preferred compositions and preparations according to the invention are prepared so that an oral 15 dosage unit form contains between 1.0-300 milligrams of active compound.
The tablets, pilis, capsules, troches and the like may also contain for example the following ingredients: a binder such as micro-crystalline cellulose, gum 20 tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating aģent such as alginic acid, Primogel, cornstarch and the like; a lubricant such as magnesium stearate or Sterotex; a glidant such as colloidal Silicon dioxide; and a sweetening aģent such 25 as sucrose or saccharin may be added or a flavouring aģent such as peppermint, methyl salicylate, or orange flavouring. When the dosage unit form is a capsule, it may contain, in addition to materiāls of the above type, a liquid carrier such as a fatty oil. Other dosage unit 30 forms may contain other various materiāls which modify the physical form of the dosage unit, for example, as coatings. Thus, tablets or pilis may be coated with sugar, shellac, or other enteric coating aģents. A syrup may contain, in addition to the active compounds, 35 sucrose as a sweetening aģent and certain preservatives, dyes, colouring and flavours. Materials used in LV 10099 197 preparing these various compositions should be pharmaceutically pure and non-toxic in the amounts used. For the purpose of parenteral therapeutic administration, the active compounds of the invention may be incorporated into a solution or suspension. Theee preparations should contain at least 0.1¾ of active compound, but may be varied between 0.5 and about 30¾ of the weight thereof. The amount of active compound in such compositions is such that a suitable dosage will be obtained. Preferred compositions and preparations according to the present inventions are prepared so that a parenteral dosage unit contains between 0.2 to 100 milligrams of active compound.
The Solutions or suspensions may also include the following components: a sterile diluent such as water for injection, saline solution/ fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial aģents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulphite; chelating aģents such as ethylenediamine-tetraacetic acid; buffers such as acetates, citrates or phosphates and aģents for the adjustment of tonicity such as sodium chloride or dextrose. The parenteral multiple dose vials may be of glass or plastics material. 198
£1ΛIMS
1. Α compound having the general formula I
wherein ---- represents a single or double bond; X represents an oxygen or sulphur atom or an imino, alkylimino, sulphinyl or sulphonyl group; W represents a valence bond or a carbonyl, thiocarbonyl, methylene or hydroxymethylene group; R2 represents a hydrogen atom or an alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, carbocyclyc, substituted carbocyclyc, heterocyclyc, substituted heterocyclyc or aroyl group; the substituents for the aforesaid substituted groups being one or more halogen atoms, such as fluorine and/or one or more alkyl, cyano, hydroxy, alkoxy, phenyl, phenoxy, trifluoromethyl, nitro, amino, alkylamino, dialkylamino, acylamino, alkylsulphonyl-amino or benzoyl groups; R3 represents a hydrogen atom or an alkyl, hydroxyalkyl, alkoxyalkil, aralkoxyalkyl, phenyl, hydroxy, alkoxy or aralkoxy group; R6 represents a hydrogen or halogen atom or a nitro, amino, alkylamino, dialkylamino, acylamino, alkyl-sulphonylamino, cyano, hydroxy, alkoxy or alkyl group; R7 represents a hydrogen atom or an alkoxy group; Y represents one of the following groups, each of which is depicted with its left hand end being the LV 10099 199 end which attaches to the heterobicyclic ring and its right hand end being the end which attaches to the group Z : (Yl) 1 n 0 1 5 (Y2) -COO- , (Y3) -CONH- , (Y4) -C0N(CH3)- , (Y5) -CON(OH)- , (Y6) -CH(OH)- , 10 (Y7) -CH(OAlkyl)- , (Y8) -CH=CH-, (Y9) -CH=CH-COO- (Υ10) -CH=CH-CONH- , (Υ11) -CH=NO- , 15 (Υ12) -CH2- , (Υ13) -CH2COO- , (Υ14) -CH2CONH- , (Υ15) -CH2NH- , (Υ16) -CH2N(CH3)- , 20 (Υ17) -CH2N(COCH3)- (Υ18) -CH2N(CONH2)- (Υ19) -CH2NHCO- , (Υ20) -CH2N(CH3)CO- (Υ21) -CH2NH-CONH- , 25 (Υ22) -CH2NHS02- , (Υ23) -CH20- , (Υ24) -CH2S- , (Υ25) -CH2SO- , (Υ26) -CH2SO2- / 30 (Υ27) -CH2SO2NH- , (Υ28) -CH2S02N(CH3)- (Υ29) -NH- , (Υ30) -N(CH3)- , (Υ31) -N(COCH3)- , 35 (Υ32) -N(CONH2)“ , (Υ33) -NHCO- , (Υ34) -N(CH3)CO- , 200 200 (Υ35) (Υ36) (Υ37) (Υ38) (Υ39) (Υ40) (Υ41) (Υ42) (Υ43) (Υ44) (Υ45) (Υ46) -NH-CONH- , -NHS02- / -Ο- , -S- , -SO- , -S02- , -S02NH- , -S02N{CH3)- , -CONHO- , -CON(COCH3)- / -CSNH- , -CSN(CH3)- , (Υ47)
-NHCOO- (Υ48) (Υ49) and -COS- Ζ represents a linear or branched chain alkylene group havlng from 1 to 6 carbon atoms and optionally having one hydroxy substituent; and B represents one of the following groups : (Bl) / \
N
N—A
wherein Q represents a methylene or ethylene group and A represents one of the following groups: (AI) a phenyl group substituted by one or more halogen atoms and/or one or more alkyl, alkoxy or hydroxy groups, (A2) a 2-pyrimidinyl group, and (A3) a group of the general formula LV 10099
201 vrtierein — - is as above defined and E represents an oxygen atom or a valence bond, (B2)
M l2 vrtierein each of Li and L2 independently represents a hydrogen atom, a phenyl, 4-fluorobenzoyl or 2-oxo-l-benzimidazolinyl group, or a group of the general formula (CH2)n-0-A wherein n is 0, 1 or 2 and A is as defined in this claim, with the proviso that Li and L2 do not both represent hydrogen atoms, (B3)
wherein each of Rio and Rn independently represents a hydrogen atom or an alkoxy or alkylthio group, Ri2 represents a hydrogen atom or an alkyl group, and n is 2 or 3,
202 wherein R12 is as defined in this claim and R13 represente a hydrogen atoi or an alkoxy group, and (B5) 0
wherein R12 1s as defined in this claim. or a prodrug, enantiomer, diastereoisomer, N-oxide or pharmaceutically acceptable salt of such a compound. 2. A compound according to claim 1, vrtierein ---- represents a double bond, X represents an oxygen atom, W represents a carbonyl group, R2 represents a phenyl group, R3 represents a methyl group,
Rg represents a hydrogen atom, and R7 represents a hydrogen atom. 3. A compound according to claim 1 or claim 2 wherein Y represents one of the groups Y2, Y3, Υ37, Υ40 or Υ41. 4. A compound according to any preceding claim wherein Z represents a trimethylene or tetramethylene group. 5. A compound according to any preceding claim wherein B represents one of the groups B1 or B3. LV 10099 203 6. A compound according to any preceding claim wherein B represents a 4-(2-methoxyphenyl)-l-piperazinyl group. 7. A compound according to any preceding claim wherein Y, Z and B together represent a 3-[4-{2--methoxyphenyl)-1-piperazinyl]-propylcarbamoyl group. 8. Any one of the following compounds: 8-{2 - [4-(2-methoxypheny 1)-l-piperazinyl]-l-oxoethyl}--3-methy1-4-oxo-2-pheny1-4 Η-1-benzopyran, 8-{2 - [4-(2-methylphenyl)-1-piperazinyl]-l-oxoethyl}-3--me thy1-4-oxo-2-pheny1-4 Η-1-benzopyran, 8-{2- [4-(2-ethoxyphenyl)-l-piperazinyl]-l-oxoethyl}-3--methyl-4-oxo-2-phenyl-4H-l-benzopyran, 8-{3- [4-(2-methoxyphenyl)-l-piperazinyl]-l-oxopropyl}--3-methy1-4-oxo-2-pheny1-4H-1-benzopyran, 8-{3-[4-(2-methoxyphenyl)-l-piperazinyl]- -p ropoxyc arbony1}-3-methy1-4-oxo-2-pheny1-4H-1- -benzopyran, 8-{2-[4-(2-methoxyphenyl)-1-piperaz inyl]--ethoxycarbony1}-3-methy1-4-oxo-2-pheny1-4H-1--benzopyran, 8-{3- [4-(2-chlorophenyl)-1-piperazinyl]--propoxycarbonyl}-3-methyl-4-oxo-2-phenyl-4H-l--benzopyran, 8-[3-(4-phenyl-l-piperazinyl)-propoxycarbonyl]-3--me t hy 1 - 4 - oxo - 2 -pheny 1 - 4H -1 -benzopyr an, 8-{3-[4-(2-methoxyphenyl)-1-piperaz inyl]--propoxycarbonyl}-3-methyl-4-oxo-2-phenyl-4H-1--benzopyran, 8-{3- [4-(2 -me thoxyphenyl) -1 -piperaz inyl ] -2 -methyl -2 --propoxycarbonyl}-3-methyl-4-oxo-2-phenyl-4H-1--benzopyran, 8-{3-[4-(2 -me thoxyphenyl) -1 -piperaz inyl ] - -p ropy1carbamoy1}-3-methy1-4-oxo-2-pheny1-4H-1- -benzopyran, 204 8-{2-[4-(2-methoxyphenyl)-l-piperazinyl]--e thylcarbamoyl}-3-methyl-4-oxo-2-phenyl-4H-1--benzopyran, 8 - {3 - [2-(2 -me thoxyphenoxy) -ethylamino ] - -propylcarbamoyl}-3-methyl-4-oxo-2-phenyl-4H-l- -benzopyran, 8-[3-(4-phenyl-l-piperazinyl)-propylcarbamoyl]-3--methy1-4-oxo-2-phenyl-4H-1-benzopyran, 8 - {N-methyl-2 - [4 - (2 -methoxyphenyl) -1 -piperazinyl] - -ethylcarbamoyl}-3-methyl-4-oxo-2-phenyl-4H-l- -benzopyran, 8-{l-hydroxy-2-[4-(2-methoxyphenyl)-l-piperazinyl]--ethyl}-3-methy1-4-oxo-2-pheny1-4H-1-benzopyran, 8-{1-hydroxy-2-[4-(2-me thylphenyl)-1-piperaz inyl]--ethyl}-3-methyl-4-oxo-2-phenyl-4H-l-benzopyran, 8-{l-hydroxy-2-[4-(2-ethoxyphenyl)-1-piperazinyl]--ethyl>-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8-{1-hydroxy-3-[4-(2-metoxyphenyl)-1-piperazinyl]--propyl}-3-methyl-4-oxo-2-phenyl-4H-l-benzopyran, 8-{1-hydroxy-4-[4-(2-methoxyphenyl)-l-piperazinyl]--butyl>-3-methyl-4-oxo-2-phenyl-4H-l-benzopyran, 8-{l-ethoxy-2-[4-(2-methoxyphenyl)-l-piperazinyl]--ethyl}-3-methyl-4-oxo-2-phenyl-4H-l-benzopyran/ 8-{N-methyl-2-[4-(2-methoxyphenyl)-l-piperazinyl]--e thy1aminome thy1}-3-me thy1-4 -oxo-2-pheny1-4H-1--benzopyran, 8-{N-acetyl-2-[4-(2-methoxyphenyl)-l-piperazinyl]--ethy1aminomethy1}-3 -methy1-4-oxo-2-pheny1-4Η-1--benzopyran, 8-[4-(2-methoxyphenyl)-l-piperazinylacetamidomethyl]--3-methyl-4-oxo-2-phenyl-4H-l-benzopyran/ 8-{N-methyl-N-[4-(2-metoxyphenyl)-l-piperazinyl]-acet-amidomethyl}-3-methyl-4-oxo-2-phenyl-4H-l-benzopyran/ 8-{2-[4-(2-methoxyphenyl)-l-piperazinyl]--ethoxymethy1}-3-methy1-4-oxo-2-pheny1-4Η-X--benzopyran, LV 10099 205 8-{2- [2-(2-ethoxyphenoxy)-ethylamino]-ethoxymethyl}-3--methy1-4-oxo-2-pheny1-4Η-1-benzopyran, hydrochloride, 8-{2-[4-(2-methoxypheny1)-1-piperaz iny1]--ethylthiomethyl}-3-methyl-4-oxo-2-phenyl-4H-l--benzopyran, 8-{2-[4-(2-methoxyphenyl)-1-piperaz iny1]- -e thy 1 sulphinylmethy1}-3-methy1-4-oxo-2-phenyl- 4 Η -1 - -benzopyran/ 8-{2-[4-(2-methoxyphenyl)-1-piperazinyl]--ethylsulphonylmethyl)-3-methyl-4-oxo-2-phenyl-4H-l--benzopyran, 8-{2-[4-(2 -methoxypheny 1) -1 -piperazinyl ] -ethylamino} --3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8-{3-[4-(2-methoxyphenyl)-l-piperazinyl]-propylamino}--3-me thy1-4-oxo-2-pheny1-4Η-1-benzopyran, 8-{4- [4- (2-methoxypheny 1) -l-piperazinyl] -butylamino}--3-methyl-4-oxo-2-phenyl-4H-l-benzopyran, 8-{N-methy1-3-[4-(2-methoxypheny1)-1-piperaz inyl]--propylamino}-3-methyl-4-oxo-2-phenyl-4H-l-benzopyran, 8-{N-acety1-3-[4-(2-methoxyphenyl)-1-piperaz inyl]--propylamino}-3-methyl-4-oxo-2-phenyl-4H-l-benzopyran, 8-{3- [4-(2-methoxyphenyl)-1-piperazinyl]--propionamido>-3-methy1-4-oxo-2-pheny1-4H-1--benzopyran, 8-{2-[4-(2-methoxypheny1)-1-piperazinyl]-ethylureido}--3-methyl-4-oxo-2-pheny1-4Η-1-benzopyran, 8-{2- [4-(2-methoxyphenyl)-l-piperazinyl]-ethoxy}-3--methyl-4-oxo-2-phenyl-4H-l-benzopyran/ 8-{3-[4-(2-methoxyphenyl)-l-piperazinyl]-propoxy}-3--methy1-4-oxo-2-pheny1-4H-1-benzopyran, 8-{4-[4-(2-methoxyphenyl)-l-piperazinyl]-butoxy}-3--me t hy 1 - 4 - oxo - 2 -pheny 1-4H-1 -benzopyr an, 8-{5- [4-(2-methoxyphenyl)-l-piperazinyl]-pentyloxy}-3--methyl-4-oxo-2-phenyl-4H-l-benzopyran, 8-{3 - [4-(2-methoxyphenyl)-l-oxo-l-piperazinyl]--propoxy>-3-methyl-4-oxo-2-phenyl-4H-l-benzopyran/ 206 8-(2-[2-(2,6-dimethoxyphenoxy)-ethylamino]-ethoxy}-3--methy1-4-oxo-2-pheny1-4 Η-1-benzopyran, 8-{2-hydroxy-3-[4-(2-methoxyphenyl)-l-piperazinyl]--propoxy}-3-methy1-4-oxo-2-pheny1-4H-1-benzopyran, 8-{3-[4-(2-methoxyphenyl)-l-piperazinyl]-propylthio)--3-me thy1-4-oxo-2-pheny1-4Η-1-benzopyran, 8-(3-[4-(2-methoxyphenyl)-1-piperazinyl]--propylsulphonyl>-3-methyl-4-oxo-2-phenyl-4H-l--benzopyran, 8-{2-[4-(2-methoxyphenyl)-l-piperazinyl]--ethylsulphamoyl>-3-methyl-4-oxo-2-phenyl-4H-l--benzopyran, 8-{N-methyl-2-[4-(2-methoxyphenyl)-1-piperazinylj- -ethylsulphamoyl}-3-methyl-4-oxo-2-phenyl-4H-l- -benzopyran, 8 - {N-carbamoyl -3 - [ 4 - (2 -methoxyphenyl) -1 -piperazinyl ] --propylamino}-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8—{4-[4-(2-methoxyphenyl)-l-piperazinyl]-l-oxobutyl}--3-methyl-4-oxo-2-pheny1-4H-1-benzopyran, 8-{3-[2-(l,4-benzodioxany1)methylamino]propylcarbamo-yl}-3-methyl-4-oxo-2-phenyl-4H-l-benzopyran/ 8-{4- [4-(2-methoxyphenyl)-1-piperazinyl]-butyl)-3--methy1-4-oxo-2-pheny1-4H-1-benzopyran, 8-[3-(4-phenyl-l-piperidinyl)-propylcarbamoyl]-3--methyl-4- -oxo-2-phenyl-4H-1-benzopyran/ 8-[3-(4,4-diphenyl-l-piperidinyl)-propylcarbamoyl]-3--me thy1-4 -oxo-2-pheny1-4Η-1-benzopyran, 8-{3-[4-(4-fluorobenzoyl)-l-piperidinyl]-propyl-c arbamoy1}-3-methyl-4-oxo-2-pheny1-4 Η-1-benzopyran, 8-{3-[4-(2-oxo-l-benzimidazolinyl)-l-piperidinyl]- -propylcarbamoyl}-3-methyl-4-oxo-2-phenyl-4H-l- -benzopyran, 8-{3-[4-(2-pyrimidinyl)-l-piperazinyl]-propylcar-bamoyl}-3-methyl-4-oxo-2-phenyl-4H-l-benzopyran, 8-{3-[4-(2-hydroxyphenyl)-1-piperazinyl]-propylcarba-moyl}-3-methyl-4-oxo-2-phenyl-4H-l-benzopyran, LV 10099 207 8-{4-[4-(2-methoxyphenyl)-1-piperazinyl]-butylcarba-moyl}-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8-{3-[4-(2-methoxyphenyl)-l-piperazinyl]-propyl-sulphamoy1}-3-methyl-4-oxo-2-pheny1-4Η-1-benzopyran, 8- {3- [N-methyl-2- (2-methoxyphenoxy) -ethylamino] --propylcarbamoyl)-3-methyl-4 -oxo - 2 -pheny1-4H-1--benzopyran, 8-{N-methyl-3-[4-(2-methoxyphenyl)-l-piperazinyl]--propionamido} -3 -methyl-4-oxo-2-phenyl-4H-l--benzopyran, 8- {3- [4- (2-methoxyphenyl) -l-piperazinyl] --propylcarbamoyl>-3-phenyl-4-oxo-4H-1-benzopyran, 8-{3-[(3,4-dihydro-l-oxo-2H-naphthyl)-methylamino}--propylcarbamoyl>-3-methyl-4-oxo-2-phenyl-4H-l--benzopyran, 8-{2-[4-(2-methoxyphenyl)-1-piperaz inyl]--ethoxycarbonyl-methyl}-3-methyl-4-oxo-2-phenyl-4H-l--benzopyran, 8-{4-[4-(2-methoxyphenyl)-l-piperazinyl]-butylsulpha-moy1>-3-methy1-4-oxo-2-pheny1-4Η-1-benzopyran# 8-{N-(2-tetrahydropyranyloxy)-3-[4-(2-methoxyphenyl)--1-piperazinyl]-propylcarbamoyl>-3-methyl-4-oxo-2--phenyl-4H-1-benzopyran, 8-{4-[4-(2 -me thoxypheny 1) -1 -piperazinyl ] -butyramido} --3-methy1-4-oxo-2-pheny1-4Η-1-benzopyran, E-8-{2-[4-(2-methoxyphenyl)-l-piperazinyl]- -ethoxyiminomethyl}-3-methyl-4-oxo-2-phenyl-4H-1- -benzopyran, 8-{N-hydroxy-3- [4- (2-methoxyphenyl) -l-piperazinyl] --propylcarbamoyl}-3-methyl-4-oxo-2-phenyl-4H-l--benzopyran, E-8-<2-{2- [4-(2-methoxyphenyl)-1-piperazinyl]--ethylcarbamoyl}-ethenyl>-3-methyl-4-oxo-2-phenyl-4H--l-benzopyran, 8-{4- [4-(2-methoxyphenyl)-1-piperazinyl]-butylsulphi-nyl>-3-methyl-4-oxo-2-phenyl-4H-l-benzopyran, 208 8- {3- [3- (2-methoxyphenoxy) -propylami.no] -propylcarba-moyl}-3-methyl-4-oxo-2-phenyl-4H-l-benzopyran, 8-{3-[2-(2 -methyl thiophenoxy) -ethylami.no] --propylcarbamoyl}-3-methyl-4-oxo-2-phenyl-4H-l--Wnzopyran, 8-{3-[2-(2,6-dimethoxyphenoxy)-ethylamino]--propylcarbamoyl>-3-methyl-4-oxo-2-phenyl-4H-l--benzopyran, 8-{3-[4-(5-chloro-2-methoxyphenyl)-l-piperazinyl]pro-py1carbamoy1}-3-methyl-4-oxo-2-pheny1-4Η-1-benzopyran, (E)-8-{4-[4-(2-methoxyphenyl)-l-piperazinyl]-1--buteny1}-3-methy1-4-oxo-2-phenyl-4H-1-benzopyran, (E)-8-<2-{2-[4-(2-methoxyphenyl)-l-piperazinyl]--ethoxycarbamoy1}-ethenyl>-3-methyl-4-oxo-2-phenyl-4H--1-benzopyran/ 8-{2-[4-(2-methoxyphenyl)-l-piperazinyl]--ethylcarbamoylmethyl}-4-oxo-2-phenyl-4H-l-benzopyran, 8-{N-acetyl-3-[4-(2-methoxyphenyl)-l-piperazinyl]--propylcarbamoyl}-3-methyl-4-oxo-2-phenyl-4H-l--benzopyran, 8-{2-[4-(2-methoxyphenyl)-l-piperazinyl]- - e t hy 1 su lphony 1 amino } - 3 -me t hy 1 - 4 - oxo - 2 -pheny 1 - 4 Η -1 - -benzopyran, 8-{3-[4-(2-methoxyphenyl)-l-piperazinyl]--propylthiocarbamoyl}-3-methyl-4-oxo-2-phenyl-4H-1--benzopyran, 8-{4- [4- (2-methoxyphenyl) -l-piperazinyl] -butylsulpho- nyl)-3-methyl-4-oxo-2-pheny1-4Η-1-benzopyran, 8-{3-[4-(2-methoxyphenyl)-1-piperaz inyl]-propylcarba- moyl}-3-hydroxymethyl-4-oxo-2-pheny1-4H-1-benzopyran, 8-{3-[4-(2-methoxyphenyl)-1-piperaz inyl ]- -propylcarbamoy1}-4-oxo-2-phenyl-4Η-1-benzopyran, 8-{3-[4-(2-methoxyphenyl)-1-piperaz inyl]- -propy1carbamoy1} - 2,3 - dihydro-4-oxo-4H-l-benzopyran, 8-{3-[4-(2-methoxyphenyl)-1-piperaz inyl]- -propylcarbamoyl)-4-oxo-4H-l-benzopyran, LV 10099 209 8-{3- [4-(2-methoxypheny1)-l-piperazinyl]-propylcarba-moyl}-6-bromo-3-methyl-4-oxo-2-phenyl-4H-l-benzopyran, 8-{3- [4-(2-methoxyphenyl)-l-piperazinyl]-propylcarba-moy1}-6-methoxy-3-methy1-4-oxo-2-phenyl-4H-1--benzopyran, 8-{3—[4-(2-methoxyphenyl)-l-piperazinyl]- -propylcarbamoy1}-6-hydroxy-3-methyl-4-oxo-2-phenyl- -4H-1-benzopyran, 8-{3- [4-(2-methoxyphenyl)-l-piperazinyl]-propylcarba-moyl}-3,6-dimethyl-4-oxo-2-phenyl-4H-1-benzopyran, 8-{3- [4-(2-methoxyphenyl)-l-piperazinyl]-propylcarba-moyl}-3-methy1-6-ni t ro-4-oxo-2-pheny1-4 Η-1-benzopyran, 8-{3-[4-(2-methoxyphenyl)-l-piperazinyl]-propylcarba-moy1}-6-amino-3-methy1-4-oxo-2-pheny1-4Η-1-benzopyran, 8-{3- [4-(2-methoxyphenyl)-l-piperazinyl]-propylcarba-moy 1 >-6-acetamido-3-methy1-4-oxo-2-pheny1-4Η-1--benzopyran, 8-{3-[4-(2-methoxypheny1)-1-piperaz inyl]--propylcarbamoyl}-6-ethylamino-3-methyl-4-oxo-2--phenyl-4H-l-benzopyran, 8-{3- [4-(2-methoxyphenyl)-l-piperazinyl]-propylcarba-moyl}-6-dimethylamino-3-methyl-4-oxo-2-phenyl-4H-l--benzopyran, 8-{3-[4-(2-methoxyphenyl)-1-piperazinyl]-propylcarba- moyl>-7-methoxy-3-methyl-4-oxo-2-phenyl-4H-l- -benzopyran, 8-{3 - [4-(2-methoxypheny1)-1-piperazinyl]-propylcarba-moyl}-3-methyl-4-oxo-2-(4-trifluoromethylpheny1)-4H-l--benzopyran, 8-{3 - [4-(2-methoxyphenyl)-1-piperazinyl]-propylcarba-moyl}-2-(4-benzoylphenyl)-3-methyl-4-oxo-4H-l--benzopyran, 8-{3- [4- (2-methoxyphenyl) -1-piperaz inyl] -propylcarba-moyl)-3-methyl-4-oxo-2- (4-phenoxyphenyl) -4H-1--benzopyran, 8-{3- [4-(2-methoxyphenyl)-1-piperazinyl]-propylcarba-moy 1 }-2/3-dimethyl-4-oxo-4Η-1-benzopyran, 210 8-{3-[4-(2-methoxyphenyl)-l-piperazinyl]-propylcarba-moyl}-2-(t-butyl)-3-methyl-4-oxo-4H-l-benzopyran, 8-{3- [4-(2-metīioxyphenyl)-l-piperazinyl]-propylcarba-moyl}-2-cyclohexyl-3-methyl-4-oxo-4H-l-benzopyran# 8-{3-[4-(2-methoxyphenyl)-l-piperazinyl]-propylcarba-moyl}-2-(2-furyl)-3-methyl-4-oxo-4H-l-benzopyran, 8-{3-[4-(2-methoxyphenyl)-l-piperazinyl]-propylcarba-moyl}-3-methyl-4-oxo-2-thienyl-4H-l-benzopyran, 8-{3- [4-(2-methoxypheny1)-l-piperazinyl]-propylcarba-moyl}-4-oxo-2-phenyl-4H-1-benzothiopyran, (E)-8-{3-[4-(2 -methoxyphenyl) -l-plperazinyl ] --propylcarbamoyl} -3 -methyl -4-oxo-2-(2 -styryl) -4H-1--benzopyran, 8-{3-[4-(2-me thoxypheny1)-1-piperaz inyl]-propylcarba-moyl > -3 -methyl -2 - (4 -methylphenyl) -4-oxo-4H-l --benzopyran, 8-{3 - [4-(2-methoxyphenyl)-1-piperazinyl]-propylcarba-moyl}-2-(4-methoxyphenyl)-3-methyl-4-oxo-4H-1--benzopyran, 8-{3-[4-(2-methoxyphenyl)-l-piperazinyl]-propylcarba-moyl}-2-(4-fluorophenyl)-3-methyl-4-oxo-4H-l--benzopyran, 8-{3-[4-(2-methoxyphenyl)-1-piperazinyl]-propylcarba-moyl > - 6 -methanesulphonylamino -3 -methyl -4-oxo-2 -phenyl --4Η-1-benzopyran, 8-{3-[4-(2-methoxyphenyl)-1-piperazinyl]-propylcarba-moyl} -3 -methyl-2-(4 -nitrophenyl) -4-oxo-4H-l--benzopyran, 8-{3-[4-(2-methoxyphenyl)-l-piperazinyl]-propylcarba-moyl} - 6 -diethoxyphosphonyloxy- 3 -methyl-4 -oxo-2-phenyl--4 Η-1-benzopyran, 8-{3-[4-(2-methoxyphenyl)-l-piperazinyl]-propylcarba- moyl}-3-methyl-4-oxo-2-trifluoromethyl-4H-l- -benzopyran, 8-{N-methyl-3-[4-(2-methoxyphenyl)-l-piperazinyl]- -propylcarbamoyl}-3-methyl-4-oxo-2-phenyl-4H-l- -benzopyran, LV 10099 211 7- {3- [4- (2-methoxyphe'nyl) -l-piperazinyl] -propylcarba-moyl)-2-benzoyl-3-ethyl-benzo[b]furan, 2 - (4 -biphenylyl)-8-{3-[4-(2 -me thoxyphenyl) -1-pipera-zinyl]-propylcarbamoyl}-3-methyl-4-oxo-4H-l--benzopyraiX/ 8- {3- [4- (2-methoxyphenyl) -l-piperazinyl] -propylcarba-moy1}-3-methyl-4-oxo-2-(3-pyridy1)-4H-1-benzopyran, 8-{3- [4-(2-acetoxyphenyl)-l-piperazinyl]-propylcarba-moyl}-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 3-methyl-8-{3-[4-(2-methylaminocarbonyloxyphenyl)-1--piperazinyl]-propylcarbamoyl)-4-oxo-2-phenyl-4H-l--benzopyran, 6- acetoxy-8-{3-[4-(2-methoxyphenyl)-l-piperazinyl]--propylcarbamoy1}-3-methy1-4-oxo-2-pheny1-4Η-1--benzopyran, (R,S)-2,3-dihydro-4-hydroxy-8-{3-[4-(2-methoxypbenyl)--l-piperazinyl]-propyloarbamoyl>-4H-l-benzopyran methanesulphonate, 2-(4-aminophenyl)-8-{3-[4-(2-methoxyphenyl)-1--piperazinyl]-propylcarbamoyl}-3-methyl-4-oxo-4H-l--benzopyran, 2-(4-acetylaminophenyl) -8-{3— [4—(2-methoxyphenyl)-1 --piperazinyl] -propylcarbamoyl) -3-methyl-4H-l--benzopyran/ 2-(4-hydroxypheny1)-8—{3—[4-(2-acetoxyphenyl)-1--piperazinyl]-propylcarbamoyl>-3-methyl-4H-l--benzopyran dihydrochloride monohydrate, 8—{3-[4—(2-methoxyphenyl)-1-piperazinyl]-propylcarba-moyl}-2-phenyl-4,Ni,N4-trioxo-4H-l-benzothiopyran monohydrate, 7- {3- [4-(2-methoxyphenyl)-l-piperazinyl]-propylcarbo-moyl}-2-phenylbenzo[b]furan, 8- {3-[4-(2-methoxyphenyl)-l-piperazinyl]-propyl-N--me thy1sulphamoy1}-3-me thy1-4 -0x0-2-pheny1-4 Η-1--benzopyran methanesulphonate, 212 8—<3—[4-(2-methoxyphenyl)-l-piperazinyl]-butyl-N--methy1 su lphamoy 1 - 3 -me t hy 1 - 4 -oxo - 2 -pheny 1-4H-1--benzopyran me thanesulphonate; or a prodrug, enantiomer, diastereoisomer, N-oxide or 5 pharmaceutically acceptable salt of such a compound. 9. A pharmaceutlcal composition comprising a compound according to any preceding claim, or a prodrug, enantiomer, diastereoisomer, N-oxide or pharmaceuti-cally acceptable salt of such a compound, in admixture with a pharmaceutically acceptable diluent or carrier. 10 LV 10099 213
ABSTRACT
Bicvclic Heterocvclic Compounds 5
There are disclosed compounds of the general formula
15 The heteroatom X is preferably oxygen, but may have other values. The group W is preferably a carbonyl group, but may have other values. The preferred heterocyclic ring is thus a 4-oxo-4H-l-benzopyran ring. This may have a wide range of R2/ R3/ R6 and R7 20 substituents. ī is a linking group, chosen from a wide range, but including -COO-, -CONH-, -0-, -SO2- and -SO2NH-. Z is an alkylene Chain, and B is a complex amine. These compounds and their prodrugs, enantio-mers, diastereoisomers, N-oxides and pharmaceutically 25 acceptable salts are useful for the treatment of hypertension and urinary tract troubles associated with benign prostatic hypertrophy, and for the treatment of other diseases. 30 35

Claims (9)

LV 10099 BICIKLISKI HETEROCIKLISKI ATVASINĀJUMI * ο PATENTA FORMULA 1. Savienojums ar vispārēju formulu IEN 10099 BICYCLE HETEROCYCLIC DERIVATIVES * ο PATENT FORMULA 1. Compound of general formula I kur ..... simbolizē vienkāršo vai dubulto saiti; 20 X simbolizē skābekļa vai sēra atomu vai imino-, alkilimino-, sulfinil- vai sulfonilgrupu; W simbolizē valences saiti vai karbonil-, tiokarbonil-, metilen- vai hidroksimetilen-grupu; 25 R2 simbolizē ūdeņraža atomu vai alkil-, aizvietotu alkil-, alkenil-, aizvietotu alkenil-, alkinil-, aizvietotu alkinil-, karbociklil-, aizvietotu karbociklil-, heterociklil-, aizvietotu heterociklil- vai aroil-grupu; iepriekš minēto aizvietotājgrupu aizvietotāji ir viens vai vairāki halogenatomi, tādi kā fluors, un/vai viena vai vairākas alkil-, ciāno-, hidroksi-, alkoksi, fenil-, fenoksi-, trifluorometil-, nitro-, amino-, alkilamino-, dialkilamino-, acilamino-, alkilsulfonilamino- vai benzoil-grupa; R3 simbolzē ūdeņraža atomu vai alkil-, hidroksialkil-, alkok-sialkil-, aralkoksialkil-, fenil-, hidroksi-, alkoksi- vai aralkoksi-grupu; 30 2 R6 simbolizē ūdeņraža vai halogēna atomu vai nitro-, amino-, alkilamino-, dialkilamino-, acilamino-, alkilsulfonilamino-, ciāno-, hidroksi-, alkoksi- vai alkil-grupu; R7 simbolizē ūdeņraža atomu vai alkoksigrupu; ο Y simbolizē vienu no sekojošām, grupām, no kurām katra ir attēlota ar tās kreisās puses galu, kas pievienots pie heterobicikliskā gredzena, un tās labās puses galu, kas pievienots pie grupas Z : (Yl) -co-, 10 (Y2 ) -coo-, (Y3) -CONH-, (Y4) -CON(CH3)-, (Y5) -CON(OH)-, (Y6) -CH(OH)-, 15 (Y7) -CH(OAlkil)-, (Y8) -CH=CH-, (Y9) -CH=CH-COO-, (Υ10) "CH=CH-CONH-, (Υ11) -CH=NO-, 20 (Υ12 ) -ch2- , (Υ13 ) -CH2COO-, (Υ14) -CH2CONH-, (Υ15) -CH2NH-, (Υ16) -CH2N(CH3)-, 25 (Υ17) -CH2N(COCH3)-, (Υ18) -CH2N(CONH2)-, (Υ19) -CH2NHCO-, (Υ20) -CH2N(CH3)CO-, (Υ21) -ČH2NH-CONH-, 30 (Υ22) -CH2NHSO2-, (Υ23) -CH2O-, (Υ24 ) -CH2S-, (Υ25) -CH2SO-, (Υ26) -CH2SO2-, 35 (Υ27) -CH2SO2NH-, 3 LV 10099 (Υ28 ) -CH2S02N(CH3)-, (Υ29 ) -NH-, (Υ30) -N(CH3)-, (Υ31) -N(COCH3)-. (Υ32) -N(CONH2)-, (Υ33 ) -NHCO-, (Υ34) -N(CH3)CO-, (Υ35 ) -NH-CONH-, (Υ36) -NHS02-, (Υ37) -o-, (Υ38) -S-, (Υ39) -so-, (Υ40) -S02-, (Υ41) -S02NH-, (Υ42) -S02N(CH3)-, (Υ43) -CONHO-, (Υ44 ) -CON(COCH3)-, (Υ45) -CSNH-, (Υ46) -CSN(CH3)-, (Υ47 ) -C0N(0-f ļ) - (Υ48) -NHCOO-, un (Υ49 ) -COS-; Z simbolizē lineāras vai sazarotas ķēdes alkilengrupu ar no 1 līdz 6 oglekļa atomiem un neobligāti ar vienu hidroksi- B aizvietotāju; unsimbolizē vienu no sekojošām grupām : (Bi) / \ nJ <* 4 kur Q simbolizē metilen- vai etilen-grupu un A simbolizē vienu no sekojošām grupām ( AI ) fenilgrupa, aizvietota ar vienu vai vairākiem halogēna atomiem un/vai vienu vai vairākām alkil-, alkoksi- vai hidroksi-grupām, (A2 ) 2-pirimidinilgrupa, un (A3 ) grupa ar vispārēju formuluwhere ..... symbolizes a simple or double link; 20 X represents an oxygen or sulfur atom or an imino, alkylimino, sulfinyl or sulfonyl group; W represents a valence bond or a carbonyl, thiocarbonyl, methylene or hydroxymethyl group; R 2 represents a hydrogen atom or an alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, substituted heterocyclyl or aroyl group; the substituents of the above-mentioned substituents are one or more halogen atoms, such as fluorine, and / or one or more alkyl, cyano, hydroxy, alkoxy, phenyl, phenoxy, trifluoromethyl, nitro, amino, alkylamino, dialkylamino. -, acylamino, alkylsulfonylamino or benzoyl; R3 represents a hydrogen atom or an alkyl, hydroxyalkyl, alkoxyalkyl, aralkoxyalkyl, phenyl, hydroxy, alkoxy or aralkoxy group; 30 2 R 6 represents a hydrogen or halogen atom or a nitro, amino, alkylamino, dialkylamino, acylamino, alkylsulfonylamino, cyano, hydroxy, alkoxy or alkyl group; R7 represents a hydrogen atom or an alkoxy group; ο Y represents one of the following groups, each of which is depicted by its left end attached to the heterobicyclic ring and its right end attached to the group Z: (Y1) -co-, 10 (Y2) - co, (Y3) -CONH-, (Y4) -CON (CH3) -, (Y5) -CON (OH) -, (Y6) -CH (OH) -, 15 (Y7) -CH (OAlkil) - , (Y8) -CH = CH-, (Y9) -CH = CH-COO-, (Υ10) " CH = CH-CONH-, (Υ11) -CH = NO-, 20 (Υ12) -ch2-, (Υ13) -CH2COO-, (Υ14) -CH2CONH-, (Υ15) -CH2NH-, (Υ16) -CH2N (CH3) -, 25 (Υ17) -CH2N (COCH3) -, (Υ18) -CH2N (CONH2) -, (Υ19) -CH2NHCO-, (Υ20) -CH2N (CH3) CO-, (Υ21) -CH2NH-CONH-, 30 (Υ22) -CH2NHSO2-, (Υ23) -CH2O-, (Υ24) -CH2S- , (Υ25) -CH2SO-, (Υ26) -CH2SO2-, 35 (Υ27) -CH2SO2NH-, 3U10099 (Υ28) -CH2SO2N (CH3) -, (Υ29) -NH-, (Υ30) -N (CH3) ) -, (Υ31) -N (COCH3) -. (Υ32) -N (CONH2) -, (Υ33) -NHCO-, (Υ34) -N (CH3) CO-, (Υ35) -NH-CONH-, (Υ36) -NHSO2-, (Υ36) - , (Υ38) -S-, (Υ39) -so-, (Υ40) -SO2-, (Υ41) -SO2NH-, (Υ42) -SO2N (CH3) -, (Υ43) -CONHO-, (Υ44) - CON (COCH3) -, (Υ45) -CSNH-, (Υ46) -CSN (CH3) -, (Υ47) -C0N (O-f) - (Υ48) -NHCOO-, and (Υ49) -COS-; Z represents a linear or branched chain alkyl group having from 1 to 6 carbon atoms and optionally one hydroxy-B substituent; and symbolizes one of the following groups: (Bi) / j < * 4 where Q represents a methylene or ethylene group and A represents one of the following groups (A 1) phenyl substituted with one or more halogen atoms and / or one or more for alkyl, alkoxy or hydroxy groups, (A2) 2-pyrimidinyl, and (A3) of the general formula kur ir kā definēts iepriekš un E simbolizē skābekļa atomu vai valences saiti, (B2)where is as defined above and E represents an oxygen atom or a valence bond, (B2) kur katrs no Li un L2 neatkarīgi simbolizē ūdeņraža atomu, fenil-, 4-fluorobenzoil- vai 2-okso-l-benzimīd-azolinil-grupu, vai grupu ar vispārēju formulu (CH2)n-0-A, kur n ir 0, 1 vai 2 un A ir kā definēts šajā punktā, ar noteikumu, ka Li un L2 abi nesimbolizē ūdeņraža atomu, (B3 ) R R -N-(CH-) -O I i nwherein each of L1 and L2 independently represents a hydrogen atom, a phenyl, a 4-fluorobenzoyl or a 2-oxo-1-benzimidazolinyl group, or a group of general formula (CH2) n-O-A, wherein n is 0, 1 or 2 and A are as defined in this paragraph, provided that Li and L2 both do not symbolize the hydrogen atom, (B3) RR -N- (CH-) -OI in 11 5 LV 10099 kur katrs Rio un Rn neatkarīgi simbolizē ūdeņraža atomu vai alkoksi- vai alkiltio-grupu, R12 simbolizē ūdeņraža atomu vai alkilgrupu, un n ir 2 vai 3, ( B4) I100 5 where each Rio and Rn independently represent a hydrogen atom or an alkoxy or alkylthio group, R12 represents a hydrogen atom or an alkyl group, and n is 2 or 3, (B4) I R, o kur R12 ir kā definēts šajā punktā un R13 simbolizē ūdeņraža atomu vai alkoksigrupu, un (B5)R, where R12 is as defined in this paragraph and R13 represents a hydrogen atom or an alkoxy group, and (B5) kur R12 ir kā definēts šajā punktā, vai šāda savienojuma proārstnieciski savienojumi, enantiomēri, diastereoizomēri, N-oksīdi vai farmaceitiski izmantojami sāļi.wherein R 12 is as defined in this paragraph, or prodrugs, enantiomers, diastereoisomers, N-oxides or pharmaceutically acceptable salts of such a compound. 2. Savienojums saskaņā ar 1. punktu, kur ..... simbolizē dubultsaiti, X simbolizē skābekļa atomu , W simbolizē karbonilgrupu, R2 simbolizē fenilgrupu , R3 simbolizē metilgrupu , R6 simbolizē ūdeņraža atomu , un R7 simbolizē ūdeņraža atomu. 6The compound of claim 1, wherein ..... represents a double bond, X represents an oxygen atom, W represents a carbonyl group, R 2 represents a phenyl group, R 3 represents a methyl group, R 6 represents a hydrogen atom, and R 7 represents a hydrogen atom. 6 3. Savienojums saskaņa ar 1. vai 2. punktu, kur Y simbolizē vienu no grupām Y2, Y3, Υ37, Υ40, vai Υ41.A compound according to claim 1 or 2, wherein Y represents one of Y2, Y3, Υ37, Υ40, or Υ41. 4. Savienojums saskaņā ar jebkuru iepriekšējo punktu, kur Z 5 simbolizē trijnetilen- vai tetrametilen-grupu.A compound according to any preceding claim, wherein Z 5 represents a triethylen or tetramethylen group. 5. Savienojums saskaņā ar jebkuru iepriekšējo punktu, kur B simbolizē vienu no grupām B1 vai B3.A compound according to any preceding claim, wherein B represents one of the groups B1 or B3. 6. Savienojums saskaņā ar jebkuru iepriekšējo punktu, kur B simbolizē 4-(2-metoksifenil)-l-piperazinilgrupu.A compound according to any preceding claim wherein B represents 4- (2-methoxyphenyl) -1-piperazinyl. 7. Savienojums saskaņā ar jebkuru iepriekšējo punktu, kur Y, Z un B kopā simbolizē 3-[4-(2-metoksifenil)-l-piperazinil]-propil- 15 karbamoilgrupu.A compound according to any preceding claim, wherein Y, Z and B together represent 3- [4- (2-methoxyphenyl) -1-piperazinyl] -propylcarbamoyl. 8. Jebkurš no sekojošiem savienojumiem: 8-{2-[4-(2-metoksifenil)-l-piperazinil]-l-oksoetil}-3-metil-4-okso-2-fenil-4H-l-benzopirāns, 20 8-{2-[4-(2-metilfenil)-l-piperazinil]-l-oksoetil}-3-metil-4-okso-2- fenil-4H-l-benzopirāns, 8-{2-[4-(2-etoksifenil)-l-piperazinil]-l-oksoetil}-3-metil-4-okso-2- fenil-4H-l-benzopirāns, 8-{3-[4-(2-metoksifenil)-l-piperazinil]-l-oksopropil}-3-metil-4-25 okso-2-fenil-4H- 1-benzopirāns, 8-{3-[4-(2-metoksifenil)-l-piperazinil]-propoksikarbonil}-3-metil- 4-okso-2-fenil-4H-l-benzopirāns, 8-{2-[4-(2-metoksifenil)-l-piperazinil]-etoksikarbonil}-3-metil-4-okso-2-fenil-4H-1-benzopirāns, 30 8-{3-[4-(2-hlorfenil)-l-piperazinil]-propoksikarbonil}-3-metil-4- okso-2-fenil-4H- 1-benzopirāns, 8-[3-(4-fenil-l-piperazinil)-propoksikarbonil]-3-metil-4-okso-2-feniI-4H-1-benzopirāns, 8-{3-[4-(2-metoksifenil)-l-piperazinil]-propoksikarbonil}-3-metil-35 4-okso-2-fenil-4H-1 -benzopirāns, 7 7 LV 10099 8-{3-[4-(2-metoksifenil)-l-piperazinil]-2-metil-2-propoksikarbo-nil} -3-metil-4-okso-2-fenil-4H- 1-benzopirāns, 8-(3-[4-(2-metoksifenil)-l-piperazinil]-propilkarbamoil}-3-metil-4-okso-2-fenil-4H-l-benzopirāns, 5 8-{2-[4-[(2-metoksifenl)-l-piperazinil]-etilkarbamoil}-3-metil-4- okso-2-fenil-4H-l-benzopirāns, 8-(3-[2-(2-metoksifenil)-etilamino]-propilkarbamoil}-3-metil-4-okso-2-fenil-4H-1-benzopirāns, 8-[3-(4-fenil-l-piperazinil)-propilkarbamoil]-3-metil-4-okso-2-10 fenil-4H-1-benzopirāns, 8-{N-metil-2-[4-(2-metoksifenil)-l-piperazinil]-etilkarbamoil}-3- metil-4-okso-2-fenil-4H-l-benzopirāns, 8-(l-hidroksi-2-[4-(2-metoksifenil)-l-piperazinilļ-etil}-3-metil-4-okso-2-fenil-4H-1-benzopirāns, 15 8-{l-hidroksi-2-[4-(2-metilfenil)-l-piperazinil]-etil}-3-metil-4- okso- 2:fenil-4H-1 -benzopirāns, 8-{l-hidroksi-2-[4-(2-etoksifenil)-l-piperazinil]-etil}-3-metil-4-okso-2-fenil-4H-1-benzopirāns, 8-{l-hidroksi-3-[4-(2-metoksifenil)-l-piperazinil]-propil}-3-metil-20 4-okso-2-fenil-4H-l-benzopirāns, 8-{l-hidroksi-4-[4-(2-metoksifenil)-l-piperazinil]-butil}-3-metil-4-okso-2-fenil-4H-1-benzopirāns, 8-{l-etokso-2-[4-(2-metoksifenil)-l-piperazinil]-etil}-3-metil-4-okso-2-fenil-4H-1-benzopirāns, 25 8-{N-metil-2-[4-(2-metoksifenil)-l-piperazinilļ-etilaminometil}-3- metil-4-okso-2-fenil-4H-l-benzopirāns, 8-{N-acetil-2-r4-(2-metoksifenil)-l-piperazinilļ-etilaminometil}-3-raetil-4-okso-2-fenil-4H-l-benzopirāns, 8-[4-(2-metoksifenil)-l-piperazinilacetamīdometil]-3-metil-4-30 okso-2-fenil-4H-1-benzopirāns, 8-{N-metil-N-[4-(2-metoksifenil)-l-piperazinil]-acetam!dometil}- 3-metil-4-okso-2-fenil-4H-l-benzopirāns, 8-{2-r4-(2-metoksifenil)-l-piperazinil]-etoksimetil}-3-metil-4- okso-2-fenil-4H-l-benzopirāns, 8 8-{2-[2-(2-etoksifenoksi)-etilaimno]-etoksimetil}-3-metil-4-okso- 2-fenil-4H-l-benzopirāns, hidrohlorids, 8-{2-[4-(2-metoksifenil)-l-piperazinil]-etiltiometil}-3-metil-4- okso-2-fenil-4H-l-benzopirāns, 8-{2-[4-(2-metoksifenil)-l-piperazinil]-etilsulfinilmetil}-3-metil-4* okso-2-fenil-4H-l-benzopirāns, 8-{2-[4-(2-metoksifenil)-l-piperazinil]-etilsulfonilmetil}-3-metil- 4-okso-2-fenil-4H-l-benzopirāns, 8-{2-[4-(2-metoksifenil)-l-piperazinil]-etilamino}-3-metil-4-okso- 2-fenil-4H-l-benzopirāns, 8- (3-[4-(2-metoksifenil)- l-piperazinil]-propilamino}-3-metil-4-okso-2-fenil-4H-l-benzopirāns, 8-{4-[4-(2-metoksifenil)-l-piperazinil]-butilamino}-3-metil-4- okso-2-fenil-4H-l-benzopirāns, 8-{N-metil"3-[4-(2-metoksifenil)-l-piperazinil]-propilamino}*3- metil-4-okso-2-fenil-4H-l-benzopirāns, 8-{N-acetil-3-[4-(2-metoksifenil)-l-piperazinil]-propilamino}-3- metil-4-okso-2-fenil-4H-l-benzopirāns, 8-{3-[4-(2-metoksifenil)-l-piperazinil]-propionaraīdo}-3-metil-4- okso-2-fenil-4H-l-benzopirāns, 8-{2-[4-(2-metoksifenil)-l-piperazinil]-etilureido}-3-metil-4-okso- 2-fenil-4H-l-benzopirāns, 8-{2-[4-(2-metoksifenil)-l-piperazinil]-etoksi}-3-metil-4-okso-2- fenil-4H-l-benzopirāns, 8-{3-[4-(2-metoksifenil)-l-piperazinil]-propoksi}-3-metil-4-okso-2-fenil-4H-1 -benzopirāns, 8-{4-[4-(2-metoksifenil)-l-piperazinil]-butoksi}-3-metil-4-okso-2- fenil-4H-l-benzopirāns, 8-{5-[4-(2-metoksifenil)-l-piperazinil]-pentiloksi}-3-metil-4-okso- 2-fenil-4H-l-benzopirāns, 8-{3-[4-(2-metoksifenil)-l-okso-l-piperazinilļ-propoksi}-3-metil-4- okso-2-fenil-4H-l-benzopirāns, 8-(2-[2-(2,6-dimetoksifenoksi)-etilamino]-etoksi}-3-metil-4-okso-2-fenil-4H-1 -benzopirāns, 9 9 LV 10099 8- f 2-hidroksi-3-[4-(2-metoksifenil)- l-piperazinil]-propoksi) -3-metil-4-okso-2-fenil-4H-l-benzopirāns, 8-{3-[4-(2-metoksifenil)-l-piperazinil]-propiltio}-3-metil-4-okso-2-fenil-4H- 1-benzopirāns, 8-{3-[4-(2-metoksifenil)-l-piperazinil]-propilsulfonil}-3-metil-4-okso-2-fenil-4H- 1-benzopirāns, 8-{2-[4-(2-metoksifenil)-l-piperazinil]-etilsulfamoil}-3-metil-4- okso-2-fenil-4H-l-benzopirāns, 8-{N-metil-2-[4-(2-metoksifeml)-l-piperazinil]-etilsulfainoil)-3- metil-4-okso-2-fenil-4H-l-benzopirāns, 8-{N-karbamoil-3-[4-(2-metoksifenil)-l-piperazinil]-propilamino}- 3- metil-4-okso-2-fenil-4H-1-benzopirāns, 8-{4-[4-(2-metoksifenil)-l-piperazinil]-l-oksobutil}-3-metil-4-okso-2-fenil-4H- 1-benzopirāns, 8- {3-[2-( 1,4-benzodioksanil)-metilamino]-propilkarbamoil}-3-metil-4-okso-2-fenil-4H-l-benzopirāns, 8-(4-[4-(2-metoksifenil)-l-piperazinil]-butil)-3-metil-4-okso-2-fenil-4H-1-benzopirāns, 8-[3-(4-fenil-l-piperidinil)-propilkarbamoil}-3-metil-4-okso-2-fenil-4H-1-benzopirāns, 8-[3-(4,4-difenil-l-piperidinil)-propilkarbamoil]-3-metil-4-okso-2-fenil-4H-1-benzopirāns, 8-{3-[4-(4-fluorbenzoil)-l-piperidinil]-propilkarbamoil-3-metil-4-okso-2-fenil-4H- 1-benzopirāns, 8-{3-[4-(2-okso-l-benzimīdazolinil)-l-piperidinilļ-propilkarba-moil)-3-metil-4-okso-2-fenil-4H-1-benzopirāns, 8-{3-[4-(2-pirimidinil)-l-piperazinil]-propilkarbamoil}-3-metil-4-okso-2-fenil-4H-l-benzopirāns, 8-(3-[4-(2-hidroksifenil)-l-piperazinil]-propilkarbamoil}-3-metil- 4- okso-2-fenil-4H-l-benzopirāns, 8-{4-f4-(2-metoksifenil)-l-piperazinil]-butilkarbamoil}-3-metil-4-okso-2-fenil-4H- 1-benzopirāns, 8-{3-[4-(2-metoksifenil)-l-piperazinil]-propilsulfamoil}-3-metil-4-okso-2-fenil-4H- 1-benzopirāns, 10 8-{3-fN-metil-2-(2-metoksifenil)-etilamino}-propilkarbamoil}-3- metil-4-okso-2-fenil-4H-l-benzopirāns, 8-{N-metil-3-[4-(2-metoksifenil)-l-piperazinil]-propionamīdo}-3- metil-4-okso-2-fenil-4H-l-benzopirāns, 8-{3-[4-(2-metoksifenil)-l-piperazinil]-propilkarbamoil}-3-fenil-4- okso-4H-l-benzopirāns, 8-{3-[(3,4-dihidro-l-okso-2H-naftil)-metilaminoļ-propilkarba-moil}-3-metil-4-okso-2-fenil-4H-l-benzopirāns, 8-{2-[4-(2-metoksifenil)-l-piperazinil]-etoksikarbonilmetil}-3-metil-4-okso-2-fenil-4H-1 -benzopirāns, 8-{4-[4-(2-metoksifenil)-l-piperazinil]-butilsulfamoil}-3-metil-4-okso-2-fenil-4H- 1-benzopirāns, 8- {N-( 2-tetrahidropiraniloksi)-3-[4-(2-metoksifenil)- 1-piperazi-nil]-propilkarbamoil}-3-metil-4-okso-2-fenil-4H-l-benzopirāns, 8-{4-[4-(2-metoksifenil)-l-piperazinil]-butiraimdo}-3-metil-4-okso-2-fenil-4H-1-benzopirāns, . E-8-(2-[4-(2-metoksifenil)-l-piperazinil]-etoksiiminometil}-3- metil-4-okso-2-fenil-4H-l-benzopirāns, 8-{N-hidroksi-3-[4-(2-metoksifenil)-l-piperazinil]-propilkarba- moil}-3-metil-4-okso-2-fenil-4H-l-benzopirāns, E-8-<2-{2-[4-(2-metoksifenil)-l-piperazinil]-etilkarbamoil}- etenil>-3-metil-4-okso-2-fenil-4H-l-benzopirāns, 8-{4-[4-(2-metoksifenil)-l-piperazinil]-butilsuIfinil}-3-metil4- okso-2-fenil-4H- 1-benzopirāns, 8-{3-f3-(2-metoksifenoksi)-propilaminoļ-propilkarbamoil}-3- metil-4-okso-2-fenil-4H-l-benzopirāns, 8-{3-[2-(2-metiltiofenoksi)-etilamino]-propilkarbamoilļ-3-metil-4-okso-2-fenil-4H-1-benzopirāns, 8-{3-[2-(2,6-dimetoksifenoksi)-etilamino]-propilkarbamoil}-3- metil-4-okso-2-fenil-4H-l-benzopirāns, 8-{3-[4-(5-hlor-2-metoksifenil)-l-piperazinil]-propilkarbamoil}-3-metil-4-okso-2-fenil-4H- 1-benzopirāns, (E)-8-{4-r4-(2-metoksifenil)-l-piperazinil]-l-butenil}-3-metil-4-okso-2-fenil-4H-1-benzopirāns, LV 10099 Π (E)-8-<2-{2-[4-(2-metoksifenil)-l-piperazinill-etoksikarbonil}-etenil>-3-metil-4-okso-2-fenil-4H-l-benzopirāns, 8-(2-[4-(2-metoksifenil)-l-piperazinil]-etilkarbamoilmetil}--4-okso-2-fenil-4H-1-benzopirāns, 5 8-{N-acetil-3-[4-(2-metoksifenil)-l-piperazinil]-propilkarbamoil}- 3- metil-4-okso-2-fenil-4H-l-benzopirāns, 8-{2-[4-(2-metoksifenil)-l-piperazinil]-etilsulfonilamino}-3-metil- 4- okso-2-fenil-4H-l-benzopirāns, 8- {3-[4-(2-metoksifenil)- l-piperazinil]-propiltiokarbamoil}-3-10 metil-4-okso-2-fenil-4H-l-benzopirāns, 8-{4-[4-(2-metoksifenil)-l-piperazinil]-butilsiilfonil}-3-metil-4- okso-2-fenil-4H-l-benzopirāns, 8- {3-[4-(2-metoksifenil)-l-piperazinil]-propilkarbamoil}-3-hidroksimetil-4-okso-2-fenil-4H-l-benzopirāns, 15 8-{3-[4-(2-metoksifenil)-l-piperazinil]-propilkarbamoil}-4-okso-2- fenil-4H- 1-benzopirāns, 8-{3-[4-(2-metoksifenil)-l-piperazinil]-propilkarbamoil}-2,3-dihidro-4-okso-4H- 1-benzopirāns, 8-{3-[4-(2-metoksifenil)-l-piperazinil]-propilkarbamoil}-4-okso-20 4H-1-benzopirāns, 8-{3-[4-(2-metoksifenil)-l-piperazinil]-propilkarbamoil}-6-brom- 3-metil-4-okso-2-fenil-4H-l-benzopirāns, 8-{3-[4-(2-metoksifenil)-l-piperazinil]-propilkarbamoil)-6- metoksi-3-metil-4-okso-2-fenil-4H-l-benzopirāns, 25 8-{3-[4-(2-metoksifenil)-l-piperazinil]-propilkarbamoil}-6- hidroksi-3-metil-4-okso-2-fenil-4H-l-benopirāns, 8-{3-[4-(2-metoksifenil)-l-piperazinil]-propilkarbamoil}-3,6-dimetil-4-okso-2-fenil-4H-l-benzopirāns, 8-{3-[4-(2-metoksifenil)-l-piperazinil]-propilkarbamoil}-3-metil-30 6-nitro-4-okso-2-fenil-4H-l-benzopirāns, 8-{3-[4-(2-metoksifenil)-l-piperazinil]-propilkarbamoil}-6-amino-3-metil-4-okso-2-fenil-4H-l-benzopirāns, 8-{3-[4-(2-metoksifenil)-l-piperazinil]-propilkarbamoil)-6-acetamīdo-3-metil-4-okso-2-fenil-4H- 1-benzopirāns, 12 8-{3-[4-(2-metoksifenil)-l-piperazinil]-propilkarbamoil}-6- etilamino-3-metil-4-okso-2-fenil-4H-l-benzopirāns, 8- {3-[4-(2-metoksifenil)- l-piperazinil]-propilkarbamoil}-6-dimetilamino-3-metil-4-okso-2-fenil-4H-l-benzopirāns, 5 8-{3-[4-(2-metoksifenil)-l-piperazinil]-propilkarbamoil}-7- metoksi-3-metil-4-okšo-2-fenil-4H-1-benzopirāns, 8-{3-[4-(2-metoksifenil)-l-piperazinil]-propilkarbamoilļ-3-metil-4-okso-2-(4-trifluormetilfenil)-4H-l-benzopirāns, 8- (3-[4-(2-metoksifenil)- l-piperazinil]-propilkarbamoil}-2-(4-10 benzoilfenil)-3-metil-4-okso-4H-l-benzopirāns, 8-{3-[4-(2-metoksifenil)-l-piperazinil]-propilkarbamoil}-3-metil- 4-okso-2-(4-fenoksifenil)-4H-l-benzopirāns, 8- {3-[4-(2-metoksifenil)- l-piperazinil]-propilkarbamoil}-2,3-dimetil-4-okso-4H- 1-benzopirāns, 15 8-{3-[4-(2-metoksifenil)-l-piperazinil]-propilkarbamoil}-2-(t- butil)-3-metil-4-okso-4H-l-benzopirāns, 8-{3-[4-(2-metoksifenil)-l-piperazinil]-propilkarbamoil}-2-cikloheksil-3-metil-4-okso-4H-l-benzopirāns, 8-{3-[4-(2-metoksifenil)-l-piperazinil]-propilkarbamoil}-2-(2-20 furil)-3-metil-4-okso-4H-1-benzopirāns, 8-{3-[4-(2-metoksifenil)-l-piperazinil]-propilkarbamoil}-3-metil-4-okso-2-tienil-4H-1-benzopirāns, 8-{3-[4-(2-metoksifenil)-l-piperazinil]-propilkarbamoil}-4-okso-2 fenil-4H-l-benzotiopirāns, 25 (E)-8-{3-[4-(2-metoksifenil)-l-piperazinil]-propilkarbamoil}-3- metil-4-okso-2-(2-stiril)-4H-l-benzopirāns, 8-{3-[4-(2-metoksifenil)-l-piperazinil]-propilkarbamoil}-3-metil-2-(4-metilfenil)-4-okso-4H-l-benzopirāns, 8- {3-[4-(2-metoksifenil)- l-piperazinil]-propilkarbamoil}-2-(4-30 metoksifenil)-3-metil-4-okso-4H-l-benzopirāns, 8-{3-[4-(2-metoksifenil)-l-piperazinil]-propilkarbamoil}-2-(4- fluorfenil)-3-metil-4-okso-4H-l-benzopirāns, 8-(3-[4-(2-metoksifenil)-l-piperazinil]-propilkarbamoil}-6- metānsulfonilamino-3-metil-4-okso-2-fenil-4H-l-benzopirāns, ,, L.V 10099 13 8-{3-[4-(2-metoksifenil)-l-piperazinil]-propilkarbamoil}-3-metil- 2- (4-nitrofenil)-4-okso-4H-1-benzopirāns, 8-{3-r4-(2-metoksifenil)-l-piperazinil]-propilkarbamoil}-6-diet-oksifosfoniloksi-3-metil-4-okso-2-fenil-4H-l-benzopirāns, 5 8-{3-[4-(2-metoksifenil)-l-piperazinil]-propilkarbamoil}-3-metil* 4-okso-2-trifluormetil-4H-l-benzopirāns, 8-{N-metil-3-[4-(2-metoksifenil)-l-piperazinil]-propilkarbamoil}- 3- metil-4-okso-2-fenil-4H- 1-benzopirāns, 7- (3-[4-(2-metoksifenil)- l-piperazinill-propilkarbamoil}-2- 10 benzoil-3-etil-benzo[b]furāns, 2- (4-bifenilil)-8-{3-[4-(2-metoksifenil)-l-piperazinilļ-propil-karbamoil}-3-metil-4-okso-4H-l-benzopirāns, 8- {3-[4-(2-metoksifenil)-l-piperazinil]-propilkarbamoil}-3-metil- 4- okso-2-(3-piridil)-4H-l-benzopirāns, 15 8-(3-[4-(2-acetoksifenil)-l-piperazinil]-propilkarbamoil}-3-metil- 1- 4-okso-2-fenil-4H-1-benzopirāns, 3- metil-8-{3-r4-(2-metilaminokarboniloksifenil)-l-piperazinilļ-propilkarbamoil}-4-okso-2-fenil-4H-l-benzopirāns, 6- acetoksi-8-{3-[4-(2-metoksifenil)-l-piperazinilļ-propilkarba- 20 moil)-3-metil-4-okso-2-fenil-4H-l-benzopirāns, (R,S)-2,3-dihidro-4-hidroksi-8-{3-[4-(2-metoksifenil)-l-pipe-razinil]-propilkarbamoil}-4H-l-benzopirāna metānsulfonāts, 2- (4-aminofenil)-8-{3-[4-(2-metoksifenil)-l-piperazinil]-propil-karbamoil}-3-metil-4-okso-4H-l-benzopirāns, 25 2-(4-acetilaminofenil)-8-{3-[4-(2-metoksifenil)-l-piperazinil]- propilkarbamoil}-3-metil-4H-l-benzopirāns, 2-(4-hidroksifenil)-8-{3-[4-(2-metoksifenil)-l-piperazinil]-propilkarbamoil}-3-metil-4H-l-benzopirāna dihidrohlorida mo-nohidrāts, 30 8-{3-[4-(2-metoksifenil)-l-piperazinil]-propilkarbamoil}-2-fenil- 4,NļN4-triokso-4H-l-benzotiopirāna monohidrāts, 7- {3-[4-(2-metoksifenil)-l-piperazinil]-propilkarbamoil}-2-fenilbenzo[b] furāns, 8- {3-[4-(2-metoksifenil)-l-piperazinil]-propil-N-metilsulfamoil}-3- 35 metil-4-okso-2-fenil-4H-l-benzopirāna metānsulfonāts, 14 8-{3-r4-(2-metoksifenil)-l-piperazinil]-butil-N-metilsulfamoil-3* meiil-4-okso-2-fenil-4H-l-benzopirāna metānsulfonāts. vai šāda savienojuma proārstniecisks savienojums, enantiomērs, diastereoizomērs, N-oksīds vai farmaceitiski atļauts sāls.8. Any of the following compounds: 8- {2- [4- (2-Methoxyphenyl) -1-piperazinyl] -1-oxoethyl} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 20 8- {2- [4- (2-Methylphenyl) -1-piperazinyl] -1-oxoethyl} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {2- [4- (2-ethoxyphenyl) -1-piperazinyl] -1-oxoethyl} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {3- [4- (2-methoxyphenyl) -1- piperazinyl] -1-oxopropyl} -3-methyl-4-25 oxo-2-phenyl-4H-1-benzopyran, 8- {3- [4- (2-methoxyphenyl) -1-piperazinyl] propoxycarbonyl} -3 Methyl 4-oxo-2-phenyl-4H-1-benzopyran, 8- {2- [4- (2-methoxyphenyl) -1-piperazinyl] ethoxycarbonyl} -3-methyl-4-oxo-2-phenyl -4H-1-Benzopyran, 30 8- {3- [4- (2-Chloro-phenyl) -1-piperazinyl] -propoxycarbonyl} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- [3- (4-phenyl-1-piperazinyl) propoxycarbonyl] -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {3- [4- (2-methoxyphenyl) -1- piperazinyl] -propoxycarbonyl} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 7,7 LV 10099 8- {3- [4- (2-methoxyphenyl) -1-piperazinyl] -2- methyl-2-pro Poxycarbonyl} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- (3- [4- (2-methoxyphenyl) -1-piperazinyl] propylcarbamoyl} -3-methyl-4 oxo-2-phenyl-4H-1-benzopyran, 8- {2- [4 - [(2-methoxyphenyl) -1-piperazinyl] ethylcarbamoyl} -3-methyl-4-oxo-2-phenyl-4H 1-Benzopyran, 8- (3- [2- (2-methoxyphenyl) -ethylamino] -propylcarbamoyl} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- [3- (4 -phenyl-1-piperazinyl) -propylcarbamoyl] -3-methyl-4-oxo-2-10 phenyl-4H-1-benzopyran, 8- {N-methyl-2- [4- (2-methoxyphenyl) -1- piperazinyl] -ethylcarbamoyl} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- (1-hydroxy-2- [4- (2-methoxyphenyl) -1-piperazinyl] ethyl} -3 methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {1-hydroxy-2- [4- (2-methylphenyl) -1-piperazinyl] ethyl} -3-methyl-4- oxo-2: phenyl-4H-1-benzopyran, 8- {1-hydroxy-2- [4- (2-ethoxyphenyl) -1-piperazinyl] ethyl} -3-methyl-4-oxo-2-phenyl 4H-1-Benzopyran, 8- {1-Hydroxy-3- [4- (2-methoxyphenyl) -1-piperazinyl] propyl} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran , 8- {1-hydroxy-4- [4- (2-methoxyphen yl) -1-piperazinyl] butyl} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {1-ethoxy-2- [4- (2-methoxyphenyl) -1-piperazinyl] ] -ethyl} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {N-methyl-2- [4- (2-methoxyphenyl) -1-piperazinyl] ethylaminomethyl} -3 Methyl 4-oxo-2-phenyl-4H-1-benzopyran, 8- {N-acetyl-2- [4- (2-methoxyphenyl) -1-piperazinyl] ethylaminomethyl} -3-raethyl-4-oxo-2 -phenyl-4H-1-benzopyran, 8- [4- (2-methoxyphenyl) -1-piperazinylacetamide] -3-methyl-4-30 oxo-2-phenyl-4H-1-benzopyran, 8- {N-methyl -N- [4- (2-methoxyphenyl) -1-piperazinyl] -acetamomethyl} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {2-r4- (2- methoxyphenyl) -1-piperazinyl] -ethoxymethyl} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, δ 8- {2- [2- (2-ethoxyphenoxy) -ethylimino] ethoxymethyl} - 3-Methyl-4-oxo-2-phenyl-4H-1-benzopyran, hydrochloride, 8- {2- [4- (2-methoxyphenyl) -1-piperazinyl] ethylthiomethyl} -3-methyl-4-oxo 2-Phenyl-4H-1-benzopyran, 8- {2- [4- (2-methoxyphenyl) -1-piperazinyl] -ethylsulfinylmethyl} -3-methyl-4 * oxo-2-phenyl-4H-1-benzopyrene 9- {2- [4- (2-Methoxyphenyl) -1-piperazinyl] -ethylsulfonylmethyl} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {2- [4- (2-Methoxyphenyl) -1-piperazinyl] ethylamino} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- (3- [4- (2-methoxyphenyl) -1-piperazinyl] -propylamino} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {4- [4- (2-methoxyphenyl) -1-piperazinyl] butylamino} -3-methyl-4- oxo-2-phenyl-4H-1-benzopyran, 8- {N-methyl " 3- [4- (2-methoxyphenyl) -1-piperazinyl] propylamino} -3-methyl-4-oxo-2-phenyl 4H-1-benzopyran, 8- {N-acetyl-3- [4- (2-methoxyphenyl) -1-piperazinyl] -propylamino} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {3- [4- (2-Methoxyphenyl) -1-piperazinyl] -propionarid} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {2- [4- (2 -methoxyphenyl) -1-piperazinyl] -ethylureido} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {2- [4- (2-methoxyphenyl) -1-piperazinyl] ethoxy } -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {3- [4- (2-methoxyphenyl) -1-piperazinyl] propoxy} -3-methyl-4-oxo 2-phenyl-4H-1-benzopyr 8, 8- {4- [4- (2-methoxyphenyl) -1-piperazinyl] -butoxy} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {5- [4- (2-Methoxyphenyl) -1-piperazinyl] pentyloxy} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {3- [4- (2-methoxyphenyl) -1-oxo 1-piperazinyl-propoxy} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- (2- [2- (2,6-dimethoxyphenoxy) -ethylamino] -ethoxy} -3-methyl -4-Oxo-2-phenyl-4H-1-benzopyran, 9,9-LV-10099 8- f 2-Hydroxy-3- [4- (2-methoxyphenyl) -1-piperazinyl] propoxy) -3-methyl-4 oxo-2-phenyl-4H-1-benzopyran, 8- {3- [4- (2-methoxyphenyl) -1-piperazinyl] propylthio} -3-methyl-4-oxo-2-phenyl-4H-1 benzopyran, 8- {3- [4- (2-methoxyphenyl) -1-piperazinyl] -propylsulfonyl} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {2- [4] (2-Methoxyphenyl) -1-piperazinyl] ethylsulfamoyl} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {N-methyl-2- [4- (2-methoxyphenyl) 1-piperazinyl] ethylsulfanyl) -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {N -carbamoyl-3- [4- (2-methoxyphenyl) -1-piperazinyl] - propylamino} -3-methyl-4-one oxo-2-phenyl-4H-1-benzopyran, 8- {4- [4- (2-methoxyphenyl) -1-piperazinyl] -1-oxobutyl} -3-methyl-4-oxo-2-phenyl-4H- 1-Benzopyran, 8- {3- [2- (1,4-benzodioxanyl) -methylamino] -propylcarbamoyl} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- (4- [ 4- (2-Methoxyphenyl) -1-piperazinyl] butyl) -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- [3- (4-phenyl-1-piperidinyl) propylcarbamoyl } -3-Methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- [3- (4,4-diphenyl-1-piperidinyl) -propylcarbamoyl] -3-methyl-4-oxo-2- phenyl-4H-1-benzopyran, 8- {3- [4- (4-fluorobenzoyl) -1-piperidinyl] -propylcarbamoyl-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- { 3- [4- (2-Oxo-1-benzimidazolinyl) -1-piperidinyl] propylcarbamoyl) -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {3- [4- (2-Pyrimidinyl) -1-piperazinyl] propylcarbamoyl} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- (3- [4- (2-hydroxyphenyl) -1-piperazinyl] -propylcarbamoyl} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {4- [4- (2-methoxyphenyl) -1-piperazinyl] butylcarbamoyl} -3-methyl-4-oxo -2-phenyl-4H- 1-Benzopyran, 8- {3- [4- (2-methoxyphenyl) -1-piperazinyl] -propylsulfamoyl} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 10 8- {3- n-Methyl-2- (2-methoxyphenyl) -ethylamino} -propylcarbamoyl} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {N-methyl-3- [4- (2 -methoxyphenyl) -1-piperazinyl] -propionamide} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {3- [4- (2-methoxyphenyl) -1-piperazinyl] propylcarbamoyl } -3-phenyl-4-oxo-4H-1-benzopyran, 8- {3 - [(3,4-dihydro-1-oxo-2H-naphthyl) methylamino-propylcarbamoyl] -3-methyl-4 oxo-2-phenyl-4H-1-benzopyran, 8- {2- [4- (2-methoxyphenyl) -1-piperazinyl] -ethoxycarbonylmethyl} -3-methyl-4-oxo-2-phenyl-4H-1 benzopyran, 8- {4- [4- (2-methoxyphenyl) -1-piperazinyl] -butylsulfamoyl} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {N- (2) -tetrahydropyranyloxy) -3- [4- (2-methoxyphenyl) -1-piperazinyl] -propylcarbamoyl} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {4- [4] - (2-methoxyphenyl) -1-piperazinyl] butyrylamdo} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran,. E-8- (2- [4- (2-Methoxyphenyl) -1-piperazinyl] ethoxyiminomethyl} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {N-hydroxy-3 - [4- (2-Methoxyphenyl) -1-piperazinyl] -propylcarbamoyl} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, E-8- < 2- {2- [ 4- (2-Methoxyphenyl) -1-piperazinyl] ethylcarbamoyl} ethenyl > -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {4- [4- (2-methoxyphenyl) -1-piperazinyl] butylsulfinyl} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {3- [3- (2-methoxyphenoxy) propylamino] propylcarbamoyl} -3-methyl-4-oxo -2-phenyl-4H-1-benzopyran, 8- {3- [2- (2-methylthiophenoxy) -ethylamino] -propylcarbamoyl-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {3- [2- (2,6-Dimethoxyphenoxy) -ethylamino] -propylcarbamoyl} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {3- [4- (5-chloro) -2-methoxyphenyl) -1-piperazinyl] -propylcarbamoyl} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, (E) -8- {4- [4- (2-methoxyphenyl) -1] piperazinyl] -1-butenyl} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, LV 10099 Π (E) -8- < 2- {2- [4- (2-methoxyphenyl) ) -l Piperazinyl-ethoxycarbonyl-ethenyl > -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- (2- [4- (2-methoxyphenyl) -1-piperazinyl] -ethylcarbamoylmethyl} - 4-Oxo-2-phenyl-4H-1-benzopyran, 8- {N-acetyl-3- [4- (2-methoxyphenyl) -1-piperazinyl] -propylcarbamoyl} -3-methyl-4-oxo-2 -phenyl-4H-1-benzopyran, 8- {2- [4- (2-methoxyphenyl) -1-piperazinyl] -ethylsulfonylamino} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8 - {3- [4- (2-Methoxyphenyl) -1-piperazinyl] -propylthiocarbamoyl} -3-10-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {4- [4- (2 -methoxyphenyl) -1-piperazinyl] butylsilfonyl} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {3- [4- (2-methoxyphenyl) -1-piperazinyl] propylcarbamoyl } -3-hydroxymethyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {3- [4- (2-methoxyphenyl) -1-piperazinyl] -propylcarbamoyl} -4-oxo-2-phenyl -4H-1-benzopyran, 8- {3- [4- (2-methoxyphenyl) -1-piperazinyl] -propylcarbamoyl} -2,3-dihydro-4-oxo-4H-1-benzopyran, 8- {3- [4- (2-Methoxyphenyl) -1-piperazinyl] -propylcarbamoyl} -4-oxo-4H-1-benzopyran, 8- { 3- [4- (2-Methoxyphenyl) -1-piperazinyl] -propylcarbamoyl} -6-bromo-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {3- [4- ( 2-Methoxyphenyl) -1-piperazinyl] -propylcarbamoyl) -6-methoxy-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {3- [4- (2-methoxyphenyl) - 1-piperazinyl] -propylcarbamoyl} -6-hydroxy-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {3- [4- (2-methoxyphenyl) -1-piperazinyl] propylcarbamoyl } -3,6-Dimethyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {3- [4- (2-methoxyphenyl) -1-piperazinyl] -propylcarbamoyl} -3-methyl-30 -Nitro-4-oxo-2-phenyl-4H-1-benzopyran, 8- {3- [4- (2-methoxyphenyl) -1-piperazinyl] -propylcarbamoyl} -6-amino-3-methyl-4-oxo -2-Phenyl-4H-1-benzopyran, 8- {3- [4- (2-methoxyphenyl) -1-piperazinyl] propylcarbamoyl) -6-acetamide-3-methyl-4-oxo-2-phenyl-4H - 1-benzopyran, 12 8- {3- [4- (2-methoxyphenyl) -1-piperazinyl] propylcarbamoyl} -6-ethylamino-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {3- [4- (2-Methoxyphenyl) -1-piperazinyl] -propylcarbamoyl} -6-dimethylamino-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 5- 8- {3- [4- (2-Methoxyphenyl) -1-piperazinyl] -propylcarbamoyl} -7-methoxy-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 8- {3- [4- (2-Methoxyphenyl) -1-piperazinyl] propylcarbamoyl-3-methyl-4-oxo-2- (4-trifluoromethylphenyl) -4H-1-benzopyran, 8- (3- [4- (2-methoxyphenyl) ) -1-Piperazinyl] -propylcarbamoyl} -2- (4-10 benzoylphenyl) -3-methyl-4-oxo-4H-1-benzopyran, 8- {3- [4- (2-methoxyphenyl) -1-piperazinyl] ] -propylcarbamoyl} -3-methyl-4-oxo-2- (4-phenoxyphenyl) -4H-1-benzopyran, 8- {3- [4- (2-methoxyphenyl) -1-piperazinyl] propylcarbamoyl} -2 , 3-dimethyl-4-oxo-4H-1-benzopyran, 8- {3- [4- (2-methoxyphenyl) -1-piperazinyl] propylcarbamoyl} -2- (t-butyl) -3-methyl- 4-oxo-4H-1-benzopyran, 8- {3- [4- (2-methoxyphenyl) -1-piperazinyl] propylcarbamoyl} -2-cyclohexyl-3-methyl-4-oxo-4H-1-benzopyran, 8- {3- [4- (2-Methoxyphenyl) -1-piperazinyl] -propylcarbamoyl} -2- (2-20 furyl) -3-methyl-4-oxo-4H-1-benzopyran, 8- {3- [4- (2-Methoxyphenyl) -1-piperazinyl] -propylcarbamoyl} -3-methyl-4-oxo-2-thienyl-4H-1-benzopyran, 8- {3- [4- (2-methoxy) ifenyl) -1-piperazinyl] -propylcarbamoyl} -4-oxo-2-phenyl-4H-1-benzothiopyran, 25 (E) -8- {3- [4- (2-methoxyphenyl) -1-piperazinyl] propylcarbamoyl} -3-methyl-4-oxo-2- (2-styryl) -4H-1-benzopyran, 8- {3- [4- (2-methoxyphenyl) -1-piperazinyl] propylcarbamoyl} -3-methyl-2 - (4-methylphenyl) -4-oxo-4H-1-benzopyran, 8- {3- [4- (2-methoxyphenyl) -1-piperazinyl] propylcarbamoyl} -2- (4-30 methoxyphenyl) -3- Methyl 4-oxo-4H-1-benzopyran, 8- {3- [4- (2-methoxyphenyl) -1-piperazinyl] propylcarbamoyl} -2- (4-fluorophenyl) -3-methyl-4-oxo 4H-1-benzopyran, 8- (3- [4- (2-methoxyphenyl) -1-piperazinyl] propylcarbamoyl} -6-methanesulfonylamino-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 1 H-10099 13 8- {3- [4- (2-Methoxyphenyl) -1-piperazinyl] -propylcarbamoyl} -3-methyl-2- (4-nitrophenyl) -4-oxo-4H-1-benzopyran, 8 - {3- [4- (2-methoxyphenyl) -1-piperazinyl] -propylcarbamoyl} -6-diethoxyphosphonyloxy-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 5- 8- {3- [4- (2-Methoxyphenyl) -1-piperazinyl] propylcarbamoyl} -3-methyl * 4-oxo-2-trifluoromethyl-4H- 1-Benzopyran, 8- {N-methyl-3- [4- (2-methoxyphenyl) -1-piperazinyl] -propylcarbamoyl} -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, 7- (3- [4- (2-Methoxyphenyl) -1-piperazinyl-propylcarbamoyl] -2-benzoyl-3-ethyl-benzo [b] furan, 2- (4-biphenyl) -8- {3- [4- (2-Methoxyphenyl) -1-piperazinyl-propylcarbamoyl} -3-methyl-4-oxo-4H-1-benzopyran, 8- {3- [4- (2-methoxyphenyl) -1-piperazinyl] -propylcarbamoyl} -3-methyl-4-oxo-2- (3-pyridyl) -4H-1-benzopyran, 8- (3- [4- (2-acetoxyphenyl) -1-piperazinyl] propylcarbamoyl} -3-methyl) 1-4-Oxo-2-phenyl-4H-1-benzopyran, 3-methyl-8- {3- [4- (2-methylaminocarbonylphenyl) -1-piperazinyl] propylcarbamoyl} -4-oxo-2-phenyl-4H- 1-Benzopyran, 6-acetoxy-8- {3- [4- (2-methoxyphenyl) -1-piperazinyl-propylcarbamoyl) -3-methyl-4-oxo-2-phenyl-4H-1-benzopyran, (R, S) -2,3-Dihydro-4-hydroxy-8- {3- [4- (2-methoxyphenyl) -1-piperazinyl] -propylcarbamoyl} -4H-1-benzopyran methanesulfonate, 2- ( 4-Aminophenyl) -8- {3- [4- (2-methoxyphenyl) -1-piperazinyl] propylcarbamoyl} -3-methyl -4-Oxo-4H-1-benzopyran, 2- (4-acetylaminophenyl) -8- {3- [4- (2-methoxyphenyl) -1-piperazinyl] propylcarbamoyl} -3-methyl-4H-1-yl benzopyran, 2- (4-hydroxyphenyl) -8- {3- [4- (2-methoxyphenyl) -1-piperazinyl] -propylcarbamoyl} -3-methyl-4H-1-benzopyran, dihydrochloride monohydrate, 30- { 3- [4- (2-Methoxyphenyl) -1-piperazinyl] -propylcarbamoyl} -2-phenyl-4, N, N-4-trioxo-4H-1-benzothiopyran monohydrate, 7- {3- [4- (2-methoxyphenyl) - 1-Piperazinyl] -propylcarbamoyl} -2-phenylbenzo [b] furan, 8- {3- [4- (2-methoxyphenyl) -1-piperazinyl] -propyl-N-methylsulfamoyl} -3- 35 methyl-4-oxo -2-Phenyl-4H-1-benzopyran methanesulfonate, 14- {3- [4- (2-methoxyphenyl) -1-piperazinyl] -butyl-N-methylsulfamoyl-3-methyl-4-oxo-2-phenyl-4H -1-benzopyran methane sulfonate. or a prodrug, enantiomer, diastereoisomer, N-oxide or pharmaceutically acceptable salt of such a compound. 9. Farmaceitisks sastāvs, kas satur savienojumu saskaņā ar jebkuru iepriekšējo punktu, vai šāda savienojuma proārstniecisku savienojumu, enantiomēru, diastereoizomēru, N-oksīdu vai farmaceitiski atļautu sāli, maisījumā ar farmaceitiski atļautu atšķaidītāju vai nesēju.'A pharmaceutical composition comprising a compound according to any one of the preceding claims, or a prodrug, enantiomer, diastereoisomer, N-oxide or pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable diluent or carrier.
LVP-93-136A 1992-02-25 1993-02-24 Bicyclic heterocyclic compounds LV10099B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI920408A IT1254469B (en) 1992-02-25 1992-02-25 BENZOPYRANIC AND BENZOTHIOPYRANIC DERIVATIVES
US07/888,775 US5403842A (en) 1992-02-25 1992-05-26 Benzopyran and benzothiopyran derivatives

Publications (2)

Publication Number Publication Date
LV10099A LV10099A (en) 1994-05-10
LV10099B true LV10099B (en) 1995-02-20

Family

ID=26330842

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-93-136A LV10099B (en) 1992-02-25 1993-02-24 Bicyclic heterocyclic compounds

Country Status (25)

Country Link
EP (1) EP0558245A1 (en)
JP (1) JPH069606A (en)
AU (2) AU3629693A (en)
BG (1) BG61946B1 (en)
CA (1) CA2090156A1 (en)
CZ (1) CZ205994A3 (en)
DZ (1) DZ1666A1 (en)
EE (1) EE03177B1 (en)
EG (1) EG20333A (en)
FI (1) FI943876A (en)
HR (1) HRP930210A2 (en)
HU (1) HUT72448A (en)
IL (1) IL104824A (en)
LT (1) LT3038B (en)
LV (1) LV10099B (en)
MX (1) MX9300977A (en)
NO (1) NO943140D0 (en)
NZ (1) NZ245995A (en)
PL (1) PL175556B1 (en)
SG (1) SG65570A1 (en)
SI (1) SI9300094A (en)
SK (1) SK280143B6 (en)
TW (1) TW382628B (en)
WO (1) WO1993017007A1 (en)
ZA (1) ZA931278B (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9300312A (en) * 1992-01-23 1993-07-31 Pfizer BENZOPYRANIC AND RELATED ANTAGONISTS OF LTB.
FR2689127B1 (en) * 1992-03-31 1994-05-06 Adir Cie NEWS 3 ', 5' -DITERTBUTYL-4'-HYDROXY FLAVONES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
IT1266582B1 (en) * 1993-07-30 1997-01-09 Recordati Chem Pharm (DI) AZACYLO-HEXANIC AND DIAZACYLO-HEPTANIC DERIVATIVES
GB9317071D0 (en) * 1993-08-17 1993-09-29 Univ Strathclyde Flavonoids
ES2159622T3 (en) * 1994-01-14 2001-10-16 Azwell Inc DERIVED FROM DIAZACICLOALCANOALQUILSULFONAMIDA.
FR2717175B1 (en) * 1994-03-11 1996-06-14 Adir New alkylaminoindane compounds, processes for their preparation and pharmaceutical compositions containing them.
ES2101620B1 (en) * 1994-03-18 1998-04-01 Ferrer Int NEW COMPOUND DERIVED FROM CHROMENE.
IL112764A0 (en) * 1994-03-18 1995-05-26 Ferrer Int New chromene derivatives
US5760040A (en) * 1994-03-30 1998-06-02 Zeria Pharmaceutical Co., Ltd. Indole derivative for treating overproduction of dihydrotestosterone
US5503843A (en) * 1994-04-22 1996-04-02 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
DE4425146A1 (en) * 1994-07-15 1996-01-18 Basf Ag Use of heterocyclic compounds
GB9417135D0 (en) * 1994-08-23 1994-10-12 Medinnova S F Method
CA2188924C (en) * 1995-02-28 2008-04-08 Hirokazu Annoura Arylpiperidine and arylpiperazine derivatives and drugs containing the same
GB9507288D0 (en) * 1995-04-07 1995-05-31 Sod Conseils Rech Applic Phenoxyethylamine derivatives with high affinity for 5-HT1A receptors
US5859014A (en) * 1995-06-09 1999-01-12 Syntex (U.S.A.) Inc. Pyrimidinedione, pyrimidinetrione, triazinedione and tetrahydroquinazolinedione derivatives as α1 -adrenergic receptor antagonists
ES2157366T3 (en) * 1995-06-09 2001-08-16 Hoffmann La Roche DERIVATIVES OF PYRIMIDINDIONA, PIRIMIDINTRIONA, TRIACINDIONA AS ANTAGONISTS OF ALFA-1-ADRENERGIC RECEPTORS.
JPH0967367A (en) * 1995-06-23 1997-03-11 Suntory Ltd Thiopyran derivative
AU4153496A (en) * 1995-10-20 1997-05-07 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
IT1282705B1 (en) * 1996-02-28 1998-03-31 Recordati Chem Pharm USE OF 5-HT | A SEROTONINERGIC RECEPTOR ANTAGONISTS FOR THE TREATMENT OF URINARY INCONTINENCE
US5990114A (en) * 1996-02-28 1999-11-23 Recordati, S.A., Chemical And Pharmaceutical Company Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence
JP2000506157A (en) * 1996-03-08 2000-05-23 サンテラボ (2-Aminoethyl) benzofuran derivatives, their production and their therapeutic use
FR2745815B1 (en) * 1996-03-08 1998-06-26 Synthelabo BENZOFURANE DERIVATIVES, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
AU3817197A (en) * 1996-08-22 1998-03-06 Hoechst Marion Roussel, Inc. Troponyl piperazines as selective dopamine d4 receptor ligands
AU2002300904B2 (en) * 1997-05-12 2004-12-23 Ortho-Mcneil Pharmaceutical, Inc. Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia
EP0984777B1 (en) 1997-05-12 2003-09-17 Ortho-Mcneil Pharmaceutical, Inc. Arylsubstituted piperazines useful in the treatement of benign prostatic hyperlasia
AU7455798A (en) 1997-06-04 1998-12-21 Nippon Shoji Kaisha, Ltd. Process for producing piperazinesulfonamide derivatives and salts thereof
WO1999003833A1 (en) * 1997-07-15 1999-01-28 Sankyo Company, Limited Piperazine derivatives
US6387909B1 (en) 1999-07-30 2002-05-14 Recordati S.A. Chemical And Pharmaceutical Company Thienopyranecarboxamide derivatives
US6306861B1 (en) 1999-07-30 2001-10-23 Recordati S.A. Chemical And Pharmaceutical Company Thienopyrancecarboxamide derivatives
IT1313581B1 (en) * 1999-07-30 2002-09-09 Recordati Chem Pharm TIENOPIRANCARBOSSAMIDICI DERIVATIVES.
DE19941657A1 (en) * 1999-09-01 2001-03-08 Schwabe Willmar Gmbh & Co Cinnamic acid nitriles, process for their preparation and use
US6403594B1 (en) 1999-10-18 2002-06-11 Recordati, S.A. Chemical And Pharmaceutical Company Benzopyran derivatives
IT1314192B1 (en) * 1999-10-18 2002-12-06 Recordati Chem Pharm BENZOPYRANIC DERIVATIVES
JP2002113006A (en) 2000-10-10 2002-04-16 Toshiba Medical System Co Ltd Method of setting for diagnostic apparatus, and diagnostic instrument
CN1150176C (en) 2002-05-22 2004-05-19 上海医药工业研究院 Aralkylone pipeazine derivative and its application
US7247725B2 (en) * 2002-10-30 2007-07-24 Merck & Co., Inc. Gamma-aminoamide modulators of chemokine receptor activity
BRPI0511834A (en) 2004-07-14 2008-01-08 Ptc Therapeutics Inc methods for treating hepatitis c
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2006019832A1 (en) 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines for treating hepatitis c
BRPI0608353A2 (en) 2005-02-17 2009-12-01 Wyeth Corp indole, benzothiophene, benzofuran and indene cycloalkyl fused derivatives
CN102227417B (en) * 2008-09-29 2015-09-16 西特里斯药业公司 As the chromene keto analog of Sirtuin conditioning agent
CZ304045B6 (en) 2012-04-10 2013-09-04 Univerzita Palackého Use of copper complexes containing 2-phenyl-3-hydroxyquinolin-4(1H)-one and 1,10-phenanthroline derivatives for preparing medicaments intended for the treatment of tumor diseases
CN108884049A (en) 2016-02-09 2018-11-23 法玛克亚公司 2 inhibitor of quinolinone lysyloxidase sample and application thereof
TW202031644A (en) * 2018-11-06 2020-09-01 日商第一三共股份有限公司 Benzimidazole derivative
CA3160428A1 (en) 2019-11-11 2021-05-20 Southwest Research Institute Recrystallized hi-6 dimethylsulfate
US11834441B2 (en) 2019-12-06 2023-12-05 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
EP4347031A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
TW202334089A (en) 2021-11-02 2023-09-01 美商夫雷爾醫療公司 Pparg inverse agonists and uses thereof
CN115160279B (en) * 2022-07-27 2023-11-24 中国药科大学 Benzopyrone compounds, pharmaceutical compositions and uses

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2921070A (en) * 1957-11-05 1960-01-12 Recordati Lab Farmacologico S Basic esters of 3-methylflavone-8-carboxylic acid
GB1156973A (en) 1965-07-06 1969-07-02 Quinazoline Derivatives
DE2123923A1 (en) * 1971-05-14 1972-11-23 Boehringer Mannheim Gmbh, 6800 Mannheim Square bracket on omega- (Flavon-7yl-oxy) -alkyl Square bracket on -pigerazine derivatives and process for their preparation
NZ200981A (en) 1981-07-17 1984-10-19 Recordati Chem Pharm 3-methylflavone-8-carboxylic acid derivatives and pharmaceutical compositions
JPS60202872A (en) * 1984-03-27 1985-10-14 Kaken Pharmaceut Co Ltd Benzofuran derivative, its preparation, and hypotensive agent containing said derivative as active component
US4678787A (en) * 1985-01-30 1987-07-07 Warner-Lambert Company 4H-1-benzopyran-4-ones and their sulfur containing analogs
JPS63139180A (en) * 1986-12-02 1988-06-10 Tanabe Seiyaku Co Ltd Carboxylic acid derivative
IL87451A0 (en) * 1987-09-04 1989-01-31 Tanabe Seiyaku Co Benzofuran derivatives,their preparation and pharmaceutical compositions containing them
US5278174A (en) * 1990-06-04 1994-01-11 Scios Nova, Inc. Sigma binding site agents

Also Published As

Publication number Publication date
AU3377393A (en) 1993-08-26
AU3629693A (en) 1993-09-13
EE03177B1 (en) 1999-04-15
LT3038B (en) 1994-09-25
JPH069606A (en) 1994-01-18
AU660067B2 (en) 1995-06-08
MX9300977A (en) 1993-12-01
HU9402443D0 (en) 1994-10-28
IL104824A0 (en) 1993-06-10
SK100794A3 (en) 1995-04-12
ZA931278B (en) 1993-11-18
PL175556B1 (en) 1999-01-29
EP0558245A1 (en) 1993-09-01
EG20333A (en) 1998-10-31
FI943876A0 (en) 1994-08-23
FI943876A (en) 1994-08-23
IL104824A (en) 1999-12-22
SG65570A1 (en) 1999-06-22
NO943140L (en) 1994-08-25
BG61946B1 (en) 1998-10-30
HRP930210A2 (en) 1995-06-30
NZ245995A (en) 1994-09-27
NO943140D0 (en) 1994-08-25
LTIP354A (en) 1994-04-25
DZ1666A1 (en) 2002-02-17
SK280143B6 (en) 1999-09-10
CA2090156A1 (en) 1993-08-26
LV10099A (en) 1994-05-10
CZ205994A3 (en) 1995-02-15
HUT72448A (en) 1996-04-29
WO1993017007A1 (en) 1993-09-02
BG98990A (en) 1995-05-31
SI9300094A (en) 1993-09-30
TW382628B (en) 2000-02-21

Similar Documents

Publication Publication Date Title
AU660067B2 (en) Benzopyranone derivatives and analogues
RU2128656C1 (en) Heterobicyclic compound, pharmaceutical composition, methods of synthesis of heterobicyclic compound
US5474994A (en) Bicyclic heterocyclic derivatives having α1 -adrenergic and 5HT1A
US5605896A (en) Bicyclic heterocyclic derivatives having α1 adrenergic and 5HT1A activities
EP0585913B1 (en) Condensed heterocyclic compounds, their production and use
IE850684L (en) 2-oxindole-1-carboxamides
EP1756083A1 (en) 3-arylsulfonyl-quinolines as 5-ht6 receptor antagonists for the treatment of cns disorders
JPH0653736B2 (en) Novel acidic indole compound
DK162443B (en) 1,3-DIACYL-2-OXINDOL COMPOUNDS AND 1-ACYL-2-OXINDOL COMPOUNDS FOR USE AS INTERMEDIATES IN THEIR PREPARATION
EP0264883A2 (en) Substituted pyridine derivatives
CA2094774A1 (en) Pharmaceutical composition containing quinoline and quinazoline derivatives and novel compounds therefor
FI80691C (en) FOERFARANDE FOER FRAMSTAELLNING AV BENSOTIOFENER OCH BENSOFURANER MED ANTIALLERGISK AKTIVITET.
KR970011580B1 (en) Novel benzothiophens having antiallergic activity
FI62077B (en) PROCEDURE FOR THE FRAMEWORK OF PHARMACEUTICAL PRODUCTS PHENOXYETHYLPIPERIDINOPROPANOLDERIVAT
PL170726B1 (en) Method of obtaining 2-substituted quinolines
EP0153818B1 (en) 1,3-disubstituted 2-oxindoles as analgesic and anti-inflammatory agents
NL8002024A (en) 6-SUBSTITUTED PYRANO COMPOUNDS AND THEIR APPLICATION IN PHARMACY.
FI80270C (en) Process for the preparation of analgesic and anti-inflammatory 1,3-diacyl-2-oxoindole compounds and intermediates
JPH0625213A (en) Flavone derivative
FR2717479A1 (en) Novel 3- (omega-benzoylpiperidino) alkyl) -4H-benzopyran-4-ones, their preparation and their therapeutic application.
IE57689B1 (en) 1,3-disubstituted oxindoles as analgesic and antiinflammatory agents